

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**FOURTH INTERIM FEE APPLICATION OF FTI CONSULTING, INC. FOR
COMPENSATION EARNED AND EXPENSES INCURRED FOR THE PERIOD FROM
SEPTEMBER 19, 2019 THROUGH JANUARY 31, 2021**

Name of Applicant:	FTI Consulting, Inc.
Name of Client:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Period for which Compensation and Expense Reimbursement Are Sought in this Application:	September 19, 2019 through January 31, 2021
Petition Date:	September 16, 2019
Retention Date:	December 2, 2019, <i>nunc pro tunc</i> to September 19, 2019
Total Amount of Compensation and Expense Reimbursement Sought to be Allowed in this Application:	\$1,653,287.00
Total Amount of Compensation Sought to be Allowed in this Application:	\$1,653,287.00
Total Amount of Expense Reimbursement Sought to be Allowed in this Application:	\$0.00

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Total Amount of Compensation and Expense Reimbursement Previously Allowed Pursuant to the Interim Compensation Order:	\$681,094.00
Compensation Sought in this Application and Already Paid Pursuant to the Interim Compensation Order:	\$0.00
Expenses Sought in this Application and Already Paid Pursuant to the Interim Compensation Order:	\$0.00
Blended Hourly Rate of Included Professionals:	\$782.99
Number of Professionals Included in This Application:	13

This is a: ____ monthly X interim ____ final application

FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, (“**FTI**”) financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants (the “**Committee**”) of Purdue Pharma L.P., et al. (the “**Debtors**”), hereby makes its Fourth Interim Fee Application for Compensation Earned and Expenses Incurred for the Period from September 19, 2019 through January 31, 2021 (this “**Application**”) and respectfully represents as follows:

Introduction

1. FTI provided services to the Committee in accordance with the instructions and directions of the Committee. FTI is compensated on an hourly fee basis, plus reimbursement of actual and necessary expenses incurred by FTI.

2. By this Application, FTI seeks allowance of (i) compensation for actual and necessary professional services rendered by FTI as financial advisor to the Committee for the period from September 19, 2019 through January 31, 2021 (the “**Compensation Period**”) in the

amount of \$1,653,287.00 and (ii) reimbursement for expenses incurred in the Compensation Period in the amount of \$0.00, for a total of \$1,653,287.00 for the Compensation Period.

3. The statutory bases for the relief requested herein are sections 330 and 331 of title 11 of the United States Code (the “**Bankruptcy Code**”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”), and Rule 2016-1 of the Local Rules for the United States Bankruptcy Court for the Southern District of New York (the “**Local Rules**”), and the United States Trustee’s Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed Under 11 U.S.C. § 330 for Attorneys in Larger Chapter 11 Cases, effective as of November 1, 2013 (the “**U.S. Trustee Guidelines**”). This Application has been prepared in accordance with General Order M-447, the Amended Guidelines for Fees and *Disbursements for Professionals in the Southern District of New York* (June 17, 2013) promulgated pursuant to Local Bankruptcy Rule 2016-1(a) (the “**Local Guidelines**”), and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [Docket No. 529] (the “**Interim Compensation Order**”).

4. This Application summarizes the services rendered by FTI on behalf of the Committee during the Compensation Period. While it is not possible or practical to describe each and every activity undertaken by FTI, FTI has maintained contemporaneous time records which include a detailed chronology of the daily services rendered, describing the precise nature of the work, the specific tasks performed, and the time expended by each professional. A breakdown of the hours and fees by professional is annexed hereto as **Exhibit A**. A breakdown of the hours and fees by task code is annexed hereto as **Exhibit B**. A detailed copy of the time records for the Compensation Period is annexed hereto as **Exhibit C**.

5. In accordance with the Interim Compensation Order, FTI has requested payment for 80% of the fees for actual and necessary services incurred during the Compensation Period in the amount of \$1,322,629.60 and for 100% of the expenses incurred during the Compensation Period in the amount of \$0.00 for a total amount of \$1,322,629.60. FTI submitted monthly fee statements during the Compensation Period, summarized as follows:

Docket No./Filed	Compensation Period	Fees and Expenses Incurred			Monthly Amounts Requested	Payments Received as of the Date of this
		Fees (100%)	Fees (80%)	Expenses (100%)	Fees (80%) + Expenses (100%)	
Docket No. 2031 Filed on 11/24/2020	September 19, 2019 - September 30, 2020	\$ 44,462.00	\$ 35,569.60	\$ -	\$ 35,569.60	\$ -
Docket No. 2154 Filed on 12/18/2020	October 1, 2020 - October 31, 2020	356,078.50	284,862.80	-	\$ 284,862.80	-
Docket No. 2308 Filed on 1/20/2021	November 1, 2020 - November 30, 2020	450,827.00	360,661.60	-	360,661.60	-
Docket No. 2503 Filed on 3/17/2021	December 1, 2020 - December 31, 2020	308,146.00	246,516.80	-	246,516.80	-
Docket No. 2504 Filed on 3/17/2021	January 1, 2021 - January 31, 2021	493,773.50	395,018.80	-	395,018.80	-
Total		\$ 1,653,287.00	\$ 1,322,629.60	\$ -	\$ 1,322,629.60	\$ -

6. As of the date of this Application, FTI is owed \$1,653,287.00 for professional fees and \$0.00 for actual and necessary expenses for a total of \$1,653,287.00.

Jurisdiction

7. The Court has jurisdiction over this Application under 28 U.S.C. § 1334. Venue of this proceeding is proper pursuant to 28 U.S.C. §§ 1408 and 1409. This is a core proceeding within the meaning of 28 U.S.C. § 157(b)(2).

Background

8. On September 16, 2019 (the “**Petition Date**”), the Debtors each filed with the United States Bankruptcy Court for the Southern District of New York (this “**Court**”) their voluntary petitions for relief under chapter 11 of the Bankruptcy Code. For the bankruptcy process,

the Debtors selected Davis Polk & Wardwell as counsel (“**Davis Polk**”) and AlixPartners LLP as financial advisor (“**Alix**”).

9. The Debtors continue to operate their businesses and manage their properties as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

10. On September 18, 2019, the Court entered an order [Docket No. 59] authorizing the joint administration and procedural consolidation of the Debtors’ chapter 11 cases pursuant to Bankruptcy Rule 1015(b). No examiner has been appointed in the chapter 11 cases pursuant to section 1104 of the Bankruptcy Code.

11. On November 21, 2019, the Court entered its Interim Compensation Order [Docket No. 529] establishing the procedures for interim compensation and reimbursement of expenses incurred by professionals retained by the Debtors pursuant to sections 327 or 1103 of the Bankruptcy Code (“**Retained Professionals**”).

12. On December 2, 2019, the Court entered the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [Docket No. 553] (the “**Retention Order**”).

13. During the Compensation Period, FTI has represented the Committee, in connection with these chapter 11 cases, including with respect to, among other things, the Debtors’ domestic and international business plans, employee compensation plans, and historical cash transfers. The fees earned and the expenses incurred by FTI in connection with these activities are the subject of this Application and are described in more detail below and the exhibits hereto.

Terms and Conditions of Employment

14. FTI is compensated on an hourly fee basis, plus reimbursement of actual and necessary expenses incurred by FTI. For further information regarding the terms and

conditions of FTI's retention, please see the Retention Order. The Committee has been given the opportunity to review and approve this Application.

Summary of FTI's Services Rendered

15. During the Compensation Period, FTI provided extensive financial services to the Committee. The primary services rendered by FTI include, but are not limited to, the categories set forth below (each a "**Task Code**") which were billed pursuant to the requirements of Section C(8)(c) of the U.S. Trustee Guidelines:

- a. **Task Code 1: Current Operating Results & Events (32.7 Hours):** During the Compensation Period, time detail under this task code related to FTI's work evaluating the Debtors' monthly operating reports, results, and current events. FTI prepared analyses comparing the Debtors' YTD performance relative to their business plans and prepared presentations to share findings and update the Committee.
- b. **Task Code 6: Asset Sales (76.4 Hours):** During the Compensation Period, time under this task code relates to FTI's work reviewing, analyzing, and preparing presentation materials related to proposed bids to purchase the Debtors' operations. FTI coordinated with other professionals to evaluate the economics of the various bids, participated in calls with relevant parties and stakeholders to understand key transaction considerations, and conducted diligence on other strategic alternatives against a potential sale of the businesses.
- c. **Task Code 7: Analysis of Domestic Business Plan (410.5 Hours):** During the Compensation Period, FTI undertook detailed diligence of the Debtors'

revisions to the go-forward business plan including, (i) a thorough evaluation of financial forecasts and projections for both business segments and product-level detail, (ii) analysis of historical performance of the domestic business, (iii) participation in meetings with key employees and advisors of the Debtors, and the (iv) preparation of related analyses for the Committee and other stakeholders. FTI also reviewed and conducted diligence on the reasonableness of the Debtors' proposed public health initiatives and their potential impact to the Debtors' financial performance as well as assessed various sensitivity scenarios surrounding the Debtors' OxyContin sales forecasts. FTI prepared comprehensive presentations for the Committee to summarize the various analyses prepared on the Debtors' go-forward business plan.

- d. **Task Code 10: Analysis of Tax Issues (63.8 Hours):** During the Compensation Period, FTI was involved in analyzing and reviewing the impact of various tax-related matters, including potential tax liabilities from the sale of the IAC businesses, taxes resulting from the go-forward strategy of the domestic Purdue business, and evaluating tax considerations with regards to structuring issues. FTI participated in calls and meetings with both Counsel and other tax professionals to discuss the related analyses and prepare relevant materials to share with the Committee on these issues.
- e. **Task Code 16: Analysis, Negotiate and Form of POR & DS (697.3 Hours):** Entries under this task code relate to FTI's work during the Compensation Period focused on evaluating potential go-forward scenarios for the Purdue business to maximize distributable value to claimant groups, preparation and

participation in mediation efforts with Sackler-related parties, and analyzing potential recoveries under various strategic alternatives to inform structuring considerations. In conducting analyses related to the go-forward scenarios, FTI performed significant diligence into the Debtors' existing business plan and re-forecasted sales figures, working alongside the Debtors and the UCC to estimate distributable value under various sale and operating scenarios, reflecting updated bid proposals, the Debtors' latest thinking with regards to the go-forward performance of the Company, and input from UCC professionals with regards to sensitivity assumptions.

- f. **Task Code 18: Review of Historical Transactions (475.0 Hours):** During the Compensation Period, FTI performed significant work to evaluate the various historical cash, non-cash, and intercompany transfers between the Purdue and Rhodes businesses, the IACs, and other Sackler-owned legal entities / the Sackler family. This workstream involved significant effort in reviewing reports and supporting financial data prepared and provided by the Debtors and Sackler family's professionals as well as numerous correspondences with the UCC to review their analyses and findings. In addition, significant diligence of the historical royalty agreements and comparable agreements and analyses of balance sheet assets and liabilities of the Sackler families and their trusts was conducted, with findings summarized in presentations to the Committee.
- g. **Task Code 21: General Mtgs with Counsel and/or Ad Hoc Committee (47.0 Hours):** During the Compensation Period, FTI participated on numerous calls and meetings with the Committee and its counsel. During these calls and

meetings, FTI discussed with the Committee and its counsel several key issues at hand, next steps, and the presentations of various analyses prepared by FTI's team.

- h. **Task Code 28: Review of IAC Business (142.4 Hours):** During the Compensation Period, FTI analyzed and performed diligence of the IACs' businesses and operations. FTI continued to produce analyses related to the IACs' revised September business plan, evaluated the IAC's updated December projections and forecasts for the international business between 2021-2025, and assessed YTD performance through the final quarter of 2020. In addition, FTI participated in meetings with key IAC employees and advisors on various matters, including strategic initiatives for the updated 2021 business plan, YTD performance with the IAC CEO and CFO, the status of the sale process and related considerations with the IAC's investment banker, the status of vendor due diligence conducted, and evaluation of the IAC business plan by external advisors. Throughout the Compensation Period, FTI prepared as needed, presentations to update the Committee on the latest status of diligence on the IACs. Additional time spent in this task code includes the coordination of ongoing diligence efforts with the Committee's and the Debtors' advisors.

Basis for Relief Requested

16. Section 331 of the Bankruptcy Code provides for interim compensation of professionals and incorporates the substantive standards of section 330 of the Bankruptcy Code that govern the Court's award of such compensation. See 11 U.S.C. § 331. Section 330 provides that the Court may award a professional employed under section 327 "reasonable compensation

for actual, necessary services” and “reimbursement for actual, necessary expenses.” 11 U.S.C. § 330(a)(1). Section 330(a)(3) also outlines specific criteria that the Court shall consider in determining the amount of reasonable compensation, including:

- a. the time spent on such services;
- b. the rates charged for such services;
- c. whether the services were necessary to the administration of, or beneficial at the time at which the service was rendered toward the completion of, a case under this title;
- d. whether the services were performed within a reasonable amount of time commensurate with the complexity, importance, and nature of the problem, issue, or task addressed;
- e. with respect to a professional person, whether the person is board certified or otherwise has demonstrated skill and experience in the bankruptcy field; and
- f. whether the compensation is reasonable based on the customary compensation charged by comparably skilled practitioners in cases other than cases under this title.

17. All of the services for which FTI seeks compensation were necessary for, beneficial to, and in the best interests of the Committee. FTI’s fees are reasonable given the size and complexity of the Debtors’ cases.

18. All of the services for which interim compensation is sought herein were rendered for and on behalf of the Committee. FTI respectfully submits that the professional services rendered were necessary, appropriate, and have contributed to the effective administration

of the Debtors' chapter 11 cases and maximization of value. It is respectfully submitted that the services rendered to the Committee were performed efficiently, effectively, and economically, and the results have benefitted the Committee.

19. The hourly rates that FTI has charged are consistent with the market rate for comparable services. The hourly rates and fees charged by FTI are the same as those generally charged to, and paid by, FTI's other clients. FTI regularly reviews its hourly rates on an annual basis and, accordingly, the rates included in this Application reflect an ordinary course hourly rate increase.

20. Whenever possible, FTI sought to minimize the costs of its services to the Committee by utilizing talented junior professionals to handle more routine aspects of case administration. A small group of the same FTI professionals was utilized for the vast majority of the work in these cases to minimize the costs of intra-FTI communication and education about the Debtors' circumstances.

21. FTI believes that the expenses incurred are reasonable and economical relative to the services required by the Committee and were incurred as a direct result of FTI's representation of the Committee. These expenses are the type customarily charged to non-bankruptcy clients of FTI. None of the expenses relate to non-reimbursable overhead. FTI has adhered to allowable rates for expenses as fixed by 2016-1 of the Local Rules for the United States Bankruptcy Court of the Southern District of New York.

22. In accordance with the factors enumerated in section 331 of the Bankruptcy Code, the amounts requested herein are fair and reasonable given (i) the complexity of the cases, (ii) the time expended, (iii) the nature and extent of services rendered, (iv) the value of such services, and (v) the costs of comparable services other than in a case under the Bankruptcy Code.

23. FTI submits that pursuant to the criteria normally examined in bankruptcy cases and based upon the factors considered in accordance with sections 330 and 331 of the Bankruptcy Code and Bankruptcy Rule 2016, the results achieved provide more than sufficient justification for approval of compensation sought by FTI.

WHEREFORE, FTI respectfully requests that the Court enter an order:

- a. Granting this Application;
- b. Awarding FTI, on an interim basis, compensation for professional services rendered during the Compensation Period in the amount of \$1,653,287.00 and reimbursement of actual, reasonable and necessary expenses incurred by FTI during the Compensation Period in the amount of \$0.00;

Dated: New York, New York
March 17, 2021

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**CERTIFICATION UNDER GUIDELINES FOR FEES AND DISBURSEMENTS FOR
PROFESSIONALS IN RESPECT OF THE FOURTH APPLICATION OF FTI
CONSULTING, INC. FOR INTERIM COMPENSATION AND REIMBURSEMENT OF
EXPENSES**

I, Matthew Diaz, hereby certify that:

1. I am a Senior Managing Director with the applicant firm, FTI Consulting Inc., (together with its wholly owned subsidiaries and independent contractors, “**FTI**”), as financial advisor for the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants (the “**Committee**”) for the jointly administered chapter 11 cases of Purdue Pharma L.P., et al (collectively, the “**Debtors**”), in respect of compliance with the *Amended Guidelines for Fees and Disbursements for Professionals in Southern District of New York Bankruptcy Cases* (June 17,

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

2013) promulgated pursuant to Local Bankruptcy Rule 2016-1(a) (the “**Local Guidelines**”), the *United States Trustee’s Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed Under 11 U.S.C. § 330* for Attorneys in Larger Chapter 11 Cases, effective as of November 1, 2013 (the “**U.S. Trustee Guidelines**”), and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals*, dated November 21, 2019 [Docket No. 529] (the “**Interim Compensation Order**,” and collectively with the Amended Local Guidelines and UST Guidelines, the “**Guidelines**”).

2. This certification is made in respect of FTI’s application, dated March 17, 2021 (the “**Application**”), for interim compensation and reimbursement of expenses for the period commencing September 19, 2019, through and including January 31, 2021, (the “**Fourth Interim Compensation Period**”) in accordance with the Guidelines.

In respect of section B.1 of the Local Guidelines, I certify that:

- (a) I have read the application;
- (b) To the best of my knowledge, information, and belief formed after reasonable inquiry, the fees and disbursements sought fall within the Local Guidelines;
- (c) The Application respectfully requests that this Court enter an Order awarding FTI \$1,653,287.00 as compensation for services rendered during the Fourth Interim Compensation Period and \$0.00 as reimbursement of reasonable actual and necessary expenses incurred in connection with such services;
- (d) The fees and disbursement requested in the Application are billed in accordance with practices customarily employed by FTI and generally accepted by FTI’s clients; and
- (e) In providing a reimbursable service, FTI does not make a profit on that service, whether the service is performed by FTI in-house or through a third party.

3. In respect of section B.2 of the Local Guidelines and as required by the Interim Compensation Order, I certify that FTI has provided, on a monthly basis or as soon as reasonably possible, statements of FTI's fees and disbursements accrued during the previous month, to the Debtors and the Committee.

4. In respect of section B.3 of the Local Guidelines, I certify that the Debtors, the United States Trustee for the Region 2 and the Committee are each being provided a copy of the Application.

Dated: New York, New York
March 17, 2021

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021¹

Professional	Position	Specialty	Blended Billing Rate^{2,3}	Total Hours	Total Fees
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,095.68	385.9	422,824.5
Simms, Steven	Senior Managing Director	Restructuring	1,295.00	25.8	33,411.0
Joffe, Steven	Senior Managing Director	Tax	1,129.59	29.6	33,436.0
Bradley, Adam	Senior Managing Director	International Healthcare	1,160.00	5.0	5,800.0
Broadhead, Gary	Managing Director	International Healthcare	1,000.00	1.0	1,000.0
Blonder, Brian	Managing Director	Intellectual Property	749.06	121.0	90,636.0
Suric, Emil	Senior Director	Healthcare Valuation	836.72	40.2	33,636.0
Knechtel, Karl	Senior Director	Restructuring	845.00	2.5	2,112.5
Shah, Jayshree	Senior Director	International Healthcare	930.00	1.0	930.0
Bromberg, Brian	Director	Restructuring	821.97	712.3	585,487.0
Kim, Ye Darm	Senior Consultant	Restructuring	586.21	678.8	397,918.0
Kurtz, Emma	Consultant	Restructuring	426.80	107.2	45,753.0
Hellmund-Mora, Marili	Project Assistant	Restructuring	285.83	1.2	343.0
Grand Total				2,111.5	\$ 1,653,287.00

1. Includes allocation-related fees incurred between September 19, 2019 through January 31, 2021

2. Blended billing rates are presented and reflect ordinary course rate increases and increases due to change in titles.

3. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
SUMMARY OF HOURS BY TASK
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021¹

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	32.7	18,108.5
2	Cash & Liquidity Analysis	2.3	2,555.0
6	Asset Sales	76.4	63,162.0
7	Analysis of Domestic Business Plan	410.5	326,426.0
8	Valuation and Related Matters	0.6	651.0
9	Analysis of Employee Comp Programs	21.2	17,954.5
10	Analysis of Tax Issues	63.8	62,779.0
13	Analysis of Other Miscellaneous Motions	2.0	2,170.0
16	Analysis, Negotiate and Form of POR & DS	697.3	547,677.0
18	Review of Historical Transactions	475.0	358,392.5
19	Case Management	31.1	19,841.5
20	General Mtgs with Debtor & Debtors' Prof	1.1	1,193.5
21	General Mtgs with Counsel and/or Ad Hoc Committee	47.0	44,795.5
22	Meetings with Other Parties	12.1	13,128.5
24	Preparation of Fee Application	41.7	26,422.5
28	Review of IAC Business Plan	142.4	100,852.0
29	Intercreditor Allocation	53.8	46,635.5
GRAND TOTAL^{2,3}		2,111.5	\$ 1,653,287.00

1. Includes allocation-related fees incurred between September 19, 2019 through January 31, 2021

2. Blended billing rates are presented and reflect ordinary course rate increases and increases due to change in titles.

3. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
1	10/5/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/6/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/7/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/8/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/9/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/12/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/13/2020	Simms, Steven	1.7	Participate in call with Debtor on go-forward operations issues.
1	10/13/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/14/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/15/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/19/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/20/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/23/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/26/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/27/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/28/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/28/2020	Diaz, Matthew	0.4	Review news coverage on the DOJ settlement.
1	10/29/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	10/30/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/2/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/3/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/4/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/5/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/6/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/9/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/10/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/11/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/12/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/13/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/15/2020	Diaz, Matthew	0.5	Review of the July operating results.
1	11/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
1	11/17/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/18/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/18/2020	Diaz, Matthew	0.5	Review the 3rd monitor report.
1	11/18/2020	Diaz, Matthew	1.1	Review the Debtors' presentation on the domestic September YTD results.
1	11/19/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/20/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/23/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/24/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/25/2020	Kurtz, Emma	0.3	Correspond w/ Debtors' advisors re: clearance to share September YTD results with Committee.
1	11/25/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	11/30/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/1/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/1/2020	Diaz, Matthew	0.3	Review the updated Nalmafene Oct YTD spend.
1	12/2/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/3/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/4/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/7/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/8/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/9/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/10/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/11/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/14/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/15/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/16/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/17/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/18/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/21/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	12/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/4/2021	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/5/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/6/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/7/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/8/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/11/2021	Kurtz, Emma	0.9	Draft summary of current financials and business lines to share with Counsel for Director search.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
1	1/11/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/12/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/13/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/14/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/15/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/19/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/20/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/21/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/22/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/25/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/26/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/27/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/28/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	1/28/2021	Diaz, Matthew	1.1	Review Purdue historical financial statements and operating results.
1	1/29/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			32.7	
2	12/1/2020	Diaz, Matthew	0.6	Review of the updated cash flow and holdings reports.
2	1/12/2021	Diaz, Matthew	0.6	Review the domestic business budget to actual results.
2	1/12/2021	Diaz, Matthew	0.5	Review the updated domestic cash flow analysis.
2	1/13/2021	Diaz, Matthew	0.6	Review the updated domestic cash flow analysis.
2 Total			2.3	
6	1/11/2021	Kim, Ye Darm	0.7	Participate in call re: OxyContin sales for bid.
6	1/11/2021	Kim, Ye Darm	0.9	Review updated bid proposal.
6	1/12/2021	Bromberg, Brian	1.0	Discuss updated bid proposal with Houlihan.
6	1/12/2021	Bromberg, Brian	0.8	Discuss updated bid proposal with team.
6	1/12/2021	Kim, Ye Darm	0.8	Participate in discussion re: bid diligence analysis.
6	1/12/2021	Kurtz, Emma	0.2	Participate in internal call to discuss bid proposal and how to value the bid.
6	1/12/2021	Kim, Ye Darm	0.8	Participate on call re: revised bid proposal discussion.
6	1/12/2021	Diaz, Matthew	0.7	Perform detailed review of the updated bid received.
6	1/12/2021	Kim, Ye Darm	0.8	Review HL draft bid diligence presentation.
6	1/12/2021	Kurtz, Emma	0.4	Review proposed bid to understand terms and payout structure.
6	1/12/2021	Bromberg, Brian	3.5	Review terms of the updated bid proposal.
6	1/13/2021	Bromberg, Brian	0.8	Continue review of updated buyer bid model.
6	1/13/2021	Bromberg, Brian	0.3	Discuss buyer bid with Houlihan team.
6	1/13/2021	Kurtz, Emma	0.7	Discuss internally re: bid and modeling of proposed payout to various creditor groups.
6	1/13/2021	Bromberg, Brian	0.9	Discuss updated buyer bid financial inputs with team.
6	1/13/2021	Bromberg, Brian	0.7	Discuss updated buyer bid with counsel.
6	1/13/2021	Bromberg, Brian	1.0	Discuss updated buyer bid with Debtor team.
6	1/13/2021	Bromberg, Brian	1.0	Discuss updated buyer bid with Houlihan team.
6	1/13/2021	Diaz, Matthew	0.5	Participate in a call with counsel to discuss the proposed bid.
6	1/13/2021	Diaz, Matthew	1.1	Participate in a call with HL to discuss the bid presentation and related next steps.
6	1/13/2021	Diaz, Matthew	0.8	Participate in a call with the Debtors to discuss the proposed bid.
6	1/13/2021	Kim, Ye Darm	0.8	Participate in call to discuss bid diligence.
6	1/13/2021	Kim, Ye Darm	1.1	Participate in call with Debtors re: bid diligence.
6	1/13/2021	Kim, Ye Darm	1.5	Participate in call with HL to discuss bid diligence.
6	1/13/2021	Bromberg, Brian	1.0	Participate in Committee call re: updated bid.
6	1/13/2021	Diaz, Matthew	1.6	Review the sensitivity and royalty analysis on the proposed bid.
6	1/13/2021	Bromberg, Brian	1.8	Review updated buyer bid financial model.
6	1/14/2021	Bromberg, Brian	0.8	Review proposed economics of the updated bid.
6	1/14/2021	Kim, Ye Darm	2.7	Review supporting schedules for bid proposal.
6	1/15/2021	Bromberg, Brian	0.9	Discuss updated bid proposal with Houlihan.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
6	1/15/2021	Diaz, Matthew	1.2	Participate in a call with HL to discuss the cash flows and related implications of the bid.
6	1/15/2021	Kim, Ye Darm	1.0	Participate in call re: revised bid supporting schedules.
6	1/15/2021	Kim, Ye Darm	1.2	Process revisions to revised bid forecast comparison analysis.
6	1/15/2021	Diaz, Matthew	1.6	Review of the bid financing package.
6	1/15/2021	Bromberg, Brian	3.7	Review updated bid financial model.
6	1/16/2021	Bromberg, Brian	2.2	Finalize and share bridge of bid forecasts to business plan.
6	1/16/2021	Diaz, Matthew	0.3	Participate in a call with HL to discuss the bid received.
6	1/16/2021	Diaz, Matthew	0.6	Participate in a call with Province on the bid received.
6	1/16/2021	Diaz, Matthew	1.0	Participate in a call with the Debtors on the bid received.
6	1/16/2021	Bromberg, Brian	1.0	Participate in call with Debtors re: bid proposal.
6	1/16/2021	Kim, Ye Darm	0.9	Participate in call with Debtors re: revised bid diligence.
6	1/16/2021	Bromberg, Brian	1.0	Participate in call with UCC re: updated bid proposal.
6	1/16/2021	Kim, Ye Darm	0.3	Participate in pre-call with financial advisors re: revised bid diligence.
6	1/16/2021	Bromberg, Brian	1.0	Review diligence questions for bidder.
6	1/16/2021	Kim, Ye Darm	0.9	Review revised bid diligence questions list.
6	1/16/2021	Diaz, Matthew	1.5	Review the bid received and the related cash flows and due diligence list.
6	1/19/2021	Simms, Steven	0.3	Review updates on proposed bid diligence items.
6	1/20/2021	Bromberg, Brian	1.0	Coordinate buyer diligence with UCC and Debtor advisors.
6	1/20/2021	Diaz, Matthew	1.0	Participate in a call with bidder to discuss open questions on his bid.
6	1/20/2021	Kim, Ye Darm	1.1	Participate in call with Debtors re: bid proposal diligence workplan.
6	1/20/2021	Bromberg, Brian	1.2	Participate in call with potential buyer.
6	1/20/2021	Bromberg, Brian	0.8	Participate in debrief call after call with potential buyer.
6	1/20/2021	Kim, Ye Darm	0.7	Participate in follow-up call re: bid proposal next steps.
6	1/20/2021	Kim, Ye Darm	0.7	Review bid financing letters.
6	1/20/2021	Kim, Ye Darm	0.6	Review bid proposal diligence responses to question list.
6	1/20/2021	Bromberg, Brian	1.5	Review buyer materials to prepare for call with buyer.
6	1/21/2021	Kim, Ye Darm	1.8	Create live version of bid model to allow for sensitivities.
6	1/21/2021	Bromberg, Brian	0.6	Discuss bidder licensing modeling with Debtors.
6	1/21/2021	Kim, Ye Darm	0.8	Participate on call w/ HL and PJT re: dynamic bid model analysis.
6	1/21/2021	Kim, Ye Darm	1.2	Review HL dynamic bid model
6	1/22/2021	Kim, Ye Darm	1.1	Participate in call with AHC re: bid scenario.
6	1/22/2021	Kim, Ye Darm	1.2	Prepare comparative analysis re: bid and core business distributable value scenarios.
6	1/22/2021	Suric, Emil	1.0	Review bid proposal economics analysis and prepare for discussion.
6	1/25/2021	Simms, Steven	0.4	Participate in correspondence re: proposed bid.
6	1/26/2021	Bromberg, Brian	1.7	Review new bid proposal materials.
6	1/26/2021	Bromberg, Brian	1.5	Review product forecast information re: bidder.
6	1/26/2021	Diaz, Matthew	0.8	Review the updated bid proposal analysis.
6	1/27/2021	Bromberg, Brian	1.3	Discuss potential buyer proposal with Houlihan and counsel.
6	1/27/2021	Diaz, Matthew	0.6	Participate (partially) in a call with Counsel to consider certain aspects of the bid.
6	1/27/2021	Kim, Ye Darm	1.5	Participate in call re: bid proposal next steps.
6	1/27/2021	Diaz, Matthew	0.7	Review of the questions on the proposed bid.
6	1/31/2021	Diaz, Matthew	1.3	Review of the Province analysis on the proposed bid.
6 Total			76.4	
7	9/29/2020	Kim, Ye Darm	0.6	Participate in call re: OxyContin sensitivity cases.
7	9/29/2020	Kim, Ye Darm	0.4	Review OxyContin sales forecasts for high case scenarios.
7	10/1/2020	Kim, Ye Darm	1.0	Participate in call with Debtors' advisors re: OxyContin forecasts.
7	10/1/2020	Bromberg, Brian	0.8	Participate in call with Debtors on the updated OxyContin forecast.
7	10/1/2020	Diaz, Matthew	0.7	Participate in call with the Debtors to discuss the updated OxyContin forecast.
7	10/1/2020	Suric, Emil	2.8	Prepare analyses re: OxyContin forecast sensitivity relative to Debtors' plan.
7	10/1/2020	Bromberg, Brian	0.3	Prepare for call with Debtors on the updated OxyContin forecast.
7	10/1/2020	Suric, Emil	0.8	Prepare OxyContin forecast sensitivity presentation.
7	10/1/2020	Diaz, Matthew	1.1	Review the Debtors' updated domestic business plan.
7	10/11/2020	Kim, Ye Darm	0.9	Review historical OxyContin gross-to-net sales analyses.
7	10/12/2020	Kim, Ye Darm	2.2	Prepare analysis of illustrative impact of removal of OxyContin dosages.
7	10/12/2020	Bromberg, Brian	2.2	Review diligence follow up list for the NCSG.
7	10/13/2020	Bromberg, Brian	0.8	Participate in call with Committee re: Purdue go-forward strategy and Sackler Assets
7	10/13/2020	Bromberg, Brian	0.7	Participate in call with Debtors re: Purdue go-forward strategy.
7	10/14/2020	Bromberg, Brian	0.7	Review domestic business plan diligence files from the Debtors.
7	10/14/2020	Diaz, Matthew	2.1	Review the updated Purdue business plan.
7	10/16/2020	Bromberg, Brian	3.7	Create cash flow bridge to the Debtors' new business plan.
7	10/16/2020	Bromberg, Brian	1.0	Review new business plan diligence update files from the Debtors.
7	10/17/2020	Bromberg, Brian	1.0	Finalize and distribute bridge analysis to internal team.
7	10/17/2020	Kim, Ye Darm	1.2	Prepare bridge of the updated business plan distributable value.
7	10/19/2020	Kurtz, Emma	0.5	Discuss cash flow bridge form previous business plan to latest business plan.
7	10/19/2020	Kim, Ye Darm	0.8	Participate in discussion re: domestic business plan cash flow bridge.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
7	10/19/2020	Bromberg, Brian	1.3	Participate in discussion re: domestic business plan cash flow bridge.
7	10/19/2020	Bromberg, Brian	2.1	Review the domestic business plan cash flow bridge analysis.
7	10/19/2020	Diaz, Matthew	0.8	Review the updated business plan and the related exhibits to the go forward structure.
7	10/19/2020	Diaz, Matthew	1.1	Review the updated business plan bridge reconciliation.
7	10/20/2020	Bromberg, Brian	0.8	Review Debtor analysis on Rhodes savings.
7	10/20/2020	Bromberg, Brian	1.2	Review Debtor pipeline products for upcoming call.
7	10/20/2020	Kim, Ye Darm	0.6	Review Debtors' materials re: savings from the Rhodes Tech sale.
7	10/21/2020	Diaz, Matthew	0.9	Review the updated business plan analysis and related sensitivity cases.
7	10/22/2020	Bromberg, Brian	1.2	Continue review of Debtor pipeline products for upcoming call.
7	10/23/2020	Bromberg, Brian	0.7	Review Debtors' pipeline diligence with team.
7	10/26/2020	Kim, Ye Darm	0.6	Review Rhodes pipeline product forecasts.
7	10/26/2020	Bromberg, Brian	0.8	Review Rhodes pipeline product forecasts.
7	10/27/2020	Kim, Ye Darm	0.8	Participate in a call with the Debtors re: pipeline updates and current progress.
7	10/27/2020	Diaz, Matthew	0.8	Participate in a call with the Purdue management team to review the current progress made on the pipeline products.
7	10/27/2020	Suric, Emil	1.0	Participate in call re: Debtors' pipeline updates.
7	10/27/2020	Bromberg, Brian	0.7	Participate in call with Debtors on current progress of pipeline products.
7	10/27/2020	Bromberg, Brian	0.7	Review Debtors' pipeline diligence with team.
7	10/27/2020	Bromberg, Brian	1.3	Review newly uploaded dataroom documents re: PHI and PBC.
7	10/27/2020	Diaz, Matthew	0.8	Review the Debtors' latest PHI update.
7	10/27/2020	Kim, Ye Darm	1.5	Review updates on PHIs and HRT provided in the dataroom.
7	10/28/2020	Bromberg, Brian	2.4	Review analysis between business plan and cash flow presentation.
7	10/28/2020	Bromberg, Brian	0.9	Review the new Debtor presentation on PBC considerations.
7	10/30/2020	Bromberg, Brian	0.9	Continue review bridging analysis to latest PJT presentation.
7	10/30/2020	Bromberg, Brian	2.2	Review the bridge analysis to latest PJT presentation.
7	11/2/2020	Bromberg, Brian	0.5	Follow up on Rhodes Pipeline with Debtors.
7	11/2/2020	Kim, Ye Darm	0.4	Review PHI and Rhodes pipeline follow up requests.
7	11/5/2020	Kim, Ye Darm	0.6	Continue updating distributable value bridge to September business plan forecasts.
7	11/5/2020	Kim, Ye Darm	1.9	Prepare summary bridge of distributable value to September business plan forecasts.
7	11/5/2020	Kim, Ye Darm	1.3	Review historical OxyContin margins and prepare comparative analysis.
7	11/6/2020	Suric, Emil	0.9	Perform IMS data review for Rhodes pipeline forecasts.
7	11/6/2020	Kim, Ye Darm	1.1	Process revisions to the distributable value bridge to the September business plan forecasts.
7	11/6/2020	Kim, Ye Darm	1.6	Review segment level profitability forecasts re: cash flow analyses.
7	11/6/2020	Diaz, Matthew	1.3	Review the distributable value bridge to the Debtors' updated distributable value analysis.
7	11/9/2020	Suric, Emil	2.8	Perform Rhodes pipeline product due diligence analysis and sensitivity.
7	11/9/2020	Suric, Emil	2.2	Perform Rhodes pipeline product due diligence and sensitivity analysis.
7	11/9/2020	Bromberg, Brian	0.8	Review Rhodes pipeline product forecasts.
7	11/9/2020	Bromberg, Brian	1.5	Review the Debtors' latest business plan presentation.
7	11/9/2020	Bromberg, Brian	1.9	Review the domestic business plan sensitivity scenarios.
7	11/10/2020	Bromberg, Brian	0.6	Discuss bridge analysis with Debtors.
7	11/10/2020	Bromberg, Brian	1.0	Discuss domestic business plan sensitivity assumptions with team.
7	11/10/2020	Diaz, Matthew	1.0	Review of the domestic business plan analysis and related case next steps.
7	11/10/2020	Kim, Ye Darm	1.2	Review Rhodes pipeline forecast analysis.
7	11/10/2020	Kim, Ye Darm	1.8	Review September business plan refresh presentation by the Debtors.
7	11/10/2020	Kim, Ye Darm	1.8	Update internal Rhodes pipeline forecast analysis for latest Debtor assumptions.
7	11/11/2020	Kim, Ye Darm	0.6	Process updates to OxyContin margin forecast comparative analysis.
7	11/11/2020	Bromberg, Brian	1.0	Review cash flow bridge analysis to Debtors' latest plan.
7	11/11/2020	Diaz, Matthew	0.5	Review of potential due diligence to be considered to be provided to a potential buyer.
7	11/11/2020	Kim, Ye Darm	0.4	Review Rhodes pipeline forecasts relative to managements' updated assumptions.
7	11/11/2020	Kim, Ye Darm	1.1	Update OxyContin margin forecast comparative analysis.
7	11/12/2020	Bromberg, Brian	0.8	Discuss domestic business plan sensitivity assumptions with team.
7	11/12/2020	Kim, Ye Darm	0.6	Participate in call re: domestic business plan sensitivities.
7	11/12/2020	Kurtz, Emma	1.9	Prepare analysis of YTD September domestic results to include in evaluation of business plan projections.
7	11/12/2020	Bromberg, Brian	1.8	Review domestic business plan sensitivity analyses.
7	11/12/2020	Diaz, Matthew	0.6	Review of the OxyContin margin forecast analysis.
7	11/12/2020	Kim, Ye Darm	0.7	Review OxyContin margin forecasts from the business plan.
7	11/12/2020	Kim, Ye Darm	0.9	Review September YTD results against business plan.
7	11/12/2020	Suric, Emil	0.5	Update Rhodes pipeline product sensitivities based on new data from client.
7	11/13/2020	Kim, Ye Darm	3.1	Prepare draft presentation re: domestic business plan sensitivities.
7	11/13/2020	Bromberg, Brian	2.8	Review domestic business plan sensitivities analysis slides.
7	11/13/2020	Bromberg, Brian	1.2	Review net distributable value bridge analysis to Debtors' latest business plan.
7	11/13/2020	Kim, Ye Darm	0.6	Review updated internal Rhodes pipeline forecasts analysis.
7	11/13/2020	Kim, Ye Darm	0.4	Update distributable value bridge to September forecasts for new cash savings.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
7	11/14/2020	Kim, Ye Darm	1.5	Process revisions to presentation re: September business plan sensitivities.
7	11/15/2020	Bromberg, Brian	1.4	Prepare responses to questions on domestic business plan analysis.
7	11/15/2020	Diaz, Matthew	0.5	Review the Project Catalyst transaction and related impact on the business plan.
7	11/16/2020	Bromberg, Brian	0.5	Discuss cash flows analysis with PJT.
7	11/16/2020	Diaz, Matthew	1.0	Participate in a call with the Debtors to discuss revisions to the business plan.
7	11/16/2020	Kim, Ye Darm	1.0	Participate in call re: Purdue business plan projections.
7	11/16/2020	Bromberg, Brian	1.5	Prepare for Purdue internal team discussion.
7	11/16/2020	Kim, Ye Darm	2.1	Process revisions re: September business plan sensitivity analysis.
7	11/16/2020	Bromberg, Brian	1.0	Review domestic business plan sensitivity deck.
7	11/16/2020	Diaz, Matthew	0.9	Review the domestic business plan sensitivity analysis.
7	11/17/2020	Bromberg, Brian	0.6	Discuss domestic business plan sensitivities with Houlihan team.
7	11/17/2020	Kim, Ye Darm	1.8	Process revisions to presentation re: September business plan sensitivities.
7	11/17/2020	Kim, Ye Darm	1.5	Process revisions to the September business plan sensitivity considerations presentation.
7	11/17/2020	Diaz, Matthew	0.6	Review certain business plan materials being provided to a 3rd party.
7	11/17/2020	Bromberg, Brian	0.7	Review diligence materials to be provided to potential buyer.
7	11/17/2020	Bromberg, Brian	1.8	Review domestic business plan sensitivity analysis slides.
7	11/17/2020	Bromberg, Brian	1.0	Review domestic due diligence status with internal team.
7	11/17/2020	Suric, Emil	0.6	Update Rhodes pipeline product sensitivities for new data production.
7	11/18/2020	Bromberg, Brian	1.2	Review Rhodes pipeline and create request for Debtors.
7	11/19/2020	Bromberg, Brian	0.7	Continue review of the Rhodes pipeline and create request for Debtors.
7	11/19/2020	Bromberg, Brian	1.8	Discuss domestic cash flows analysis with internal team.
7	11/19/2020	Kim, Ye Darm	0.8	Review Rhodes pipeline product supporting files.
7	11/20/2020	Diaz, Matthew	0.7	Participate in a call with the Debtors to discuss the PHI.
7	11/20/2020	Bromberg, Brian	1.2	Participate in call with Debtors re: PHI.
7	11/20/2020	Bromberg, Brian	0.7	Participate in call with potential buyer.
7	11/23/2020	Bromberg, Brian	1.2	Create and review distributable value scenario cash flow assumptions.
7	11/23/2020	Bromberg, Brian	1.0	Discuss distributable value scenario with Houlihan.
7	11/23/2020	Bromberg, Brian	0.8	Discuss HL presentation re: distributable value cases with Houlihan.
7	11/23/2020	Bromberg, Brian	1.2	Participate in call with team re: distributable value scenario distributable value.
7	11/23/2020	Bromberg, Brian	2.3	Review and discuss core only business plan scenario.
7	11/23/2020	Bromberg, Brian	1.7	Review and edit distributable value scenario cash flow assumptions.
7	11/23/2020	Bromberg, Brian	0.5	Review and finalize cash flow bridge analysis.
7	11/24/2020	Diaz, Matthew	2.6	Detail review of the updated business plan slides for the AHC.
7	11/24/2020	Bromberg, Brian	0.6	Discuss distributable value numbers and related assumptions with Houlihan.
7	11/24/2020	Bromberg, Brian	0.8	Discuss distributable value numbers and related assumptions with the Debtors.
7	11/24/2020	Bromberg, Brian	0.7	Discuss distributable value scenario presentation with team.
7	11/24/2020	Suric, Emil	0.5	Participate in discussions on due diligence findings for OxyContin.
7	11/24/2020	Bromberg, Brian	1.6	Review forecasts and assumptions for distributable value numbers versus public benefit cash flows.
7	11/24/2020	Bromberg, Brian	0.5	Review latest business plan sensitivities presentation.
7	11/24/2020	Bromberg, Brian	0.7	Review new distributable value scenario presentation slides.
7	11/24/2020	Diaz, Matthew	0.6	Review of the updated OxyContin sensitivity analysis.
7	11/24/2020	Bromberg, Brian	1.0	Review operating cash flow assumptions.
7	11/24/2020	Bromberg, Brian	0.8	Review OxyContin forecast assumptions for scenario analysis.
7	11/25/2020	Bromberg, Brian	0.6	Review Houlihan presentation re: strategic alternatives.
7	11/25/2020	Diaz, Matthew	1.1	Review of the business plan materials provided to potential buyer.
7	11/25/2020	Suric, Emil	1.1	Review OxyContin sensitivities performed, methodology relied on and produce support for generic conversation rate assumptions used.
7	11/25/2020	Bromberg, Brian	0.7	Review PEO information in slides for clearance.
7	11/29/2020	Diaz, Matthew	1.9	Review the updated presentation on the business plan and the distributable value analysis.
7	11/30/2020	Bromberg, Brian	1.7	Create diligence request list for Debtors.
7	11/30/2020	Bromberg, Brian	0.5	Participate in discussion re: OxyContin forecast with internal team.
7	11/30/2020	Bromberg, Brian	1.3	Participate in meeting with Debtors re: PHI status.
7	11/30/2020	Diaz, Matthew	1.3	Participate on call with Debtors re: the PHI program.
7	11/30/2020	Suric, Emil	0.6	Perform research on ANDA timelines.
7	11/30/2020	Kim, Ye Darm	1.0	Review dataroom documents to identify decline curve forecasts.
7	12/1/2020	Bromberg, Brian	0.7	Discuss domestic sale values with Houlihan team.
7	12/2/2020	Bromberg, Brian	1.5	Participate in weekly Committee call re: Sackler negotiations and sale alternatives.
7	12/4/2020	Bromberg, Brian	0.6	Participate in call with counsel re: domestic entities diligence workplan.
7	12/4/2020	Bromberg, Brian	0.5	Prepare for call with counsel re: domestic entities diligence.
7	12/8/2020	Bromberg, Brian	2.8	Review bridge analysis of the latest domestic business plan.
7	12/8/2020	Diaz, Matthew	0.7	Review the updated business plan forecast reconciliation analysis.
7	12/9/2020	Bromberg, Brian	1.1	Review domestic business plan bridge analysis.
7	12/9/2020	Bromberg, Brian	2.0	Review Houlihan cash flow analysis on domestic plan.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
7	12/11/2020	Diaz, Matthew	0.8	Review the reconciliation of the segment business plan projections.
7	12/11/2020	Diaz, Matthew	0.5	Review the updated regulatory analysis.
7	12/13/2020	Diaz, Matthew	0.6	Review the updated segment cash flows of the business plan.
7	12/15/2020	Bromberg, Brian	0.5	Discuss OxyContin projections with internal team.
7	12/15/2020	Kim, Ye Darm	0.7	Participate in call with FTI pharma operations expert re: LOE assumptions.
7	12/15/2020	Suric, Emil	0.5	Participate on call re: LOE assumptions on OxyContin.
7	12/15/2020	Bromberg, Brian	1.5	Review cash flow public entity slides.
7	12/15/2020	Diaz, Matthew	0.6	Review the Oxy patent portfolio and related next steps.
7	12/16/2020	Bromberg, Brian	2.3	Create bridge to latest business plan scenario cash flows.
7	12/16/2020	Diaz, Matthew	0.8	Participate in a call with the Debtor to discuss the updated business plan.
7	12/16/2020	Kim, Ye Darm	0.9	Participate in call re: takeaways from call with PJT on the 2021 business plan.
7	12/16/2020	Bromberg, Brian	1.7	Participate in call with Committee re: plan B considerations.
7	12/16/2020	Kim, Ye Darm	0.5	Participate in call with PJT re: 2021 domestic business plan.
7	12/16/2020	Bromberg, Brian	1.2	Participate in calls with Debtors re: 2021 budget overview.
7	12/16/2020	Kurtz, Emma	0.5	Participate on call with Debtors' advisors to discuss the domestic 2021 business plan.
7	12/18/2020	Suric, Emil	1.5	Discuss with management on OxyContin LOE assumptions.
7	12/18/2020	Diaz, Matthew	0.6	Participate in a call with Houlihan re the revised business plan.
7	12/18/2020	Diaz, Matthew	1.1	Participate in a call with the Debtors to discuss the OxyContin patent calendar.
7	12/18/2020	Bromberg, Brian	1.1	Participate in call with Debtors re: LOE assumptions.
7	12/18/2020	Bromberg, Brian	0.4	Prepare core business only cash flow scenario.
7	12/18/2020	Diaz, Matthew	0.7	Review of the OxyContin patent calendar and related next steps coming out of the call with the Debtors.
7	12/18/2020	Bromberg, Brian	0.9	Review OxyContin patent LOE assumptions.
7	12/21/2020	Kurtz, Emma	1.1	Attend call with Houlihan to discuss the latest domestic business plan and updates to the analysis for the Committee.
7	12/21/2020	Kurtz, Emma	1.1	Attend call with team to discuss revised domestic business plan and changes from prior business plan.
7	12/21/2020	Diaz, Matthew	3.1	Detail review of the updated Purdue business plan.
7	12/21/2020	Bromberg, Brian	1.0	Discuss new business plan with Houlihan team.
7	12/21/2020	Bromberg, Brian	1.3	Discuss new domestic business plan with team.
7	12/21/2020	Diaz, Matthew	1.1	Participate in a call with Houlihan re: the updated Purdue business plan.
7	12/21/2020	Kim, Ye Darm	0.7	Participate in call re: updated domestic business plan diligence.
7	12/21/2020	Kim, Ye Darm	1.1	Participate in call with HL re: updated domestic business plan.
7	12/21/2020	Kurtz, Emma	2.1	Prepare analysis of historical performance vs projected performance of Rhodes, Adhansia and Avrio segments to evaluate business plan projections.
7	12/21/2020	Kim, Ye Darm	2.2	Prepare analysis of Rhodes cash flow bridges re: updated December business plan.
7	12/21/2020	Kim, Ye Darm	2.8	Prepare bridging analysis to December business plan cash flows.
7	12/21/2020	Kurtz, Emma	1.1	Prepare revisions to update slides for the Committee re: domestic business and distributable value per internal comments.
7	12/21/2020	Kurtz, Emma	0.8	Prepare updates to net distributable value slides for the Committee to incorporate revised business plan analysis.
7	12/21/2020	Kim, Ye Darm	0.9	Process revisions to the December business plan bridging analysis.
7	12/21/2020	Bromberg, Brian	4.3	Review new domestic business plan model.
7	12/22/2020	Bromberg, Brian	2.5	Prepare bridges for updated business plan and scenarios.
7	12/22/2020	Bromberg, Brian	2.6	Review new core only business scenario based on new business plan.
7	12/22/2020	Bromberg, Brian	3.7	Update for new scenarios in presentation.
7	12/23/2020	Bromberg, Brian	0.7	Finalize and send core only business scenario forecasts to Debtors for review.
7	12/23/2020	Bromberg, Brian	2.0	Participate in call with Debtors on public health initiatives.
7	12/23/2020	Bromberg, Brian	1.8	Review updated bridge analysis from prior business plan.
7	12/28/2020	Kim, Ye Darm	0.7	Continue processing revisions to slides re: contingencies per Dec business plan.
7	12/28/2020	Bromberg, Brian	1.2	Discuss distributable value scenarios with team.
7	12/28/2020	Bromberg, Brian	0.8	Discuss domestic plan updates with team.
7	12/28/2020	Bromberg, Brian	1.3	Discuss scenarios presentation with Houlihan team.
7	12/28/2020	Kim, Ye Darm	0.6	Participate in discussion re: updated contingencies per Dec business plan.
7	12/28/2020	Kim, Ye Darm	0.4	Process revisions to contingencies slides re: Dec business plan.
7	12/28/2020	Kim, Ye Darm	2.6	Process revisions to slides re: upsides for Dec business plan.
7	12/29/2020	Bromberg, Brian	1.0	Review revised domestic business plan slides for presentation.
7	12/31/2020	Bromberg, Brian	1.9	Discuss business plan downside and upside scenarios.
7	1/1/2021	Bromberg, Brian	3.3	Iterate versions of scenario slides with Houlihan team.
7	1/4/2021	Bromberg, Brian	0.7	Discuss scenarios presentation with Houlihan team.
7	1/4/2021	Bromberg, Brian	0.8	Discuss status of domestic business plan diligence workstreams with internal team.
7	1/4/2021	Suric, Emil	0.8	Participate in Internal discussion with team to discuss updated/refreshed forecasts and sensitivities on OxyContin for revised business plan.
7	1/4/2021	Kim, Ye Darm	0.5	Participate on call re: OxyContin forecast assumptions.
7	1/4/2021	Bromberg, Brian	3.3	Perform research re: managed care assumptions.
7	1/4/2021	Bromberg, Brian	0.9	Prepare for call on domestic diligence workstream status.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
7	1/4/2021	Bromberg, Brian	1.5	Research and respond to questions from Debtors re: business plan diligence.
7	1/4/2021	Bromberg, Brian	0.6	Review core scenarios with Debtor advisors.
7	1/4/2021	Suric, Emil	2.1	Review information provided by management and the latest analysis of business plan.
7	1/4/2021	Bromberg, Brian	2.3	Review latest OxyContin forecasting assumptions.
7	1/4/2021	Bromberg, Brian	2.2	Review scenarios presentation in response to UCC questions.
7	1/4/2021	Kim, Ye Darm	0.4	Review slides re: downside case from Debtors.
7	1/4/2021	Diaz, Matthew	1.1	Review the latest domestic December business plan.
7	1/4/2021	Diaz, Matthew	0.8	Review the updated OxyContin downside case.
7	1/4/2021	Bromberg, Brian	2.8	Summarize notes on managed care assumptions.
7	1/5/2021	Suric, Emil	2.9	Continue refresh of OxyContin sensitivities and independent forecasts for base case.
7	1/5/2021	Diaz, Matthew	1.1	Detail review of the OxyContin forecast and related sensitivities.
7	1/5/2021	Bromberg, Brian	0.9	Discuss OxyContin forecast with internal team.
7	1/5/2021	Bromberg, Brian	1.1	Discuss OxyContin forecast with valuation team.
7	1/5/2021	Bromberg, Brian	0.8	Finalize draft domestic scenarios presentation.
7	1/5/2021	Kurtz, Emma	1.1	Participate in call to discuss OxyContin downside forecast.
7	1/5/2021	Bromberg, Brian	0.8	Participate in call with UCC advisors.
7	1/5/2021	Bromberg, Brian	0.5	Participate in pre call with Houlihan team re: scenarios presentation.
7	1/5/2021	Bromberg, Brian	2.3	Prepare for call with UCC advisors on scenarios.
7	1/5/2021	Suric, Emil	1.0	Prepare updated base and low case scenarios along with a presentation of a bridge to the prior sensitivity analysis.
7	1/5/2021	Suric, Emil	1.2	Refresh OxyContin sensitivities and independent forecasts for illustrative downside case.
7	1/5/2021	Bromberg, Brian	3.2	Review downside cases for business plan diligence.
7	1/6/2021	Kim, Ye Darm	1.1	Participate in AHC meeting re: mediation.
7	1/6/2021	Bromberg, Brian	0.8	Review contingencies backup and assumptions for scenarios presentation.
7	1/6/2021	Kim, Ye Darm	0.4	Review support documents for contingency estimates.
7	1/7/2021	Bromberg, Brian	1.0	Discuss contingencies assumptions with internal team.
7	1/7/2021	Bromberg, Brian	1.3	Discuss OxyContin forecast assumptions with team.
7	1/8/2021	Bromberg, Brian	1.3	Participate in OxyContin forecast call with Debtors.
7	1/8/2021	Bromberg, Brian	0.7	Prepare for call on OxyContin forecast diligence.
7	1/8/2021	Bromberg, Brian	1.6	Prepare summary of OxyContin forecast diligence call for internal use.
7	1/8/2021	Bromberg, Brian	0.5	Review domestic business scenario sensitivities.
7	1/8/2021	Diaz, Matthew	0.4	Review notes and related next steps coming out of OxyContin forecast diligence call.
7	1/9/2021	Bromberg, Brian	0.5	Confirm PEO sharing issues with Debtors re: domestic business plan.
7	1/11/2021	Bromberg, Brian	0.7	Continue review of Rhodes segment level financial information.
7	1/11/2021	Suric, Emil	1.5	Prepare downside case sensitivity analysis and review of call notes.
7	1/11/2021	Bromberg, Brian	1.1	Prepare OxyContin call agenda.
7	1/11/2021	Suric, Emil	1.1	Review business plan and prepare agenda for discussion with management.
7	1/11/2021	Diaz, Matthew	0.8	Review of OxyContin forecast due diligence and related question list for the call with the Debtors.
7	1/11/2021	Bromberg, Brian	1.2	Review OxyContin forecast diligence items with internal team.
7	1/11/2021	Bromberg, Brian	1.0	Review Rhodes segment level financial information.
7	1/12/2021	Diaz, Matthew	1.1	Participate in a call with Purdue to discuss the OxyContin forecast.
7	1/12/2021	Kim, Ye Darm	0.7	Participate in call re: OxyContin forecast assumptions analysis.
7	1/12/2021	Bromberg, Brian	1.1	Participate in call with Debtors on OxyContin and Adhansia.
7	1/12/2021	Kim, Ye Darm	1.1	Participate in call with Debtors to discuss OxyContin / Adhansia forecast assumptions with the commercial team.
7	1/12/2021	Suric, Emil	1.2	Participate in due diligence call with Purdue management.
7	1/12/2021	Suric, Emil	0.5	Participate in regroup to discuss commentary provided by Management on due diligence call.
7	1/12/2021	Suric, Emil	0.4	Prepare for call with Purdue Management to discuss updated business plan assumptions.
7	1/12/2021	Suric, Emil	0.8	Process updates to base case and downside case based on Management commentary provided in due diligence call.
7	1/12/2021	Bromberg, Brian	1.7	Review analysis of license payments.
7	1/12/2021	Diaz, Matthew	1.1	Review the updated OxyContin forecast sensitivity.
7	1/13/2021	Kim, Ye Darm	0.5	Recalculate pipeline operating profit assumptions in new business plan.
7	1/13/2021	Kim, Ye Darm	0.9	Review pipeline operating profit assumptions.
7	1/13/2021	Bromberg, Brian	1.0	Review royalty model.
7	1/13/2021	Suric, Emil	0.5	Update base case and downside case scenario for updated prescription data provided on OxyContin.
7	1/14/2021	Suric, Emil	0.5	Conduct further sensitivity on base case scenario regression.
7	1/14/2021	Suric, Emil	2.0	Model an upside case scenario based on longer assumed patent life.
7	1/14/2021	Suric, Emil	0.6	Review new data provided by Management detailing forecasts.
7	1/14/2021	Bromberg, Brian	0.5	Review newly uploaded OxyContin information.
7	1/14/2021	Kim, Ye Darm	2.4	Review updated forecast supporting schedules provided in the dataroom.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
7	1/14/2021	Kim, Ye Darm	0.7	Review updated FTI OxyContin forecast analysis.
7	1/14/2021	Suric, Emil	2.5	Update base case and downside case scenarios based on detailed forecasts provided by Management.
7	1/15/2021	Kim, Ye Darm	1.3	Compare forecasts in revised bid schedules with Debtors' assumptions.
7	1/15/2021	Kim, Ye Darm	3.2	Compare operating expense and sales assumptions in revised bid forecasts relative to Debtors' assumptions.
7	1/15/2021	Kim, Ye Darm	1.8	Compare product forecasts in revised bid schedules to the latest business plan.
7	1/15/2021	Bromberg, Brian	2.3	Edit bridge from bid proposal forecasts to business plan.
7	1/15/2021	Kim, Ye Darm	0.4	Review pipeline cash flow assumptions from Debtors.
7	1/15/2021	Diaz, Matthew	1.2	Review the December business plan model.
7	1/18/2021	Bromberg, Brian	1.2	Review latest Debtor business plan forecasts.
7	1/19/2021	Bromberg, Brian	1.0	Continue to finalize draft of domestic business scenarios presentation to send to UCC.
7	1/19/2021	Bromberg, Brian	0.9	Discuss domestic business scenarios with Houlihan.
7	1/19/2021	Bromberg, Brian	1.0	Finalize draft of domestic business scenarios presentation to send to UCC.
7	1/19/2021	Bromberg, Brian	2.7	Provide comments on domestic business scenario slides.
7	1/19/2021	Bromberg, Brian	1.7	Review bridge files for domestic business scenarios.
7	1/20/2021	Bromberg, Brian	1.0	Discuss domestic business plan diligence with Houlihan.
7	1/20/2021	Bromberg, Brian	0.7	Discuss restricted cash with Houlihan and Debtors.
7	1/20/2021	Kim, Ye Darm	1.8	Prepare bridge analysis to Debtor core case.
7	1/20/2021	Kim, Ye Darm	1.2	Review PJT presentation re: segment level cash flows and compare to December business plan.
7	1/20/2021	Diaz, Matthew	1.4	Review the proposed opex budgeted amounts and projected savings.
7	1/20/2021	Bromberg, Brian	1.4	Review updates to the domestic business scenarios presentation.
7	1/20/2021	Kim, Ye Darm	0.7	Review YTD cost files provided by the Debtors.
7	1/21/2021	Bromberg, Brian	2.2	Create updated core case scenario cash flow.
7	1/21/2021	Bromberg, Brian	1.7	Discuss and edit plan B scenario presentation.
7	1/21/2021	Kurtz, Emma	0.3	Discuss internally re: latest business plan projections and operating expenses benchmarking to comparable companies.
7	1/21/2021	Bromberg, Brian	0.7	Discuss operating expense benchmarking with team.
7	1/21/2021	Bromberg, Brian	0.7	Discuss scenarios presentation with UCC advisors.
7	1/21/2021	Kim, Ye Darm	0.4	Participate on call re: OpEx analysis.
7	1/21/2021	Kim, Ye Darm	0.2	Participate on call re: OpEx analysis.
7	1/21/2021	Kim, Ye Darm	1.6	Prepare comparative OpEx analysis.
7	1/21/2021	Bromberg, Brian	2.8	Review bidder licensing scenario model.
7	1/21/2021	Kim, Ye Darm	0.5	Review OpEx analysis comp set.
7	1/21/2021	Bromberg, Brian	1.2	Review scenarios presentation in response to UCC edits.
7	1/22/2021	Bromberg, Brian	1.0	Create update core case scenario cash flow.
7	1/22/2021	Bromberg, Brian	1.0	Discuss Plan B scenarios with counsel.
7	1/22/2021	Bromberg, Brian	1.1	Discuss update to scenarios presentation with Houlihan.
7	1/22/2021	Bromberg, Brian	1.6	Participate in call with Committee on domestic business scenarios analysis.
7	1/22/2021	Bromberg, Brian	0.8	Participate in call with UCC re: domestic business scenarios joint presentation.
7	1/22/2021	Bromberg, Brian	1.3	Prepare forecasts re: liquidity scenarios.
7	1/22/2021	Kim, Ye Darm	1.6	Process revision to OpEx comp analysis.
7	1/22/2021	Kim, Ye Darm	0.3	Process revisions to the OxyContin upside/downside impact slides.
7	1/22/2021	Kim, Ye Darm	1.1	Process revisions to upside and downside business plan considerations.
7	1/22/2021	Bromberg, Brian	2.1	Review domestic business plan model to compare with scenarios.
7	1/22/2021	Bromberg, Brian	1.2	Review updated slides for scenarios presentation.
7	1/22/2021	Kim, Ye Darm	0.3	Update the OxyContin upside/downside impact slide.
7	1/23/2021	Bromberg, Brian	1.2	Create new slides for scenarios presentation.
7	1/23/2021	Bromberg, Brian	1.8	Discuss updated scenarios model and presentation with team.
7	1/23/2021	Bromberg, Brian	2.3	Review Plan B presentation and provide comments.
7	1/23/2021	Bromberg, Brian	3.7	Review scenarios model and provide comments to Houlihan.
7	1/23/2021	Kim, Ye Darm	0.4	Update slide re: open items on Debtors' forecasts.
7	1/24/2021	Bromberg, Brian	2.5	Comment on and process revisions new slides re: domestic business scenarios.
7	1/24/2021	Bromberg, Brian	1.3	Prepare bridge of prior and updated cash balance assumptions.
7	1/24/2021	Bromberg, Brian	2.7	Review and process revisions to new waterfall slides.
7	1/24/2021	Bromberg, Brian	3.0	Review new version of scenarios model and provide comments.
7	1/25/2021	Bromberg, Brian	0.7	Discuss domestic scenarios presentation with UCC.
7	1/25/2021	Bromberg, Brian	1.1	Participate in call on domestic scenarios with UCC.
7	1/25/2021	Bromberg, Brian	0.7	Participate in pre call on domestic business scenarios.
7	1/25/2021	Kim, Ye Darm	1.2	Prepare analysis re: OpCo cash flows bridge with Debtors' figures.
7	1/25/2021	Bromberg, Brian	1.3	Review domestic business historical working capital movements.
7	1/25/2021	Diaz, Matthew	1.2	Review the OpCo analysis and projected savings assumptions.
7	1/26/2021	Suric, Emil	0.8	Conduct market research on inhalers.
7	1/26/2021	Bromberg, Brian	1.3	Finalize and send Excel to Debtor advisors re: new scenario.
7	1/26/2021	Kim, Ye Darm	1.4	Link bridge analysis to Debtors' source files.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
7	1/26/2021	Kim, Ye Darm	0.4	Participate in call re: clean bridge to Debtor figures.
7	1/26/2021	Kim, Ye Darm	0.9	Prepare presentation slide re: opex comparison analysis.
7	1/26/2021	Bromberg, Brian	0.8	Review historical working capital movements.
7	1/26/2021	Bromberg, Brian	1.5	Review Houlihan cash flow model.
7	1/26/2021	Kim, Ye Darm	0.6	Update bridge analysis for updated opex comparison analysis.
7	1/26/2021	Kim, Ye Darm	1.3	Update bridge analysis to Debtor's core only figures.
7	1/26/2021	Bromberg, Brian	0.8	Work on comparable operating expense slide.
7	1/27/2021	Bromberg, Brian	1.8	Continue to bridge segment cash flow numbers from prior analysis.
7	1/27/2021	Bromberg, Brian	0.8	Discuss new domestic business scenario with Debtor advisors.
7	1/27/2021	Kim, Ye Darm	0.4	Process updates to OpEx comparison slide for updated figures.
7	1/27/2021	Bromberg, Brian	3.5	Review bridge analysis re: cash flow numbers from prior analysis.
7	1/27/2021	Kim, Ye Darm	0.8	Review Debtors' prior opioid only case for assumptions re: bridging analysis.
7	1/28/2021	Bromberg, Brian	0.6	Discuss Purdue liquidity with internal healthcare team.
7	1/29/2021	Bromberg, Brian	0.9	Review updated Houlihan model on cash flow scenarios.
7 Total			410.5	
8	11/6/2020	Diaz, Matthew	0.6	Review of the Houlihan analysis re: potential buyer bid.
8 Total			0.6	
9	10/9/2020	Bromberg, Brian	0.5	Discuss the latest KEIP proposal with counsel.
9	10/9/2020	Diaz, Matthew	0.4	Participate in a call with counsel to discuss the insider compensation plans.
9	10/9/2020	Bromberg, Brian	1.0	Review KEIP and KERP support files to evaluate the updated proposal.
9	10/9/2020	Diaz, Matthew	0.7	Review the latest insider compensation plans and UCC proposal.
9	10/9/2020	Bromberg, Brian	0.9	Review the UCC's latest KEIP proposal.
9	10/9/2020	Kim, Ye Darm	1.6	Review UCC KEIP settlement proposal and compare with historical payout.
9	10/10/2020	Diaz, Matthew	0.6	Review the updated KEIP proposal.
9	10/11/2020	Diaz, Matthew	0.7	Review the latest proposed employee compensation and KEIP plans.
9	10/12/2020	Diaz, Matthew	0.9	Review the updated UCC KEIP proposal.
9	10/13/2020	Diaz, Matthew	0.6	Continue review of the KEIP proposal.
9	10/15/2020	Diaz, Matthew	0.9	Participate in a call with the UCC, company and NCSG to discuss certain KEIP and KERP participants.
9	10/15/2020	Bromberg, Brian	1.2	Participate in call with Debtor advisors re: KERP identified individuals.
9	10/16/2020	Diaz, Matthew	0.3	Participate in a call with Alix to discuss the KEIP proposal.
9	10/16/2020	Diaz, Matthew	0.8	Review the updated KEIP proposal.
9	10/18/2020	Kim, Ye Darm	0.9	Prepare analysis re: Debtors' updated KEIP proposal to prior compensation figures.
9	10/18/2020	Diaz, Matthew	0.4	Review analysis re: historical senior employee compensation comparables.
9	10/18/2020	Bromberg, Brian	0.8	Review the Debtors' counterproposal offer on KEIP figures.
9	10/18/2020	Kim, Ye Darm	0.6	Review the Debtors' KEIP counterproposal figures.
9	10/18/2020	Diaz, Matthew	0.5	Review the updated executive compensation proposal.
9	10/21/2020	Diaz, Matthew	0.4	Review the Debtors' updated KEIP proposal.
9	10/31/2020	Bromberg, Brian	1.0	Participate in call on KEIP with UCC and NCSG and prepare summary for distribution to internal team.
9	11/2/2020	Kim, Ye Darm	1.1	Analyze proposed UCC compensation adjustment analysis figures to prior compensation.
9	11/2/2020	Bromberg, Brian	1.3	Continue to review KEIP proposals analysis by UCC.
9	11/2/2020	Kim, Ye Darm	0.8	Prepare responses re: questions on UCC's proposed CEO compensation.
9	11/2/2020	Bromberg, Brian	0.7	Review KEIP proposals by UCC.
9	11/2/2020	Kim, Ye Darm	0.5	Review UCC proposed CEO Compensation reductions.
9	11/3/2020	Bromberg, Brian	0.6	Review KEIP proposals and correspond with Counsel.
9	11/3/2020	Diaz, Matthew	0.5	Review proposed Landau compensation adjustments by the UCC.
9 Total			21.2	
10	10/1/2020	Bromberg, Brian	0.7	Participate in tax call re: structuring considerations.
10	10/12/2020	Bromberg, Brian	0.7	Discuss NCSG tax questions with counsel.
10	10/13/2020	Joffe, Steven	1.0	Participate in call re: IAC tax considerations.
10	10/13/2020	Joffe, Steven	1.4	Participate in call with Debtors re: tax considerations.
10	10/15/2020	Bromberg, Brian	0.5	Correspond with tax counsel on IACs tax considerations.
10	10/15/2020	Joffe, Steven	0.5	Review of post-emergence structuring presentation for potential tax issues.
10	10/21/2020	Joffe, Steven	0.5	Participate in call re: domestic business tax structuring considerations.
10	10/21/2020	Kim, Ye Darm	0.5	Review tax settlement structure presentation from BR.
10	10/27/2020	Joffe, Steven	1.0	Participate in call with committee regarding Purdue v. Sacklers tax considerations.
10	10/28/2020	Joffe, Steven	1.1	Participate in call with AHC re: tax considerations.
10	10/30/2020	Bromberg, Brian	0.3	Discuss tax diligence questions with team.
10	10/30/2020	Diaz, Matthew	0.9	Participate in a call with the AHC's tax advisors to discuss tax implications of the proposed go forward structure.
10	10/30/2020	Bromberg, Brian	0.8	Participate in call on tax strategy and considerations.
10	10/30/2020	Kim, Ye Darm	0.4	Participate in call re: potential operating tax impact analysis.
10	10/30/2020	Joffe, Steven	0.5	Participate in call with counsel re: tax calculations from operations.
10	10/30/2020	Bromberg, Brian	0.9	Review current tax considerations diligence question list.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
10	10/30/2020	Bromberg, Brian	0.5	Review historical tax analyses provided to counsel.
10	11/5/2020	Bromberg, Brian	0.5	Participate in call with Debtor Advisors re: IAC tax considerations.
10	11/5/2020	Joffe, Steven	1.0	Participate in call with KPMG and Counsel regarding IAC tax considerations.
10	11/5/2020	Bromberg, Brian	1.0	Participate in IAC tax call with KPMG and Counsel.
10	11/9/2020	Bromberg, Brian	0.8	Coordinate tax discussions with Debtors.
10	11/12/2020	Bromberg, Brian	0.9	Participate in call AHC tax counsel re: IAC tax considerations.
10	11/12/2020	Joffe, Steven	2.8	Participate in call with AHC and Debtors re: tax structuring considerations.
10	11/12/2020	Joffe, Steven	0.7	Participate in meeting with AHC re: tax considerations.
10	11/12/2020	Diaz, Matthew	0.8	Participate in tax call with the AHC tax advisors to discuss go forward and IAC tax issues.
10	11/13/2020	Diaz, Matthew	0.5	Participate in a tax call with the Debtors to discuss go forward tax implications.
10	11/13/2020	Kim, Ye Darm	1.0	Participate in call re: domestic business tax considerations.
10	11/13/2020	Bromberg, Brian	0.8	Participate in call re: domestic tax considerations call.
10	11/13/2020	Bromberg, Brian	1.1	Participate in call with Counsel re: IAC tax considerations call.
10	11/13/2020	Joffe, Steven	1.5	Participate in call with counsel re: tax structuring considerations.
10	11/13/2020	Bromberg, Brian	0.5	Review prior presentations to prepare for tax calls.
10	11/19/2020	Joffe, Steven	0.9	Participate in discussion with KPMG regarding IAC tax considerations.
10	11/19/2020	Bromberg, Brian	1.0	Participate in tax call with KPMG re: IAC tax considerations.
10	11/23/2020	Joffe, Steven	0.2	Review latest term sheets for tax implications.
10	11/29/2020	Diaz, Matthew	1.8	Review KPMG's updated tax analysis.
10	11/30/2020	Bromberg, Brian	0.8	Participate in meeting re: KPMG tax analysis.
10	11/30/2020	Joffe, Steven	0.9	Participate in meeting re: KPMG tax analysis.
10	11/30/2020	Diaz, Matthew	1.3	Review KPMG's updated tax analysis.
10	11/30/2020	Joffe, Steven	3.0	Review KPMG's updated tax analysis.
10	12/1/2020	Joffe, Steven	1.5	Participate in call with IAC tax advisors.
10	12/1/2020	Bromberg, Brian	1.1	Participate in call with IAC tax advisors.
10	12/1/2020	Bromberg, Brian	0.7	Participate in pre call re: IAC tax.
10	12/2/2020	Diaz, Matthew	0.8	Review the updated IAC tax analysis.
10	12/3/2020	Bromberg, Brian	0.8	Continue to discuss transfer pricing tax issue with team.
10	12/3/2020	Bromberg, Brian	1.0	Discuss transfer pricing tax issues with team.
10	12/3/2020	Bromberg, Brian	1.0	Discuss transfer pricing tax summary with team.
10	12/3/2020	Bromberg, Brian	1.2	Prepare transfer pricing tax summary.
10	12/3/2020	Bromberg, Brian	0.8	Process revisions to transfer pricing and tax impact slides.
10	12/3/2020	Joffe, Steven	0.8	Review and discuss transfer pricing presentation and tax impact.
10	12/3/2020	Diaz, Matthew	0.6	Review draft slide summarizing KPMG's tax analysis.
10	12/3/2020	Diaz, Matthew	1.5	Review KPMG's updated IAC tax analysis.
10	12/4/2020	Joffe, Steven	0.8	Participate in discussion with counsel regarding tax analysis presentation.
10	12/4/2020	Bromberg, Brian	0.6	Update tax impact summary slides for internal comments.
10	12/7/2020	Bromberg, Brian	0.5	Continue processing revisions to tax impact summary slides for internal comments.
10	12/8/2020	Bromberg, Brian	0.4	Discuss tax impact summary slides with Debtor and UCC advisors.
10	12/9/2020	Joffe, Steven	2.3	Review tax impact summary slides and discuss with AHC.
10	12/10/2020	Bromberg, Brian	0.9	Create draft tax diligence question list for KPMG.
10	12/10/2020	Bromberg, Brian	0.4	Discuss tax impact summary slides with internal team.
10	12/11/2020	Diaz, Matthew	0.6	Review the updated KPMG tax analysis.
10	12/15/2020	Bromberg, Brian	1.1	Continue drafting tax diligence questions for KPMG.
10	12/30/2020	Bromberg, Brian	0.5	Participate in call with Huron re: tax analysis.
10	1/4/2021	Bromberg, Brian	0.7	Review updated IAC tax questions.
10	1/6/2021	Joffe, Steven	0.5	Participate in AHC professionals call re: tax issues.
10	1/11/2021	Bromberg, Brian	1.0	Participate in a call with KPMG and the other key case stakeholders.
10	1/11/2021	Diaz, Matthew	1.0	Participate in a call with KPMG and the other key case stakeholders.
10	1/11/2021	Diaz, Matthew	0.4	Participate in a call with the AHC professionals to discuss IAC tax due diligence.
10	1/11/2021	Diaz, Matthew	0.3	Participate in a tax call with Province to discuss IAC tax implications.
10	1/11/2021	Diaz, Matthew	0.6	Preparation for the IAC tax call with KPMG and other key case stakeholders.
10	1/11/2021	Bromberg, Brian	0.5	Prepare for call with KPMG and the other key case stakeholders.
10	1/13/2021	Joffe, Steven	0.5	Participate in AHC call re: tax issues.
10	1/19/2021	Joffe, Steven	0.3	Participate in AHC call re: IAC tax issues.
10	1/22/2021	Joffe, Steven	1.1	Participate in AHC professionals call re: tax issues.
10	1/27/2021	Joffe, Steven	1.0	Participate in AHC professionals call re: tax issues.
10 Total			63.8	
11	11/18/2020	Diaz, Matthew	0.5	Review detailed correspondence on the DOJ court hearing.
11 Total			0.5	
13	11/12/2020	Diaz, Matthew	0.6	Review objections/statements re: the DOJ settlement.
13	11/12/2020	Diaz, Matthew	0.6	Review the UCC statement on the DOJ motion.
13	11/13/2020	Diaz, Matthew	0.3	Review the DOJ letter in response to various objections.
13	12/2/2020	Diaz, Matthew	0.5	Review the exclusivity extension motion.
13 Total			2.0	

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	10/1/2020	Bromberg, Brian	2.1	Complete preparation of draft mediation preparation materials.
16	10/1/2020	Kim, Ye Darm	0.6	Continue processing revisions for draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	2.1	Continue to prepare draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Bromberg, Brian	3.1	Create mediation preparation materials for the committee.
16	10/1/2020	Kim, Ye Darm	0.4	Participate in call re: presentation for Mediation Phase 2 prep.
16	10/1/2020	Bromberg, Brian	0.9	Participate in discussion re: draft mediation preparation materials.
16	10/1/2020	Kim, Ye Darm	0.6	Participate in internal call for workplan on the presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	2.2	Prepare draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	2.8	Process revisions and updated draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	1.9	Process revisions to draft slides for presentation re: Mediation Phase 2 prep.
16	10/1/2020	Kim, Ye Darm	0.8	Review post tax values of assets re: Mediation Phase 2 preparation deck.
16	10/1/2020	Bromberg, Brian	3.2	Review the latest mediation update presentation to the AHC.
16	10/1/2020	Kim, Ye Darm	0.7	Update draft slides for presentation re: Mediation Phase 2 prep.
16	10/2/2020	Kim, Ye Darm	0.5	Participate in discussion re: Mediation Phase 2 Report.
16	10/2/2020	Bromberg, Brian	1.0	Participate in discussion with team re: revisions to the latest mediation presentation.
16	10/2/2020	Bromberg, Brian	1.9	Perform QC on Mediation Phase 2 presentation.
16	10/2/2020	Kim, Ye Darm	1.2	Prepare updated value scenarios for latest OxyContin forecast figures.
16	10/2/2020	Kim, Ye Darm	1.4	Process additional revisions to the draft slides for presentation re: Mediation Phase 2 prep.
16	10/2/2020	Bromberg, Brian	2.1	Process revisions on the latest mediation presentation.
16	10/2/2020	Kim, Ye Darm	2.3	Process revisions to the draft slides for presentation re: Mediation Phase 2 prep.
16	10/2/2020	Diaz, Matthew	2.6	Review and edit presentation to the AHC subcommittee on the Sackler mediation.
16	10/4/2020	Diaz, Matthew	1.4	Review the updated presentation on the Sackler mediation.
16	10/5/2020	Diaz, Matthew	1.1	Participate in a call with the AHC professionals to discuss the Sackler mediation report.
16	10/5/2020	Kim, Ye Darm	1.0	Participate in call with Counsel re: Mediation Phase 2 overview presentation.
16	10/5/2020	Bromberg, Brian	1.4	Participate in call with Counsel re: mediation preparation.
16	10/5/2020	Kim, Ye Darm	2.4	Process updates to Mediation Phase 2 overview presentation.
16	10/5/2020	Simms, Steven	0.6	Review draft presentation on Sackler asset diligence and current status of mediation.
16	10/5/2020	Bromberg, Brian	1.1	Review PEO information in mediation presentation slides.
16	10/5/2020	Diaz, Matthew	1.9	Review the updated draft of the Sackler mediation report.
16	10/5/2020	Bromberg, Brian	1.2	Review updated revisions on mediation prep slides.
16	10/6/2020	Bromberg, Brian	1.3	Participate in call with counsel re: mediation preparation and draft presentation.
16	10/6/2020	Kim, Ye Darm	1.6	Process updates to Mediation Phase 2 overview presentation.
16	10/6/2020	Bromberg, Brian	2.0	Review and provide revisions to the mediation presentation.
16	10/6/2020	Simms, Steven	0.9	Review draft presentation on mediation considerations.
16	10/6/2020	Diaz, Matthew	1.3	Review the updated report to the committee on the Sackler mediation.
16	10/7/2020	Kim, Ye Darm	1.7	Participate in call re: Purdue Mediation Phase 2 overview presentation.
16	10/7/2020	Bromberg, Brian	1.0	Participate in call re: status of draft mediation presentation.
16	10/7/2020	Diaz, Matthew	1.7	Participate in meeting with the AHC subcommittee to present report on topics related to the Sackler mediation.
16	10/7/2020	Diaz, Matthew	0.5	Preparation for the meeting with the AHC subcommittee on the Sackler mediation topics.
16	10/8/2020	Kim, Ye Darm	0.9	Process revisions to Mediation Phase 2 overview presentation.
16	10/8/2020	Bromberg, Brian	0.7	Review revisions incorporated into the latest draft mediation presentation.
16	10/9/2020	Bromberg, Brian	0.7	Discuss follow-up information re: mediation considerations for the NCSG.
16	10/9/2020	Kim, Ye Darm	2.0	Participate in call with AHC/NCSG re: Mediation Phase 2.
16	10/9/2020	Bromberg, Brian	0.5	Participate in call with Debtors re: sale process.
16	10/9/2020	Bromberg, Brian	2.3	Participate in call with NCSG re: mediation considerations.
16	10/9/2020	Diaz, Matthew	0.5	Participate in call with the UCC to discuss proposed inbound buyer interest.
16	10/10/2020	Bromberg, Brian	1.2	Discuss and compile follow-up information for NCSG re: mediation considerations.
16	10/11/2020	Bromberg, Brian	1.8	Participate in discussion re: follow up information for NCSG on mediation considerations.
16	10/11/2020	Diaz, Matthew	1.1	Review follow-ups from call with the NCSG re: mediation.
16	10/12/2020	Kim, Ye Darm	0.7	Participate in call re: Mediation Phase 2 overview follow ups.
16	10/12/2020	Bromberg, Brian	1.1	Participate in call with counsel and bankers re: Mediation Phase 2.
16	10/12/2020	Bromberg, Brian	1.1	Participate in call with internal team re: Mediation Phase 2.
16	10/12/2020	Kim, Ye Darm	0.6	Participate in internal call re: Mediation Phase 2 presentation follow ups.
16	10/12/2020	Diaz, Matthew	0.9	Review the updated presentation to the AHC on the Sackler mediation.
16	10/13/2020	Diaz, Matthew	1.6	Participate in a call with the Debtors to discuss their proposed post emergence structure.
16	10/13/2020	Kim, Ye Darm	1.1	Participate in call re: Mediation Phase 2 Presentation.
16	10/13/2020	Kim, Ye Darm	1.5	Participate in call with Debtors re: go-forward business considerations.
16	10/13/2020	Kim, Ye Darm	1.2	Process revisions to the Mediation Phase 2 overview presentation.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	10/15/2020	Kim, Ye Darm	0.4	Process revisions to Mediation Phase 2 overview presentation.
16	10/16/2020	Kim, Ye Darm	1.9	Assist preparation of analysis re: distributable value scenarios for trust.
16	10/16/2020	Diaz, Matthew	1.0	Participate in a call with Houlihan and counsel to discuss post emergence trust structures in connection with mediation.
16	10/16/2020	Diaz, Matthew	0.9	Participate in a call with Houlihan to discuss possible post emergence structures.
16	10/16/2020	Bromberg, Brian	1.2	Participate in call re: trust governance considerations with counsel.
16	10/16/2020	Kurtz, Emma	1.0	Participate in call to review proposed term sheet and impact to distributable value.
16	10/16/2020	Kim, Ye Darm	1.0	Participate in call with Counsel and HL re: trust considerations.
16	10/16/2020	Kim, Ye Darm	0.6	Participate in call with HL re: distributable value assumptions.
16	10/16/2020	Kim, Ye Darm	0.6	Participate in call with HL re: trust considerations.
16	10/16/2020	Kim, Ye Darm	1.2	Review analysis re: distributable value bridge to Debtors' latest plan.
16	10/16/2020	Kim, Ye Darm	0.9	Review distributable value model for prior assumptions.
16	10/18/2020	Diaz, Matthew	1.5	Participate in a call with the AHC professionals to discuss the proposed trust go-forward structure.
16	10/18/2020	Bromberg, Brian	1.7	Participate in call with counsel re: trust structuring considerations.
16	10/19/2020	Diaz, Matthew	0.6	Participate in a call with the AHC's professionals to discuss the proposed go-forward term sheet structure.
16	10/19/2020	Bromberg, Brian	1.3	Participate in call with counsel re: governance issues.
16	10/19/2020	Simms, Steven	0.6	Participate in meeting re: presentation on corporate governance items.
16	10/19/2020	Kim, Ye Darm	2.1	Prepare analysis of shortfall/surplus of distributable value from insurance and cash contributions.
16	10/19/2020	Bromberg, Brian	0.9	Review Houlihan analysis on governance structure considerations.
16	10/19/2020	Diaz, Matthew	0.5	Review the proposed go-forward trust structure term sheet.
16	10/20/2020	Kim, Ye Darm	1.8	Continue processing updates to surplus/shortfall analysis for distributable value.
16	10/20/2020	Kim, Ye Darm	0.6	Correspond with HL re: surplus/shortfall distributable value analysis.
16	10/20/2020	Bromberg, Brian	0.7	Prepare and send to Houlihan comments on trust structure analysis.
16	10/20/2020	Kim, Ye Darm	1.2	Prepare updated presentation slide re: surplus/short analysis of distributable value.
16	10/20/2020	Kim, Ye Darm	0.8	Process revisions to the surplus/shortfall distributable value analysis.
16	10/20/2020	Kim, Ye Darm	0.9	Process updates to surplus/shortfall distributable value analysis per call with HL.
16	10/20/2020	Kim, Ye Darm	1.1	Process updates to the surplus/shortfall distributable value analysis.
16	10/20/2020	Bromberg, Brian	3.1	Review and edit the trust structure cash flow analysis.
16	10/20/2020	Kim, Ye Darm	0.3	Review calculation of asset sale figures in HL presentation for distributable value analysis.
16	10/20/2020	Kim, Ye Darm	0.9	Review HL presentation on governance/trust structure.
16	10/20/2020	Bromberg, Brian	0.7	Review Houlihan's valuation analysis for distributable value.
16	10/20/2020	Kim, Ye Darm	1.3	Update the surplus/shortfall analysis for expected settlements.
16	10/21/2020	Bromberg, Brian	0.5	Discuss value shortfall analysis with Houlihan.
16	10/21/2020	Diaz, Matthew	1.0	Participate in a call with the AHC professionals to discuss the go-forward trust emergence structure.
16	10/21/2020	Bromberg, Brian	1.0	Participate in call on governance considerations with Counsel.
16	10/21/2020	Kim, Ye Darm	1.0	Participate in call re: HL Governance/Trust structure presentation.
16	10/21/2020	Bromberg, Brian	0.8	Participate in discussion re: distributable value analysis with team.
16	10/21/2020	Kim, Ye Darm	0.4	Participate in discussion with HL re: updated distributable value surplus/shortfall analysis.
16	10/21/2020	Kim, Ye Darm	0.9	Prepare updated presentation slide for updates to the distributable value analysis.
16	10/21/2020	Kim, Ye Darm	1.1	Process revisions to the surplus/shortfall distributable value analysis for trust structure considerations.
16	10/21/2020	Kim, Ye Darm	1.3	Process updates to distributable value surplus/shortfall analysis for settlement estimates.
16	10/21/2020	Kim, Ye Darm	0.6	Process updates to the distributable value surplus/shortfall analysis for the DOJ settlement.
16	10/21/2020	Bromberg, Brian	1.5	Review and process revisions to distributable value analysis based on latest discussions.
16	10/21/2020	Kim, Ye Darm	2.4	Review the DOJ settlement materials to incorporate in latest distributable value analysis.
16	10/21/2020	Bromberg, Brian	2.2	Review the latest distributable value analysis and provide revisions.
16	10/21/2020	Diaz, Matthew	0.6	Review the proposed DOJ settlement and impact on available proceeds.
16	10/21/2020	Diaz, Matthew	0.9	Review the updated go-forward trust/governance presentation.
16	10/21/2020	Kim, Ye Darm	0.7	Update presentation for latest distributable value surplus/shortfall analysis.
16	10/22/2020	Diaz, Matthew	0.5	Review the updated trust presentation on the go-forward structure.
16	10/23/2020	Bromberg, Brian	1.1	Participate in call on governance with the subcommittee.
16	10/23/2020	Diaz, Matthew	1.5	Participate in call re: Presentation to the AHC subcommittee to discuss go forward Purdue.
16	10/27/2020	Simms, Steven	0.8	Participate in call re: Sackler related diligence and investigation issues with case professionals.
16	10/27/2020	Kim, Ye Darm	1.0	Participate in meeting re: mediation strategy.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	10/27/2020	Bromberg, Brian	0.9	Participate in professionals call re: mediation strategy.
16	10/27/2020	Bromberg, Brian	0.4	Summarize call re: mediation strategy for internal distribution.
16	10/28/2020	Kim, Ye Darm	1.8	Prepare bridges of distributable value between sale case scenarios.
16	10/28/2020	Kim, Ye Darm	0.8	Review latest draft of the HL structure presentation.
16	10/28/2020	Bromberg, Brian	0.5	Review the DOJ settlement terms on impact to distributable value.
16	10/28/2020	Bromberg, Brian	0.9	Review the latest trust structure presentation.
16	10/28/2020	Diaz, Matthew	0.5	Review the updated post emergence cash flow presentation.
16	10/29/2020	Bromberg, Brian	2.1	Participate in call with NCSG re: governance structure.
16	10/29/2020	Kim, Ye Darm	1.2	Prepare additional bridge analysis of sale case scenarios.
16	10/29/2020	Kim, Ye Darm	2.6	Prepare bridge analysis to PJT's distributable value estimates.
16	10/29/2020	Kim, Ye Darm	0.9	Review PJT's presentation on distributable value estimates.
16	10/29/2020	Diaz, Matthew	0.6	Review PJT's updated distributable value analysis presentation.
16	10/30/2020	Diaz, Matthew	0.8	Participate in a call with the AHC Professionals to discuss the proposed trust structure.
16	10/30/2020	Bromberg, Brian	1.1	Participate in call re: mediation considerations.
16	10/30/2020	Kim, Ye Darm	0.6	Prepare responses re: variance to PJT distributable value estimate.
16	10/30/2020	Kim, Ye Darm	1.6	Process revisions to bridge analysis re: PJT distributable value estimates.
16	10/30/2020	Kim, Ye Darm	0.9	Reconcile variances of the bridge analysis re: PJT distributable value estimates.
16	10/30/2020	Kim, Ye Darm	0.8	Review surplus/shortfall value analysis for potential tax impacts.
16	10/30/2020	Diaz, Matthew	1.1	Review the updated company recovery analysis and reconcile to existing work.
16	11/1/2020	Diaz, Matthew	0.6	Review the updated trust structuring presentation.
16	11/2/2020	Simms, Steven	0.4	Participate on DOJ call re: plan structure issues.
16	11/2/2020	Diaz, Matthew	1.9	Review the updated cash distribution analysis.
16	11/3/2020	Kim, Ye Darm	0.6	Continue processing revisions to the updated distributable value analysis.
16	11/3/2020	Simms, Steven	1.6	Participate in call with DOJ on settlement structure.
16	11/3/2020	Bromberg, Brian	1.1	Participate in call with DOJ re: emergence structure.
16	11/3/2020	Bromberg, Brian	1.5	Perform detailed QC re: cash flow analysis on distribution structure.
16	11/3/2020	Kim, Ye Darm	2.3	Prepare updated illustrative distributable value analysis based on latest figures.
16	11/3/2020	Kim, Ye Darm	0.8	Process revisions to the updated distributable value analysis.
16	11/3/2020	Bromberg, Brian	2.5	Review cash flow analysis on distributable value.
16	11/3/2020	Kim, Ye Darm	0.8	Review draft of HL structure and economic considerations presentation.
16	11/3/2020	Diaz, Matthew	1.1	Review the updated distributable value allocation model.
16	11/4/2020	Bromberg, Brian	1.4	Devise bridge on updated structuring numbers.
16	11/4/2020	Diaz, Matthew	1.0	Participate in a call with counsel to discuss the post emergence structure.
16	11/4/2020	Simms, Steven	0.7	Participate in AHC presentation re: deal structure.
16	11/4/2020	Kim, Ye Darm	1.1	Participate in call re: structuring and economic considerations presentation.
16	11/4/2020	Bromberg, Brian	0.9	Participate in discussion re: structuring financial information with internal team.
16	11/4/2020	Bromberg, Brian	1.0	Participate in structuring considerations call with AHC.
16	11/4/2020	Kim, Ye Darm	1.4	Prepare draft presentation slides re: updated net distributable value from structuring presentation.
16	11/4/2020	Kim, Ye Darm	2.3	Prepare scenario analyses re: updated net distributable value from structuring presentation.
16	11/4/2020	Kim, Ye Darm	1.3	Process revisions to the scenario analyses re: updated net distributable value from structuring presentation.
16	11/4/2020	Bromberg, Brian	0.8	Review assumptions behind structuring presentation figures.
16	11/4/2020	Bromberg, Brian	0.7	Review presentation slides on net distributable value scenarios.
16	11/5/2020	Kim, Ye Darm	0.7	Continue processing revisions to the net distributable value scenarios analysis and presentation.
16	11/5/2020	Bromberg, Brian	1.2	Continue revise assumptions re: distributable value bridging analysis.
16	11/5/2020	Kim, Ye Darm	0.4	Correspond with HL re: distributable value assumptions.
16	11/5/2020	Diaz, Matthew	1.0	Participate in a call with Counsel to discuss the updated term sheet.
16	11/5/2020	Kim, Ye Darm	1.1	Prepare revisions to the distributable value scenario analysis and presentation.
16	11/5/2020	Bromberg, Brian	1.2	Process revisions to slides re: net distributable value.
16	11/5/2020	Kim, Ye Darm	0.9	Process revisions to the distributable value scenario analysis and presentation.
16	11/5/2020	Diaz, Matthew	0.6	Review the updated settlement term sheet.
16	11/5/2020	Bromberg, Brian	2.3	Update distributable value bridge analysis.
16	11/5/2020	Kim, Ye Darm	0.4	Update term sheet figures in the distributable value scenarios.
16	11/6/2020	Kim, Ye Darm	0.9	Continue processing revisions of distributable value bridge to September business plan forecasts.
16	11/6/2020	Kim, Ye Darm	0.4	Correspond with HL re: distributable value assumptions.
16	11/6/2020	Bromberg, Brian	1.8	Finalize distributable value bridge and send to Debtors.
16	11/6/2020	Diaz, Matthew	0.6	Participate in a call with Houlihan to discuss potential strategic alternatives for the US business.
16	11/6/2020	Diaz, Matthew	1.0	Participate in a call with the AHC, NCSG and UCC professionals to discuss possible strategic alternatives.
16	11/6/2020	Bromberg, Brian	0.8	Participate in call with Houlihan re: potential strategic alternatives.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	11/6/2020	Bromberg, Brian	1.0	Participate in call with UCC re: potential strategic alternatives.
16	11/6/2020	Bromberg, Brian	0.6	Review the latest distributable value bridge analysis.
16	11/7/2020	Bromberg, Brian	0.8	Participate in call with UCC re: strategic alternatives.
16	11/9/2020	Kim, Ye Darm	0.6	Participate in call re: bid proposal.
16	11/9/2020	Bromberg, Brian	0.3	Participate in call re: potential strategic alternatives.
16	11/9/2020	Kim, Ye Darm	0.6	Review the bid proposal.
16	11/10/2020	Kim, Ye Darm	0.3	Correspond with HL re: mediation presentation.
16	11/10/2020	Kim, Ye Darm	0.5	Participate in call re: Bates White analysis.
16	11/10/2020	Kim, Ye Darm	0.6	Participate in call re: PBC Case cash flow assumptions.
16	11/10/2020	Kim, Ye Darm	0.8	Process updates to prior draft of mediation report.
16	11/10/2020	Bromberg, Brian	1.9	Review and process updates to mediation presentation.
16	11/10/2020	Simms, Steven	0.6	Review latest presentation materials re: Sackler settlement.
16	11/10/2020	Diaz, Matthew	0.8	Review the updated PBC cash flows and reconciliation analysis.
16	11/11/2020	Diaz, Matthew	0.7	Participate in a call with the AHC professionals to discuss strategic alternatives.
16	11/11/2020	Diaz, Matthew	1.1	Participate in a call with the MSGE group to discuss the mediation 2 presentation materials.
16	11/11/2020	Bromberg, Brian	1.2	Participate in call with MSGE re: mediation progress.
16	11/11/2020	Bromberg, Brian	0.5	Participate in call with team re: potential strategic alternatives.
16	11/11/2020	Kim, Ye Darm	1.0	Participate in call with the MSGE re: mediation progress.
16	11/11/2020	Bromberg, Brian	0.8	Participate in call with UCC re: potential strategic alternatives.
16	11/11/2020	Diaz, Matthew	0.5	Preparation for the call with the MSGE group re: mediation phase 2.
16	11/11/2020	Kim, Ye Darm	1.3	Process updates to net distributable value analysis per discussions with the Debtors.
16	11/11/2020	Bromberg, Brian	1.2	Review and process updates to the mediation presentation.
16	11/11/2020	Kim, Ye Darm	0.4	Review HL updates to draft of mediation presentation.
16	11/11/2020	Kim, Ye Darm	0.5	Review latest HL Governance presentation slides re: strategic considerations.
16	11/11/2020	Kim, Ye Darm	0.4	Review latest NDV scenario presentation by HL.
16	11/11/2020	Kim, Ye Darm	0.6	Review UCC statement re: DOJ settlement.
16	11/12/2020	Kim, Ye Darm	1.1	Correspond with HL re: distributable value assumptions and prepare responses to questions.
16	11/12/2020	Diaz, Matthew	0.3	Follow up call with the AHC professionals to discuss next steps and reactions to the call with the Debtors on the post emergence.
16	11/12/2020	Diaz, Matthew	2.4	Participate in a call with the Debtors and the AHC professionals to discuss the post emergence structure.
16	11/12/2020	Simms, Steven	0.6	Participate in call re: presentation re: emergence structure issues.
16	11/12/2020	Bromberg, Brian	2.2	Participate in call with Debtors re: post emergence structure.
16	11/12/2020	Kim, Ye Darm	2.5	Participate in call with the AHC re: structuring considerations.
16	11/12/2020	Bromberg, Brian	0.4	Participate in discussion re: sale process with Houlihan.
16	11/12/2020	Bromberg, Brian	0.6	Participate in post-call re: HL discussion debrief.
16	11/12/2020	Kim, Ye Darm	0.9	Review HL's support files re: no settlement scenarios.
16	11/12/2020	Simms, Steven	1.4	Review UCC presentation on settlement items.
16	11/13/2020	Kim, Ye Darm	1.1	Update distributions calculations re: net distributable value analysis with no settlement.
16	11/15/2020	Diaz, Matthew	0.9	Review the latest Purdue proposed term sheet.
16	11/16/2020	Simms, Steven	0.8	Review latest analyses re: Sackler settlement.
16	11/17/2020	Kim, Ye Darm	0.8	Participate in call with HL re: cash flow forecasts for distributable value.
16	11/18/2020	Bromberg, Brian	1.1	Participate in Committee call re: governance structure.
16	11/19/2020	Kim, Ye Darm	1.2	Process updates to September business plan cash flow bridge.
16	11/19/2020	Kim, Ye Darm	0.6	Review updated HL distributable value cash flow assumptions.
16	11/20/2020	Diaz, Matthew	0.5	Participate in a call with a 3rd party to discuss various strategic alternatives.
16	11/20/2020	Diaz, Matthew	1.5	Participate in a call with the AHC and the NCSG to discuss the go forward post emergence structure.
16	11/20/2020	Kim, Ye Darm	0.6	Participate in call with Debtors re: potential sale of assets.
16	11/20/2020	Bromberg, Brian	2.2	Participate in call with NCSG re: governance structure.
16	11/20/2020	Diaz, Matthew	0.6	Review the Purdue alternative plan structures legal analysis.
16	11/20/2020	Diaz, Matthew	0.7	Review the updated cash flow analysis and related due diligence.
16	11/22/2020	Diaz, Matthew	1.5	Participate in a call with the case key stakeholder financial advisers re: buyer due diligence.
16	11/23/2020	Diaz, Matthew	1.0	Participate in a call with Houlihan to discuss various distributable proceeds modeling scenarios.
16	11/23/2020	Kim, Ye Darm	1.0	Participate in call re: new optimized case cash flows.
16	11/23/2020	Kim, Ye Darm	1.0	Participate in discussion with HL re: optimized CF scenario.
16	11/23/2020	Kim, Ye Darm	0.6	Participate in internal call re: updates to optimized cash flow assumptions.
16	11/23/2020	Kim, Ye Darm	1.1	Prepare analysis of optimized cash flows for distribution to Debtors and internal team.
16	11/23/2020	Kim, Ye Darm	2.3	Prepare cash flow bridge and assumptions for optimized cash flow case.
16	11/23/2020	Kim, Ye Darm	1.8	Process revisions to optimized case cash flow forecast assumptions.
16	11/23/2020	Kim, Ye Darm	0.9	Review diligence pack re: potential buyer bid.
16	11/23/2020	Kim, Ye Darm	0.9	Review HLs presentation re: cash flow cases for distributable value.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	11/23/2020	Kim, Ye Darm	1.1	Review plan draft term sheet.
16	11/23/2020	Bromberg, Brian	2.7	Review plan term sheet and provide commentary.
16	11/23/2020	Diaz, Matthew	1.4	Review the proposed Purdue plan term sheet.
16	11/23/2020	Diaz, Matthew	1.5	Review various post emergence modeling sensitivities cases.
16	11/23/2020	Kim, Ye Darm	0.4	Update cash flow bridge analysis for latest assumptions.
16	11/24/2020	Diaz, Matthew	0.9	Participate in a call with Houlihan to discuss the updated distributable value presentation.
16	11/24/2020	Diaz, Matthew	0.8	Participate in a call with the Debtors to discuss the updated distributable value scenario.
16	11/24/2020	Kim, Ye Darm	0.5	Participate in call with Debtors re: optimized cash flow scenario assumptions.
16	11/24/2020	Simms, Steven	0.6	Participate in correspondence re: Sackler settlement issues.
16	11/24/2020	Kim, Ye Darm	1.9	Prepare summary slides for inclusion into HL's strategic options presentation.
16	11/24/2020	Kim, Ye Darm	1.1	Process additional revisions to summary slides for HL's strategic options presentation.
16	11/24/2020	Kim, Ye Darm	0.9	Process revisions to summary slides for HL's strategic options presentation.
16	11/24/2020	Bromberg, Brian	0.5	Review latest analysis re: Sackler professional fees estimates.
16	11/24/2020	Kim, Ye Darm	0.9	Update optimized cash flow case assumptions for asset sale proceeds.
16	11/25/2020	Kim, Ye Darm	1.0	Participate in call with AHC and NCSG re: settlement negotiations.
16	11/25/2020	Bromberg, Brian	0.7	Participate in call with NCSG re: settlement negotiations.
16	11/25/2020	Kim, Ye Darm	0.6	Review NCSG presentation to the Sacklers.
16	11/25/2020	Diaz, Matthew	1.2	Review the distributable value calculations in the AHC presentation.
16	11/30/2020	Diaz, Matthew	1.2	Participate in a call with the mediators and the Sacklers re the term sheet and related next steps.
16	11/30/2020	Kim, Ye Darm	1.1	Participate in discussion with Sackler counsel and AHC re: settlement negotiations.
16	11/30/2020	Bromberg, Brian	1.0	Participate in meeting with NCSG re: Sackler negotiations.
16	11/30/2020	Kim, Ye Darm	1.2	Participate in post call re: Sackler negotiations status.
16	12/1/2020	Diaz, Matthew	1.0	Participate in a call with the Debtors' professionals to discuss the updated valuations by business segment.
16	12/1/2020	Bromberg, Brian	0.8	Participate in call re: sale values of domestic businesses.
16	12/1/2020	Bromberg, Brian	0.8	Prepare for call re: sale values of domestic businesses.
16	12/1/2020	Diaz, Matthew	0.4	Review of the updated Debtors' segment valuations and related impact on the recovery analysis.
16	12/2/2020	Bromberg, Brian	0.5	Discuss updated uses cash flow spreadsheet with Houlihan team.
16	12/2/2020	Bromberg, Brian	1.4	Discuss updated uses cash flow spreadsheet with internal team.
16	12/2/2020	Kim, Ye Darm	0.8	Participate in discussion w/ HL re: Counsel's distributable value sensitivity scenarios.
16	12/2/2020	Kim, Ye Darm	3.5	Prepare distributable sensitivity scenarios suggested by Counsel.
16	12/2/2020	Kim, Ye Darm	1.8	Prepare slides re: counsel's proposed distributable value sensitivity scenarios.
16	12/2/2020	Kim, Ye Darm	0.9	Process revisions to slides re: Counsel's distributable value sensitivity scenarios.
16	12/2/2020	Kim, Ye Darm	0.9	Process revisions to the slides re: Counsel's distributable value scenarios.
16	12/2/2020	Simms, Steven	0.6	Review diligence workplan re: strategic alternatives.
16	12/2/2020	Bromberg, Brian	1.5	Review Houlihan new analysis on cash flow.
16	12/2/2020	Diaz, Matthew	1.7	Review the updated distributable value analysis.
16	12/2/2020	Diaz, Matthew	0.7	Review the updated slides on the distributable value analysis.
16	12/3/2020	Bromberg, Brian	1.3	Discuss shut down costs with Houlihan.
16	12/3/2020	Bromberg, Brian	2.0	Participate in call re: DOJ and NCSG mediation positions.
16	12/3/2020	Kim, Ye Darm	1.8	Participate in meeting w/ DOJ re: go-forward considerations.
16	12/3/2020	Kim, Ye Darm	1.1	Prepare support slides for HL presentation re: strategic options.
16	12/3/2020	Diaz, Matthew	1.1	Review materials related to possible indication of interest.
16	12/3/2020	Diaz, Matthew	1.4	Review the updated distributable value recovery analysis.
16	12/4/2020	Diaz, Matthew	0.5	Participate in a call with Alix to discuss the minimum cash assumptions used in the recovery analysis.
16	12/4/2020	Diaz, Matthew	0.8	Participate in a call with Counsel to discuss the go forward structure of Purdue.
16	12/4/2020	Kim, Ye Darm	0.6	Participate in call w/ Counsel re: structuring considerations.
16	12/4/2020	Kim, Ye Darm	0.4	Review domestic business legal entity organizational structure.
16	12/4/2020	Bromberg, Brian	1.3	Review latest draft of domestic strategic alternatives presentation.
16	12/5/2020	Bromberg, Brian	2.3	Review latest draft of sale alternatives presentation.
16	12/6/2020	Diaz, Matthew	0.5	Participate in a call with Houlihan to discuss the updated distributable value presentation.
16	12/6/2020	Bromberg, Brian	1.5	Participate in call with counsel re: sale alternatives.
16	12/6/2020	Bromberg, Brian	1.5	Review sale alternatives presentation questions from Houlihan.
16	12/6/2020	Diaz, Matthew	0.8	Review the distributable value amounts to the public entities.
16	12/6/2020	Diaz, Matthew	1.2	Review the updated distributable value presentation.
16	12/7/2020	Simms, Steven	0.6	Correspond with team on latest settlement considerations.
16	12/7/2020	Kim, Ye Darm	2.8	Prepare analysis re: distributable value scenarios under current settlement terms.
16	12/7/2020	Kim, Ye Darm	1.8	Prepare presentation slides re: distributable value scenarios under current settlement terms.
16	12/7/2020	Bromberg, Brian	1.8	Review Houlihan presentation on domestic strategic alternatives.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	12/7/2020	Diaz, Matthew	1.9	Review the updated distributable value presentation
16	12/7/2020	Kim, Ye Darm	0.5	Update slides re: distributable value scenarios under current settlement assumptions.
16	12/8/2020	Bromberg, Brian	1.3	Discuss domestic strategic alternatives presentation with Houlihan.
16	12/8/2020	Bromberg, Brian	1.0	Discuss Houlihan domestic strategic alternatives presentation with internal team.
16	12/8/2020	Kim, Ye Darm	1.0	Participate in call re: cash flow assumptions in HL's deck
16	12/8/2020	Kim, Ye Darm	0.8	Participate in call re: segment level cash flow build up.
16	12/8/2020	Kim, Ye Darm	1.0	Participate in call w/ Debtors re: cash flow bridge analysis.
16	12/8/2020	Bromberg, Brian	0.8	Participate in call with Debtors re: domestic alternative scenarios.
16	12/8/2020	Kim, Ye Darm	1.5	Participate in call with HL re: cash flow risk and assumptions.
16	12/8/2020	Diaz, Matthew	1.3	Participate in conference call with Houlihan to discuss the updated distributable value deck.
16	12/8/2020	Kim, Ye Darm	3.6	Prepare analysis re: segment level cash flow build ups.
16	12/8/2020	Bromberg, Brian	1.8	Review latest draft of Houlihan presentation on domestic strategic alternatives.
16	12/8/2020	Diaz, Matthew	2.1	Review the updated Purdue distributable value deck.
16	12/9/2020	Kim, Ye Darm	1.6	Continue analysis re: build up of segment level cash flows to PBC case estimates.
16	12/9/2020	Kim, Ye Darm	0.6	Continue discussion re: HL presentation cash flow assumptions.
16	12/9/2020	Bromberg, Brian	1.2	Discuss Houlihan strategic alternatives presentation with team.
16	12/9/2020	Bromberg, Brian	0.5	Discuss strategic alternatives domestic presentation with Houlihan.
16	12/9/2020	Kim, Ye Darm	0.8	Participate in call re: core business cash flow build up.
16	12/9/2020	Bromberg, Brian	2.0	Participate in Committee call re: domestic strategic scenarios.
16	12/9/2020	Kim, Ye Darm	0.6	Participate in internal call re: HL presentation cash flow assumptions.
16	12/9/2020	Kim, Ye Darm	2.8	Prepare bottoms up analysis of core business cash flows.
16	12/9/2020	Diaz, Matthew	1.6	Review and reconcile the distributable value presentation to the underlying source documents.
16	12/9/2020	Diaz, Matthew	2.7	Review the updated distributable value presentation.
16	12/10/2020	Kim, Ye Darm	1.4	Participate in call with DOJ and NCSG re: go-forward considerations.
16	12/10/2020	Kim, Ye Darm	2.2	Process revisions to core business cash flow build up analysis.
16	12/11/2020	Diaz, Matthew	0.8	Participate in a call with the UCC's advisors to discuss possible strategic alternatives.
16	12/11/2020	Kim, Ye Darm	1.0	Participate in call with UCC re: strategic alternatives.
16	12/11/2020	Kim, Ye Darm	1.0	Participate in discussion re: core business cash flow build up.
16	12/11/2020	Kim, Ye Darm	0.6	Update core business cash flow analysis.
16	12/14/2020	Diaz, Matthew	0.5	Review parameters of distribution analysis being requested from the Debtors.
16	12/14/2020	Diaz, Matthew	0.8	Review the updated distributable value analysis.
16	12/15/2020	Kim, Ye Darm	3.1	Prepare distributable value sensitivity case analysis for new scenarios.
16	12/15/2020	Kim, Ye Darm	1.8	Prepare draft presentation slides re: new distributable value scenarios.
16	12/16/2020	Kim, Ye Darm	0.6	Process additional revisions to the distributable value sensitivity case slides.
16	12/16/2020	Kim, Ye Darm	1.2	Process revisions to distributable value sensitivity case scenario slides.
16	12/16/2020	Diaz, Matthew	0.7	Review cash flow slides related to certain strategic alternative sensitivities.
16	12/16/2020	Kim, Ye Darm	0.7	Review Counsel's alternative plan structure presentation.
16	12/17/2020	Diaz, Matthew	2.1	Review the updated distributable value analysis.
16	12/21/2020	Bromberg, Brian	2.2	Create comparison bridge analysis file for new cash flow adjustments.
16	12/21/2020	Bromberg, Brian	2.1	Edit draft slides for domestic scenarios presentation.
16	12/21/2020	Bromberg, Brian	2.7	Process revisions to slides for domestic scenarios presentation.
16	12/21/2020	Diaz, Matthew	0.8	Review presentations on alternative plan constructs.
16	12/21/2020	Diaz, Matthew	1.2	Review the updated distributable value presentation.
16	12/21/2020	Bromberg, Brian	1.3	Review updated slides for domestic scenarios presentation.
16	12/21/2020	Kim, Ye Darm	3.2	Update distributable value scenario analyses for latest business plan forecasts.
16	12/21/2020	Bromberg, Brian	1.8	Update distribution analysis based on new plan forecasts.
16	12/22/2020	Bromberg, Brian	1.9	Discuss updating all domestic strategic scenarios with Houlihan team.
16	12/22/2020	Diaz, Matthew	2.0	Participate in a call with the DOJ and key creditor groups on the updated distributable value analysis.
16	12/22/2020	Bromberg, Brian	2.0	Participate in call with DOJ and NCSG re: domestic business plan scenarios.
16	12/22/2020	Bromberg, Brian	1.3	Review updated domestic business plan scenarios.
16	12/23/2020	Bromberg, Brian	1.2	Discuss latest domestic strategic scenarios with team.
16	12/23/2020	Bromberg, Brian	2.6	Review the latest draft domestic strategic scenarios.
16	12/23/2020	Diaz, Matthew	1.6	Review the updated distributable value analysis.
16	12/23/2020	Bromberg, Brian	1.9	Update slides for domestic strategic scenarios presentation.
16	12/24/2020	Bromberg, Brian	0.8	Respond to strategic scenarios diligence questions from Houlihan.
16	12/24/2020	Bromberg, Brian	2.4	Update slides for scenarios presentation based on new numbers.
16	12/28/2020	Kim, Ye Darm	0.5	Participate in discussion re: updated strategic considerations presentation.
16	12/28/2020	Kim, Ye Darm	1.7	Process revisions to allocation model and slides for new contingencies.
16	12/28/2020	Bromberg, Brian	1.8	Process revisions to strategic alternatives appendix slides.
16	12/28/2020	Kim, Ye Darm	2.1	Process updates to strategic alternatives distributable value slides for new contingencies.
16	12/28/2020	Bromberg, Brian	1.3	Review domestic strategic alternatives slides.
16	12/28/2020	Bromberg, Brian	0.9	Review new distributable value model.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	12/28/2020	Bromberg, Brian	1.2	Review PEO information in domestic strategic alternatives slides.
16	12/28/2020	Bromberg, Brian	1.0	Review strategic alternatives appendix slides.
16	12/28/2020	Diaz, Matthew	3.1	Review the updated distributable value analysis.
16	12/28/2020	Bromberg, Brian	1.8	Update strategic alternatives appendix slides for new assumptions.
16	12/29/2020	Bromberg, Brian	1.0	Discuss strategic scenarios presentation with Houlihan team and counsel.
16	12/29/2020	Kim, Ye Darm	0.7	Participate in discussion re: revisions to contingencies re: scenarios analysis.
16	12/29/2020	Kim, Ye Darm	0.9	Process additional revisions to slide and model per HL updated contingencies.
16	12/29/2020	Kim, Ye Darm	1.6	Process updates to model and allocation slides for new contingencies for bid scenario.
16	12/30/2020	Bromberg, Brian	0.8	Participate in call with Akin and Province re: strategic scenario analysis.
16	12/30/2020	Bromberg, Brian	0.8	Review distribution slides for scenario presentation.
16	12/30/2020	Bromberg, Brian	1.7	Review Houlihan distributable model on strategic scenarios.
16	12/30/2020	Bromberg, Brian	2.2	Update team on UCC call re: scenario analysis.
16	12/31/2020	Kim, Ye Darm	0.7	Continue processing revisions to distributable value slides for updated downside contingencies.
16	12/31/2020	Bromberg, Brian	1.6	Discuss domestic business strategic scenarios presentation.
16	12/31/2020	Bromberg, Brian	1.2	Discuss strategic scenarios analysis with team.
16	12/31/2020	Bromberg, Brian	1.1	Discuss updated OxyContin forecast with team.
16	12/31/2020	Bromberg, Brian	2.8	Edit distribution slides for presentation.
16	12/31/2020	Kim, Ye Darm	1.1	Prepare revisions to distributable value slides for updated downside contingency calculations.
16	12/31/2020	Kim, Ye Darm	0.8	Prepare updated allocation analysis per HL's updated contingency calculations.
16	12/31/2020	Kim, Ye Darm	0.6	Review latest downslide slide for strategic alternatives presentation.
16	12/31/2020	Bromberg, Brian	2.0	Review net present values on strategic scenarios.
16	1/4/2021	Kim, Ye Darm	0.8	Participate in call with PJT re: distributable value scenario assumptions.
16	1/4/2021	Diaz, Matthew	2.3	Review the updated distributable value presentation.
16	1/5/2021	Diaz, Matthew	0.5	Participate in a call with Houlihan to prepare for the call with Province re: distributable value.
16	1/5/2021	Diaz, Matthew	0.7	Participate in a call with Province to discuss the distributable value analysis.
16	1/5/2021	Kim, Ye Darm	0.8	Participate in call w/ UCC re: OxyContin forecast sensitivities.
16	1/5/2021	Simms, Steven	0.6	Participate in correspondence with AHC on term sheet and mediation.
16	1/5/2021	Kim, Ye Darm	0.7	Participate in discussion re: revised OxyContin sensitivity assumptions.
16	1/5/2021	Kim, Ye Darm	0.5	Participate in pre-call with HL re: OxyContin forecast disc. with UCC.
16	1/5/2021	Diaz, Matthew	1.8	Perform final review of the Purdue distributable value presentation and provide comments to Houlihan.
16	1/5/2021	Kim, Ye Darm	0.9	Process revisions to distributable value strategic options presentation.
16	1/5/2021	Kim, Ye Darm	1.1	Review refresh of OxyContin sensitivities.
16	1/5/2021	Kim, Ye Darm	0.6	Review summary on potential downside situation re: managed care.
16	1/5/2021	Diaz, Matthew	1.1	Review the updated term sheet.
16	1/5/2021	Kim, Ye Darm	0.9	Review updated OxyContin forecasts for revised downside haircut.
16	1/6/2021	Bromberg, Brian	1.0	Participate in call re: governance for domestic business.
16	1/6/2021	Kim, Ye Darm	0.9	Review latest HL model re: distributable value scenarios.
16	1/6/2021	Diaz, Matthew	1.5	Review the updated recovery analysis presentation.
16	1/7/2021	Kim, Ye Darm	0.7	Participate in call w/ PJT re: settlement assumptions.
16	1/7/2021	Bromberg, Brian	0.7	Participate in call with Debtor advisors on settlements.
16	1/7/2021	Diaz, Matthew	0.7	Review of the distributable value analysis open due diligence and related next steps.
16	1/7/2021	Diaz, Matthew	0.6	Review the updated term sheet with the NCSG.
16	1/8/2021	Kim, Ye Darm	1.4	Participate in call w/ Debtors re: OxyContin sensitivity assumptions.
16	1/8/2021	Kim, Ye Darm	1.2	Prepare slides re: distributable value sensitivity scenarios.
16	1/8/2021	Kim, Ye Darm	0.4	Process revisions to slides re: distributable value sensitivity scenarios.
16	1/8/2021	Diaz, Matthew	1.2	Review the Province net distributable value analysis.
16	1/8/2021	Diaz, Matthew	0.6	Review the updated sensitivities on the distributable value analysis.
16	1/8/2021	Kim, Ye Darm	1.0	Review UCC presentation re: distributable value scenarios.
16	1/8/2021	Kim, Ye Darm	0.9	Update distributable value model for sensitivity toggles.
16	1/12/2021	Diaz, Matthew	0.4	Participate in a call with counsel to discuss plan b alternatives.
16	1/12/2021	Kim, Ye Darm	2.6	Prepare illustrative payout analysis re: bid diligence.
16	1/12/2021	Kim, Ye Darm	0.6	Prepare slide re: sensitivity assumptions to distributable value.
16	1/12/2021	Kim, Ye Darm	2.3	Process additional revisions to illustrative payout analysis re: bid diligence.
16	1/12/2021	Kim, Ye Darm	1.9	Process revisions to illustrative payout analysis re: bid diligence.
16	1/12/2021	Kim, Ye Darm	2.1	Process updates to the illustrative payout analysis re: bid diligence.
16	1/12/2021	Diaz, Matthew	0.9	Review the updated distributable value analysis based on the bid received.
16	1/13/2021	Diaz, Matthew	0.6	Participate in a call with Province to discuss certain strategic alternatives.
16	1/13/2021	Kim, Ye Darm	1.1	Participate in call re: illustrative payout analysis.
16	1/13/2021	Kim, Ye Darm	2.8	Process additional revisions to the illustrative payout analysis.
16	1/13/2021	Kim, Ye Darm	2.9	Process revisions to the illustrative payout analysis.
16	1/13/2021	Diaz, Matthew	0.6	Review the strategic alternatives presentation to the Committee.
16	1/14/2021	Diaz, Matthew	0.4	Draft correspondence to Counsel re: certain strategic alternatives.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	1/14/2021	Diaz, Matthew	0.4	Research and draft correspondence to Counsel in connection with certain distributable value assumptions.
16	1/14/2021	Diaz, Matthew	1.1	Review the updated distributable value analysis.
16	1/14/2021	Diaz, Matthew	0.6	Review the updated plan term sheet.
16	1/15/2021	Bromberg, Brian	0.5	Discuss plan B scenarios with team.
16	1/15/2021	Kim, Ye Darm	1.0	Participate in call re: mediation w/ NCSG.
16	1/15/2021	Bromberg, Brian	1.0	Participate in mediation call re: future of Purdue.
16	1/15/2021	Diaz, Matthew	0.9	Participate in the mediator meeting with the AHC and the NCSG.
16	1/15/2021	Kim, Ye Darm	0.6	Review latest HL distributable value analysis.
16	1/15/2021	Diaz, Matthew	0.6	Review the distributable value analysis and Province's comments to it.
16	1/16/2021	Kim, Ye Darm	3.4	Build updated distributable value model for updated scenarios.
16	1/16/2021	Kim, Ye Darm	1.2	Revise distributable value model for new assumptions.
16	1/17/2021	Kim, Ye Darm	3.3	Prepare draft presentation on distributable value scenarios and sensitivities.
16	1/17/2021	Kim, Ye Darm	1.5	Process revisions to the distributable value presentation.
16	1/17/2021	Kim, Ye Darm	2.6	Process revisions to the updated distributable model for new sensitivities.
16	1/17/2021	Kim, Ye Darm	0.9	Process revisions to the updated distributable model.
16	1/17/2021	Bromberg, Brian	3.2	Review and edit plan b scenarios slides.
16	1/18/2021	Kim, Ye Darm	2.3	Continue processing revisions to the distributable value scenarios model.
16	1/18/2021	Bromberg, Brian	1.0	Discuss plan B scenarios with team.
16	1/18/2021	Kim, Ye Darm	0.5	Participate in call re: distributable value scenarios presentation.
16	1/18/2021	Kim, Ye Darm	0.5	Participate in call w/ HL re: distributable value assumptions.
16	1/18/2021	Kim, Ye Darm	3.1	Process revisions to the distributable model scenarios presentation.
16	1/18/2021	Kim, Ye Darm	3.5	Process revisions to the distributable value scenarios model.
16	1/18/2021	Bromberg, Brian	1.2	Review and edit plan b scenarios slides.
16	1/18/2021	Diaz, Matthew	0.7	Review the updated pages to the plan term sheet.
16	1/18/2021	Diaz, Matthew	2.5	Review the updated plan b case.
16	1/19/2021	Kim, Ye Darm	0.6	Build settlement check calculation into model.
16	1/19/2021	Kim, Ye Darm	1.1	Continue processing revisions to presentation on distributable value allocation.
16	1/19/2021	Simms, Steven	0.4	Correspond with team for updates on mediation issues.
16	1/19/2021	Bromberg, Brian	1.0	Discuss plan B scenarios with team.
16	1/19/2021	Kim, Ye Darm	0.7	Participate in call with HL re: distributable value sensitivities.
16	1/19/2021	Kim, Ye Darm	0.6	Participate in discussion re: distributable value sensitivity assumptions.
16	1/19/2021	Diaz, Matthew	3.3	Perform detailed review and provide updates to the plan b report.
16	1/19/2021	Kim, Ye Darm	1.8	Prepare presentation slides re: sensitivity to distributable value scenarios.
16	1/19/2021	Kim, Ye Darm	1.4	Process revision to slides re: distributable value scenarios.
16	1/19/2021	Kim, Ye Darm	0.9	Process revisions to presentation re: distributable value sensitivity scenarios.
16	1/19/2021	Bromberg, Brian	2.8	Review and edit plan b scenarios slides.
16	1/19/2021	Kim, Ye Darm	1.6	Update analysis re: adjusted Debtor cases for distributable value.
16	1/19/2021	Kim, Ye Darm	3.2	Update model re: allocation scenarios for low sensitivities.
16	1/19/2021	Kim, Ye Darm	1.0	Update model to toggle sensitivity assumptions.
16	1/20/2021	Kim, Ye Darm	1.2	Continue preparing analysis re: cash flow bridges to distributable value scenarios.
16	1/20/2021	Kim, Ye Darm	0.4	Correspond with HL re: cash flow adjustment assumptions in distributable value calculations.
16	1/20/2021	Diaz, Matthew	1.1	Participate in a call with Burke and the other case professionals to discuss due diligence questions.
16	1/20/2021	Diaz, Matthew	1.2	Participate in a call with Houlihan, Province and the Debtors' advisors to discuss the side by side analysis.
16	1/20/2021	Kim, Ye Darm	1.1	Process revisions to allocation slides re: distributable value allocation.
16	1/20/2021	Diaz, Matthew	1.6	Review the updated plan b analysis.
16	1/20/2021	Kim, Ye Darm	1.3	Update model for latest distributable value allocation assumptions.
16	1/21/2021	Bromberg, Brian	0.8	Discuss term sheet documents and outstanding questions with team.
16	1/21/2021	Diaz, Matthew	1.1	Participate in a call with counsel to discuss the plan and certain distribution mechanisms.
16	1/21/2021	Diaz, Matthew	0.6	Participate in a call with Houlihan to discuss the recovery analysis.
16	1/21/2021	Diaz, Matthew	0.6	Participate in a call with Province to discuss the plan b analysis.
16	1/21/2021	Kim, Ye Darm	0.5	Participate in call re: additional plan b scenario.
16	1/21/2021	Kim, Ye Darm	0.3	Participate in call re: min cash distributions analysis.
16	1/21/2021	Kim, Ye Darm	0.2	Participate on call re: UCC comments to plan b deck.
16	1/21/2021	Kim, Ye Darm	1.3	Prepare sensitivity analysis of plan b scenario.
16	1/21/2021	Kim, Ye Darm	0.4	Process revisions to plan b scenarios presentation.
16	1/21/2021	Kim, Ye Darm	1.3	Process updates to additional plan b scenario analysis.
16	1/21/2021	Diaz, Matthew	0.8	Review comments from Province re: the plan b report.
16	1/21/2021	Diaz, Matthew	0.7	Review of the updated recovery analysis.
16	1/21/2021	Diaz, Matthew	0.6	Review the updated plan b presentation.
16	1/21/2021	Kim, Ye Darm	0.3	Review UCC comments re: plan b presentation.
16	1/21/2021	Kim, Ye Darm	1.1	Review updated term sheet excerpt.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	1/22/2021	Diaz, Matthew	1.1	Call with Houlihan and Province on the plan b analysis.
16	1/22/2021	Diaz, Matthew	1.1	Call with the mediation sub group to discuss the plan b analysis.
16	1/22/2021	Kim, Ye Darm	0.7	Continue review of latest HL distributable model assumptions.
16	1/22/2021	Diaz, Matthew	3.4	Perform detailed review of the updated side by side presentation
16	1/22/2021	Kim, Ye Darm	0.4	Process revisions to comparative distributable slide.
16	1/22/2021	Kim, Ye Darm	0.7	Process revisions to comparative distributable value analysis.
16	1/22/2021	Diaz, Matthew	1.3	Review of the updated plan b analysis.
16	1/22/2021	Diaz, Matthew	0.6	Review the updated distributable value downside case.
16	1/22/2021	Kim, Ye Darm	1.2	Review updated HL distributable value model.
16	1/23/2021	Kim, Ye Darm	1.0	Participate in call re: distributable value presentation assumptions.
16	1/23/2021	Kim, Ye Darm	0.3	Participate in call re: strategic options presentation.
16	1/23/2021	Diaz, Matthew	3.1	Perform detailed review and edit the side by side presentation.
16	1/23/2021	Kim, Ye Darm	1.7	Review contingency and cash flow assumptions in distributable value model.
16	1/23/2021	Kim, Ye Darm	1.2	Review draft of economic analysis of strategic options presentation.
16	1/23/2021	Kim, Ye Darm	1.1	Review updated HL Distributable Value model.
16	1/24/2021	Kim, Ye Darm	1.4	Build bridge analysis to PJT figures.
16	1/24/2021	Kim, Ye Darm	1.0	Create analysis re: min cash surplus / deficit.
16	1/24/2021	Diaz, Matthew	1.6	Perform detailed review of the allocation analysis slides of the distributable value.
16	1/24/2021	Kim, Ye Darm	3.3	Prepare allocation analysis of scenarios.
16	1/24/2021	Kim, Ye Darm	1.8	Prepare slides re: distributable value allocation scenarios.
16	1/24/2021	Kim, Ye Darm	0.8	Process revisions to distributable value allocation slides.
16	1/24/2021	Kim, Ye Darm	1.4	Process revisions to model re: distributable value allocation analysis.
16	1/24/2021	Kim, Ye Darm	0.7	Review financial support for revised bid.
16	1/24/2021	Diaz, Matthew	1.5	Review the updated plan b analysis assumptions.
16	1/24/2021	Diaz, Matthew	1.9	Review the updated side by side analysis.
16	1/24/2021	Kim, Ye Darm	1.2	Review updated distributable value allocation model.
16	1/24/2021	Kim, Ye Darm	1.1	Review updated draft of economic analysis of strategic options presentation.
16	1/25/2021	Kim, Ye Darm	1.4	Analyze Debtors' working capital changes for min cash analysis.
16	1/25/2021	Kim, Ye Darm	1.9	Continue processing revisions to presentation re: min cash distribution requirements.
16	1/25/2021	Bromberg, Brian	0.8	Discuss minimum cash sweep payments with internal team.
16	1/25/2021	Bromberg, Brian	1.3	Finalize and distribute minimum cash requirements slides.
16	1/25/2021	Diaz, Matthew	1.5	Participate in a call with the UCC and the AHC to discuss the side by side analysis.
16	1/25/2021	Simms, Steven	0.5	Participate in call on cash flow and distributions.
16	1/25/2021	Kim, Ye Darm	1.4	Participate in call with AHC re: economic analysis of strategic options.
16	1/25/2021	Kim, Ye Darm	0.7	Participate in call with UCC re: distributable value assumptions.
16	1/25/2021	Bromberg, Brian	1.3	Participate in discussion re: minimum cash sweep payments with team.
16	1/25/2021	Kim, Ye Darm	0.5	Participate in pre-call w/ HL re: economic analysis of strategic options presentation.
16	1/25/2021	Diaz, Matthew	2.4	Prepare for the call on the side by side analysis.
16	1/25/2021	Kim, Ye Darm	2.2	Process revisions to analysis re: min cash distribution requirements.
16	1/25/2021	Kim, Ye Darm	0.9	Process revisions to distributable value model with HL updates.
16	1/25/2021	Kim, Ye Darm	1.3	Process revisions to min cash analysis.
16	1/25/2021	Kim, Ye Darm	1.1	Process revisions to presentation re: min cash requirements.
16	1/25/2021	Bromberg, Brian	1.7	Review minimum cash sweep payments analysis.
16	1/25/2021	Bromberg, Brian	1.7	Review minimum cash sweep payments presentation.
16	1/25/2021	Diaz, Matthew	1.8	Review the latest plan b analysis.
16	1/25/2021	Diaz, Matthew	2.1	Review the plan min cash distributions presentation.
16	1/25/2021	Diaz, Matthew	1.2	Review the updated cash distributions analysis.
16	1/25/2021	Kim, Ye Darm	1.2	Update allocation analysis for new tax assumptions.
16	1/25/2021	Kim, Ye Darm	1.6	Update latest distributable value model for updated FTI allocation analysis.
16	1/26/2021	Bromberg, Brian	0.9	Finalize and send minimum cash slides to Houlihan.
16	1/26/2021	Diaz, Matthew	0.7	Participate in a call with counsel to discuss minimum plan distributions pursuant to a plan.
16	1/26/2021	Diaz, Matthew	0.8	Participate in a call with PJT and HL to discuss minimum plan distributions.
16	1/26/2021	Kim, Ye Darm	1.0	Participate in call re: minimum cash analysis.
16	1/26/2021	Bromberg, Brian	0.7	Participate in call re: minimum cash with counsel.
16	1/26/2021	Kim, Ye Darm	0.7	Participate in call with Counsel re: mediation status.
16	1/26/2021	Kim, Ye Darm	1.9	Prepare updated analysis re: operating expense comparison analysis to bid.
16	1/26/2021	Kim, Ye Darm	1.5	Process revisions to allocation analysis re: updated tax assumption.
16	1/26/2021	Kim, Ye Darm	1.3	Process revisions to presentation re: minimum cash analysis.
16	1/26/2021	Diaz, Matthew	0.9	Review excel model calculating minimum plan distributions.
16	1/26/2021	Kim, Ye Darm	0.4	Review HL football field analysis.
16	1/26/2021	Diaz, Matthew	1.5	Review the revised minimum cash presentation.
16	1/26/2021	Kim, Ye Darm	0.8	Update allocation slides for latest tax assumptions.
16	1/27/2021	Simms, Steven	0.4	Correspond with counsel on presentation for Company discussion on min cash payments.
16	1/27/2021	Diaz, Matthew	0.9	Participate in a call with the Debtors' advisors to discuss plan distributions.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
16	1/27/2021	Kim, Ye Darm	0.5	Participate in call re: bridging analysis for distributable value.
16	1/27/2021	Kim, Ye Darm	1.0	Participate in call re: mediation status.
16	1/27/2021	Kim, Ye Darm	1.0	Participate in call with Debtors re: distributable value assumptions.
16	1/27/2021	Kim, Ye Darm	0.3	Participate in post-call re: mediation workplan.
16	1/27/2021	Kim, Ye Darm	0.4	Participate on call re: bridging analysis for distributable values.
16	1/27/2021	Kim, Ye Darm	2.2	Prepare bridging analysis re: prior and updated distributable values.
16	1/27/2021	Kim, Ye Darm	1.7	Process revisions to bridging analysis re: distributable value.
16	1/27/2021	Kim, Ye Darm	0.9	Process updates to allocation slides for HL updated figures.
16	1/27/2021	Kim, Ye Darm	0.7	Review updated HL model re: distributable value scenarios.
16	1/28/2021	Kim, Ye Darm	0.4	Correspond with HL re: changes to scenario assumptions.
16	1/28/2021	Bromberg, Brian	1.5	Finalize and send minimum cash slides to Houlihan.
16	1/28/2021	Diaz, Matthew	0.5	Participate in a call to discuss possible revolver opportunities.
16	1/28/2021	Diaz, Matthew	0.6	Participate in a call with Houlihan on minimum plan distributions.
16	1/28/2021	Kim, Ye Darm	0.6	Process additional revisions to min cash analysis presentation.
16	1/28/2021	Kim, Ye Darm	1.3	Process revisions to minimum cash analysis presentation.
16	1/28/2021	Bromberg, Brian	1.4	Process revisions to minimum cash slides.
16	1/28/2021	Kim, Ye Darm	0.8	Process updates to min cash analysis presentation for internal comments.
16	1/28/2021	Kim, Ye Darm	0.8	Review bid diligence request list.
16	1/28/2021	Kim, Ye Darm	0.2	Review HL bid counterproposal slide.
16	1/28/2021	Kim, Ye Darm	1.1	Review HL scenarios model and updates to assumptions.
16	1/28/2021	Kim, Ye Darm	0.5	Review latest draft of strategic options presentation.
16	1/28/2021	Diaz, Matthew	0.9	Review of the updated presentation on the plan distributions.
16	1/28/2021	Simms, Steven	0.4	Review presentation for call with Company on min cash payments.
16	1/28/2021	Kim, Ye Darm	0.4	Review updated private settlement term sheet.
16	1/29/2021	Diaz, Matthew	0.8	Participate in a call with counsel and Houlihan to prepare for the call with the Debtors on the go forward Purdue structure.
16	1/29/2021	Diaz, Matthew	1.1	Participate in a call with the Debtors to discuss the go forward of Purdue.
16	1/29/2021	Bromberg, Brian	1.1	Participate in call for minimum cash discussion with Debtors.
16	1/29/2021	Simms, Steven	0.7	Participate in call with AHC professionals to prep for Call with Company on cash distributions.
16	1/29/2021	Simms, Steven	1.1	Participate in call with Debtor on cash distributions.
16	1/29/2021	Bromberg, Brian	0.8	Participate in pre call for minimum cash discussion with Debtors.
16	1/29/2021	Kim, Ye Darm	0.9	Process revisions to distributable value allocation slides for new assumptions.
16	1/29/2021	Kim, Ye Darm	0.7	Process updates to allocation slides for settlement assumptions.
16	1/29/2021	Kim, Ye Darm	0.7	Review latest HL model re: distributable value scenarios.
16	1/29/2021	Diaz, Matthew	1.3	Review of the go forward cash distributions of Purdue.
16	1/29/2021	Bromberg, Brian	1.8	Review reserve calculation for distributable value.
16	1/29/2021	Diaz, Matthew	1.8	Review the updated distributions analysis.
16	1/29/2021	Bromberg, Brian	1.1	Review updated distribution slides.
16	1/29/2021	Kim, Ye Darm	0.6	Update allocation slides to incorporate reserves.
16	1/29/2021	Kim, Ye Darm	1.3	Update distributable model for new settlement assumptions.
16	1/29/2021	Kim, Ye Darm	1.4	Update distributable model for reserve calculations.
16	1/30/2021	Kim, Ye Darm	1.0	Prepare additional sensitivities for Sackler settlement scenarios and update presentation.
16	1/30/2021	Kim, Ye Darm	1.8	Prepare analysis re: Sackler settlement sensitivities.
16	1/30/2021	Kim, Ye Darm	1.9	Prepare presentation re: Sackler settlement sensitivities.
16	1/30/2021	Kim, Ye Darm	0.9	Process revisions to allocation slides for HL's latest figures.
16	1/30/2021	Kim, Ye Darm	0.7	Process revisions to Sackler settlement sensitivity slides.
16	1/30/2021	Bromberg, Brian	2.9	Review updated Sackler contribution scenarios.
16	1/31/2021	Kim, Ye Darm	0.5	Process revisions to allocation slides for new assumptions.
16	1/31/2021	Kim, Ye Darm	0.8	Process revisions to the Sackler settlement sensitivities presentation.
16	1/31/2021	Kim, Ye Darm	0.6	Process updates to allocation model.
16	1/31/2021	Bromberg, Brian	1.0	Review latest version of domestic business scenarios presentation.
16 Total			697.3	
18	9/29/2020	Kim, Ye Darm	0.5	Participate in call re: reconciliation of AlixPartners transfers report.
18	9/29/2020	Kim, Ye Darm	2.8	Process revisions and updates to the asset and transfers diligence presentation.
18	9/30/2020	Kim, Ye Darm	2.3	Analyze the B-side asset excel spreadsheets for balance sheet items and reconciliation to report.
18	9/30/2020	Kim, Ye Darm	2.2	Process revisions to the Sackler Assets and Transfers diligence presentation.
18	9/30/2020	Kim, Ye Darm	1.2	Process revisions to the Sackler Assets and Transfers presentation for new B-side information.
18	10/5/2020	Kurtz, Emma	1.3	Participate in call with Committee advisors to discuss Sackler asset reports and sales process.
18	10/5/2020	Diaz, Matthew	0.7	Review of the updated causes of action analysis against the Sacklers.
18	10/6/2020	Diaz, Matthew	0.5	Participate in call with the UCC and KL to discuss their analysis on the causes of action.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
18	10/12/2020	Bromberg, Brian	1.0	Discuss A Side Sackler asset transfers with team.
18	10/12/2020	Bromberg, Brian	1.4	Follow up with Debtors and Counsel on outstanding diligence items re: historical transfers.
18	10/12/2020	Diaz, Matthew	0.6	Participate in a call with the counsel to discuss the A side transfers.
18	10/12/2020	Kim, Ye Darm	0.8	Participate in call re: A-Side Assets diligence.
18	10/12/2020	Kurtz, Emma	1.0	Participate in call with Counsel re: A-side net asset reports and historical cash transfers.
18	10/12/2020	Bromberg, Brian	1.9	Review A Side Sackler asset transfer files.
18	10/12/2020	Kurtz, Emma	0.9	Review Sackler net asset reports and follow-ups.
18	10/12/2020	Diaz, Matthew	1.7	Review the A side cash transfers among individuals and trusts.
18	10/13/2020	Kurtz, Emma	0.9	Analyze Sackler A side and B side net asset reports to evaluate how distributions and asset values tie.
18	10/13/2020	Kurtz, Emma	0.3	Discuss internally re: Sackler A side net asset reports and proposed analysis of transfers.
18	10/13/2020	Bromberg, Brian	0.6	Discuss Sackler transfers and asset diligence workstreams with team.
18	10/13/2020	Bromberg, Brian	0.6	Perform review of a specific Sackler investment.
18	10/13/2020	Bromberg, Brian	0.4	Perform revision and prepare revisions re: Sackler assets diligence presentation.
18	10/13/2020	Kim, Ye Darm	2.8	Prepare summary analysis of A-side historical cash flows.
18	10/13/2020	Kim, Ye Darm	1.1	Process updates to summary slides re: A-side cash flows.
18	10/13/2020	Bromberg, Brian	1.5	Review A side diligence presentation summary.
18	10/13/2020	Bromberg, Brian	1.0	Review and provide revisions to the A side asset diligence summary.
18	10/13/2020	Bromberg, Brian	1.9	Review B Side cash transfers analysis file.
18	10/13/2020	Bromberg, Brian	2.1	Review the B Side net asset presentation supporting file.
18	10/14/2020	Kim, Ye Darm	3.2	Continue preparing summary analysis of A-side distributions.
18	10/14/2020	Bromberg, Brian	2.2	Continue review and provide revisions on A side transfers diligence analysis.
18	10/14/2020	Bromberg, Brian	1.0	Finalize and distribute A side transfers diligence slides for upcoming call.
18	10/14/2020	Bromberg, Brian	1.3	Participate in call with team on A side assets and transfers.
18	10/14/2020	Bromberg, Brian	0.5	Participate in discussion of transfers diligence workplan with team.
18	10/14/2020	Kim, Ye Darm	0.6	Participate in discussion re: A-side cash flow analysis.
18	10/14/2020	Kim, Ye Darm	0.5	Participate in discussion re: next steps for A-side analysis.
18	10/14/2020	Kurtz, Emma	1.1	Participate in internal call re: Sackler asset reports and historical distributions workstreams.
18	10/14/2020	Simms, Steven	0.4	Participate in internal correspondence re: Sackler diligence items.
18	10/14/2020	Diaz, Matthew	3.1	Perform detailed review of the A side historical transfers analysis.
18	10/14/2020	Bromberg, Brian	1.5	Perform review of A side cash transfers supporting file.
18	10/14/2020	Kurtz, Emma	1.3	Prepare analysis of A side Sackler family members and trusts asset and net asset value as of September 2019.
18	10/14/2020	Kim, Ye Darm	3.4	Prepare transfers summary analysis for A-side distributions.
18	10/14/2020	Kim, Ye Darm	1.2	Process updates to analysis of A-side distributions per internal comments.
18	10/14/2020	Bromberg, Brian	0.5	Review and provide revisions on A side transfers diligence analysis.
18	10/15/2020	Bromberg, Brian	0.8	Continue review of A side cash transfers diligence analysis.
18	10/15/2020	Bromberg, Brian	0.9	Continue review of A side cash transfers diligence analysis.
18	10/15/2020	Kim, Ye Darm	1.2	Participate in call re: A-side distributions analysis.
18	10/15/2020	Bromberg, Brian	1.1	Participate in discussion on A side cash transfers with team.
18	10/15/2020	Diaz, Matthew	1.2	Perform review of the updated A side transfers analysis.
18	10/15/2020	Kim, Ye Darm	1.9	Prepare an updated question list re: A-side distributions.
18	10/15/2020	Kim, Ye Darm	0.7	Process updates to A-side distributions diligence question list.
18	10/15/2020	Bromberg, Brian	0.6	Review A side cash transfers supporting file.
18	10/15/2020	Kurtz, Emma	0.5	Review A side net asset reports and historical transfers analysis with team to identify next steps.
18	10/15/2020	Bromberg, Brian	0.9	Review and finalize draft of A side analysis for distribution to internal team.
18	10/16/2020	Bromberg, Brian	1.0	Conduct review of the B side transfers support file.
18	10/16/2020	Bromberg, Brian	1.2	Participate in discussion on transfers diligence with internal team.
18	10/16/2020	Kim, Ye Darm	0.6	Participate in discussion re: B-side transfers analysis.
18	10/16/2020	Kurtz, Emma	0.9	Participate in internal discussion re: B side net asset reports and balance sheets.
18	10/16/2020	Bromberg, Brian	1.0	Prepare for call with team re: workstreams on transfers diligence and net asset reports.
18	10/16/2020	Kim, Ye Darm	1.3	Prepare updated summary slides re: latest A-side distributions analysis.
18	10/16/2020	Kim, Ye Darm	0.6	Process updates to question list re: A-side distributions.
18	10/16/2020	Kurtz, Emma	0.3	Review outstanding items related to Sackler net asset reports and historical transfers with team.
18	10/16/2020	Bromberg, Brian	0.8	Review the B Side net asset reports and balance sheets file.
18	10/16/2020	Diaz, Matthew	0.9	Review the B side transfer analysis and financial statement disclosures.
18	10/16/2020	Bromberg, Brian	1.2	Summarize draft diligence responses to outstanding transfers workstream items.
18	10/19/2020	Bromberg, Brian	0.8	Create proposed responses list to NCSG questions on transfers diligence.
18	10/19/2020	Simms, Steven	1.2	Participate in call re: presentation on Sackler distributions and transfers.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
18	10/19/2020	Diaz, Matthew	1.0	Participate in call with the UCC and other key stakeholders to discuss the non- cash transfers.
18	10/19/2020	Bromberg, Brian	1.5	Participate in call with UCC re: non cash transfers.
18	10/19/2020	Kim, Ye Darm	1.0	Participate in meeting re: non-cash transfers analysis by the UCC.
18	10/19/2020	Kim, Ye Darm	0.8	Review implied royalty rates from UCC's non-cash transfers analysis.
18	10/19/2020	Bromberg, Brian	1.3	Review revised question list for A Side Sacklers.
18	10/19/2020	Diaz, Matthew	0.6	Review the UCC's non-cash transfer report.
18	10/19/2020	Kim, Ye Darm	1.7	Review the UCC's non-cash transfers analysis presentation.
18	10/19/2020	Bromberg, Brian	1.3	Review UCC presentation on non cash transfers.
18	10/19/2020	Kim, Ye Darm	0.8	Review updated diligence question list re: A-side distributions.
18	10/21/2020	Bradley, Adam	2.0	Review considerations re: OxyContin royalty comparables.
18	10/22/2020	Bromberg, Brian	1.1	Create follow up question list re: B side transfers.
18	10/22/2020	Bromberg, Brian	1.2	Discuss B side net asset report and transfers with internal team.
18	10/22/2020	Diaz, Matthew	1.1	Participate in a call with Huron and Province to discuss the B side transfer analysis.
18	10/22/2020	Bromberg, Brian	0.8	Participate in call with Huron re: Side B transfers.
18	10/22/2020	Bromberg, Brian	1.7	Prepare for call with Sackler advisors on B side transfers.
18	10/22/2020	Diaz, Matthew	0.4	Review next steps and workplan from call with Sackler advisors and UCC on the B side analysis.
18	10/22/2020	Diaz, Matthew	2.2	Review the B side transfers analysis.
18	10/22/2020	Diaz, Matthew	1.3	Review the Sackler B side net asset report.
18	10/23/2020	Kim, Ye Darm	2.6	Continue to prepare comparative analysis of AlixPartners' cash transfer report and UCC analysis.
18	10/23/2020	Bromberg, Brian	1.9	Discuss UCC non cash transfers report with team.
18	10/23/2020	Kim, Ye Darm	0.6	Participate in call re: UCC transfers analysis review.
18	10/23/2020	Kurtz, Emma	0.4	Participate in internal discussion re: comparison of the UCC non-cash transfers report to the Alix report to tie to financial information received.
18	10/23/2020	Kim, Ye Darm	1.8	Prepare comparative analysis to AlixPartners' non-cash transfers report and UCC analysis.
18	10/23/2020	Kim, Ye Darm	1.9	Prepare list of diligence questions re: UCC transfers review.
18	10/23/2020	Bromberg, Brian	1.5	Review Province question list on transfer diligence and provide revisions.
18	10/23/2020	Diaz, Matthew	1.7	Review the UCC's non cash transfer report and related next steps.
18	10/23/2020	Bromberg, Brian	1.5	Review UCC presentation on non cash transfers.
18	10/23/2020	Kim, Ye Darm	0.9	Review UCC's Transfers Analysis report.
18	10/26/2020	Bromberg, Brian	1.3	Continue revisions of Province's diligence question list to reflect internal analyses.
18	10/26/2020	Bromberg, Brian	1.0	Perform calculation of illustrative B Side investment returns.
18	10/26/2020	Kim, Ye Darm	1.4	Prepare model to sensitize royalty rates for transfers analysis.
18	10/26/2020	Kim, Ye Darm	0.7	Process additional revisions to the UCC Transfer Review diligence questions.
18	10/26/2020	Kim, Ye Darm	0.9	Process updates to UCC Transfers Review diligence questions.
18	10/26/2020	Kim, Ye Darm	0.7	Review analysis of B-side historical returns estimate.
18	10/26/2020	Bromberg, Brian	2.0	Review and process revisions to Province's transfers diligence question list.
18	10/26/2020	Kurtz, Emma	0.3	Review B-Side balance sheets provided by Huron as backup to the October 2019 asset report.
18	10/26/2020	Bromberg, Brian	0.7	Review B-side trust balance sheets to compare with net asset reports.
18	10/26/2020	Diaz, Matthew	1.1	Review the B side transfers analysis.
18	10/26/2020	Diaz, Matthew	0.9	Review the non cash transfer report and related diligence questions list.
18	10/29/2020	Blonder, Brian	1.0	Calls with FTI IP group and matter team. regarding royalty rates.
18	10/29/2020	Bromberg, Brian	0.6	Finalize and distribute A side transfers diligence questions to Counsel.
18	10/29/2020	Diaz, Matthew	0.5	Participate in a call with the UCC to discuss the non cash transfers report.
18	10/29/2020	Kim, Ye Darm	0.5	Participate in call with Province re: UCC Transfers Review diligence.
18	10/29/2020	Kurtz, Emma	0.7	Participate in call with UCC and Counsel to discuss UCC analysis of historical transfers.
18	10/29/2020	Bromberg, Brian	0.8	Participate in call with UCC on non cash transfers.
18	10/29/2020	Bromberg, Brian	1.0	Participate in discussion on royalties with internal team and distribute relevant historical licensing agreements.
18	10/29/2020	Blonder, Brian	0.5	Preliminary research regarding pharma industry royalty rates.
18	10/29/2020	Bromberg, Brian	2.3	Prepare for call with UCC on non cash transfers.
18	10/29/2020	Bromberg, Brian	1.2	Process revisions to illustrative B side investment return analysis file.
18	10/29/2020	Blonder, Brian	0.9	Review 10/19/2020 presentation document regarding royalty rates.
18	10/29/2020	Kim, Ye Darm	1.3	Review historical notes receivables supporting documents.
18	10/29/2020	Diaz, Matthew	0.6	Review the B side transfers and the investment return analysis.
18	10/29/2020	Diaz, Matthew	0.6	Review the non cash royalty rates used in the Ocean Tomo analysis.
18	10/29/2020	Kim, Ye Darm	0.5	Review updated B-Side implied returns analysis.
18	10/30/2020	Blonder, Brian	1.2	Conduct review of 2002 to 2005 UK license and amendments.
18	10/30/2020	Blonder, Brian	0.4	Correspond with IP team on royalty diligence issues.
18	10/30/2020	Blonder, Brian	0.8	Perform review of current licenses for 5 countries between 2016 to 2018.
18	10/30/2020	Blonder, Brian	0.9	Prepare summary schedule of license agreements reviewed including key deal terms.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
18	11/2/2020	Blonder, Brian	2.1	Begin review of current Purdue license and other IP related agreements from data room.
18	11/2/2020	Bromberg, Brian	0.6	Discuss royalty analysis follow ups with internal team.
18	11/2/2020	Diaz, Matthew	1.0	Participate in a call with Province and Ocean Tomo to discuss the comps that they used for their non cash analysis.
18	11/2/2020	Bromberg, Brian	1.1	Participate in call with Ocean Tomo re: royalty analysis.
18	11/2/2020	Blonder, Brian	1.0	Participate in call with Ocean Tomo to discuss their royalty analysis presentation document.
18	11/2/2020	Bromberg, Brian	1.1	Participate in call with team on outstanding diligence items and workstreams for transfers analyses review.
18	11/2/2020	Blonder, Brian	0.8	Participate in discussion with IP team to discuss royalty rate analysis.
18	11/2/2020	Blonder, Brian	0.9	Prepare document request list re: Ocean Tomo royalty analysis.
18	11/2/2020	Bromberg, Brian	2.3	Prepare for internal call on outstanding diligence items re: royalty analysis.
18	11/2/2020	Kim, Ye Darm	2.2	Prepare skeleton presentation re: UCC transfer analysis review.
18	11/2/2020	Kim, Ye Darm	0.5	Review draft document request list re: cash/non-cash transfers analysis diligence.
18	11/2/2020	Bromberg, Brian	1.2	Review UCC transfer analysis and prepare diligence requests.
18	11/3/2020	Blonder, Brian	1.8	Continue review of full set of Purdue license and other IP related agreements.
18	11/3/2020	Diaz, Matthew	0.3	Participate in a call on the Ocean Tomo analysis with Province.
18	11/3/2020	Diaz, Matthew	0.3	Participate in a call with Counsel on the Ocean Tomo analysis and the Sackler transfers.
18	11/3/2020	Bromberg, Brian	1.4	Prepare refine diligence requests for Ocean Tomo re: royalty analysis.
18	11/3/2020	Blonder, Brian	0.8	Review Bates White "Non-Cash Transfer" Presentation.
18	11/3/2020	Diaz, Matthew	0.6	Review items owed from Ocean Tomo and related correspondence to the UCC.
18	11/3/2020	Diaz, Matthew	0.7	Review the Ocean Tomo analysis and related follow up questions coming out of the call with them.
18	11/4/2020	Blonder, Brian	2.6	Continue review of full set of Purdue License and other agreements and create excel summary of information from agreements reviewed for royalty analysis.
18	11/4/2020	Blonder, Brian	0.9	Review analysis of OxyContin Sales by Country, Formulation and Year for royalty analysis.
18	11/4/2020	Blonder, Brian	1.2	Review Bates White preliminary transfer analysis 5/19 presentation document.
18	11/4/2020	Kim, Ye Darm	1.7	Review Bates White transfers analysis presentation and supporting forecast files.
18	11/4/2020	Bromberg, Brian	2.9	Review newly received diligence materials from Bates White.
18	11/5/2020	Blonder, Brian	2.1	Conduct preliminary review of database information for royalty agreements comparable to OxyContin.
18	11/5/2020	Blonder, Brian	0.6	Research OxyContin comparables for pharmaceutical industry royalty analysis.
18	11/6/2020	Blonder, Brian	2.6	Conduct preliminary review public information available for Ocean Tomo agreements with sales royalties.
18	11/6/2020	Blonder, Brian	1.9	Perform database search for Ocean Tomo referenced agreements focused contracts with royalties based on sales.
18	11/6/2020	Blonder, Brian	2.8	Perform preliminary inventory and rate and date review of database information for royalty analysis.
18	11/6/2020	Bromberg, Brian	0.8	Review prior mediation presentations for transfers related damages estimates.
18	11/9/2020	Bromberg, Brian	1.5	Participate in call with Bates White re: royalty analysis.
18	11/9/2020	Blonder, Brian	1.2	Participate in call with Bates White team to discuss their royalty analysis.
18	11/9/2020	Bromberg, Brian	2.0	Perform review Bates White diligence materials and analysis.
18	11/10/2020	Blonder, Brian	2.3	Create excel file summary of dates and royalty rates for agreements in database for OxyContin royalty comps.
18	11/10/2020	Blonder, Brian	0.9	Participate in call with IP team to discuss royalty analysis and follow-ups from the Bates White call.
18	11/10/2020	Bromberg, Brian	1.1	Participate in discussion re: transfers analysis with internal team.
18	11/10/2020	Bromberg, Brian	2.1	Prepare for transfers diligence workplan call with team.
18	11/10/2020	Diaz, Matthew	1.1	Review the Bates White report on the non-cash transfers.
18	11/10/2020	Kim, Ye Darm	0.7	Review transfer diligence request documents by the UCC.
18	11/11/2020	Blonder, Brian	5.2	Begin review of detailed summary of terms of selected key agreements from search of OxyContin comparables.
18	11/11/2020	Blonder, Brian	1.1	Review document containing information on OxyContin margins and profits.
18	11/11/2020	Diaz, Matthew	0.9	Review of the royalty rates benchmarks as compared to the Debtors' analysis.
18	11/12/2020	Blonder, Brian	4.7	Continue review of detailed summary of terms of selected key agreements from search of OxyContin comparables.
18	11/12/2020	Diaz, Matthew	1.9	Participate in a call with the states and the UCC to hear the UCC's presentation on potential causes of action.
18	11/12/2020	Bromberg, Brian	1.7	Participate in call with UCC re: causes of action.
18	11/12/2020	Kim, Ye Darm	1.4	Prepare revisions to UCC transfer analysis review presentation.
18	11/12/2020	Bromberg, Brian	1.3	Review outstanding diligence questions for Bates White.
18	11/13/2020	Bromberg, Brian	1.3	Participate in Bates White call re: transfer analysis.
18	11/13/2020	Kim, Ye Darm	1.1	Participate in call with Bates White re: transfer analysis.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
18	11/13/2020	Bromberg, Brian	0.5	Participate in call with Counsel re: status of transfers diligence.
18	11/13/2020	Blonder, Brian	1.3	Participate in follow up call with Bates White to continue royalty analysis discussion.
18	11/13/2020	Diaz, Matthew	0.9	Participate in the non cash transfers call with Bates White.
18	11/13/2020	Bromberg, Brian	0.8	Prepare Bates White diligence request list.
18	11/13/2020	Bromberg, Brian	0.7	Review analyses and prior presentations to prepare for Bates White call re: transfer analyses.
18	11/13/2020	Blonder, Brian	0.3	Review analysis in preparation for call with Bates White.
18	11/13/2020	Blonder, Brian	0.8	Update excel analysis summarizing agreements from OxyContin comparable search.
18	11/14/2020	Kim, Ye Darm	1.6	Review draft question list re: Asset tracing and prepare initial responses.
18	11/15/2020	Diaz, Matthew	0.4	Participate in a call with Counsel re: the open items list re ability to collect potential litigation awards.
18	11/15/2020	Kim, Ye Darm	0.7	Participate in call re: asset tracing question initial responses.
18	11/15/2020	Kim, Ye Darm	0.6	Prepare updated asset tracing questions list for Counsel.
18	11/15/2020	Diaz, Matthew	0.7	Review ability to collect open items list and reconcile to related source documents.
18	11/15/2020	Bromberg, Brian	1.1	Review Sackler asset tracing diligence questions.
18	11/15/2020	Diaz, Matthew	1.5	Review the UCC presentation on the potential causes of action.
18	11/15/2020	Diaz, Matthew	1.1	Review the updated royalty rate analysis.
18	11/16/2020	Blonder, Brian	4.1	Begin search to locate agreements listed by Ocean Tomo as comparable agreements and review information and agreements found.
18	11/16/2020	Bromberg, Brian	0.8	Finalize Bates White diligence questions list.
18	11/16/2020	Diaz, Matthew	1.1	Participate in a call with Counsel to discuss potential litigation against the Sacklers.
18	11/16/2020	Kim, Ye Darm	1.0	Participate in call re: asset tracing questions with Counsel.
18	11/16/2020	Bromberg, Brian	0.9	Participate in call re: Sackler asset tracing questions.
18	11/16/2020	Kim, Ye Darm	3.2	Prepare analysis of Sackler balance sheets by jurisdiction.
18	11/16/2020	Kim, Ye Darm	0.5	Process updates to Sackler balance sheet by jurisdiction analysis.
18	11/16/2020	Bromberg, Brian	0.9	Review FTI analysis of royalty agreements re: transfers analyses.
18	11/16/2020	Diaz, Matthew	0.5	Review info request list to the UCC re: questions on their causes of action report.
18	11/16/2020	Bromberg, Brian	1.4	Review status of Sackler assets based on materials provided.
18	11/17/2020	Blonder, Brian	5.9	Continue search to locate agreements listed by Ocean Tomo as comparable agreements and review information and agreements found.
18	11/17/2020	Bromberg, Brian	1.1	Continue to review files on situs of Sackler assets and trusts.
18	11/17/2020	Blonder, Brian	2.1	Create spreadsheet summarizing results of search for information on agreements relied on by Ocean Tomo.
18	11/17/2020	Kim, Ye Darm	0.3	Identify variances between trust net asset figures reported.
18	11/17/2020	Kim, Ye Darm	1.0	Participate in call re: B-side equity roll analysis.
18	11/17/2020	Kim, Ye Darm	0.6	Participate in call re: updated balance sheet summary analysis.
18	11/17/2020	Kim, Ye Darm	1.0	Participate in call w/ UCC re: avoidance actions.
18	11/17/2020	Bromberg, Brian	0.7	Participate in call with Huron re: Side B transfers.
18	11/17/2020	Kim, Ye Darm	1.6	Prepare abridged equity roll analysis.
18	11/17/2020	Kim, Ye Darm	2.1	Prepare abridged tracing analysis for Theresa Sackler related trust assets.
18	11/17/2020	Kim, Ye Darm	0.7	Prepare response re: trust asset variances between reports.
18	11/17/2020	Kim, Ye Darm	1.7	Prepare summary analysis of Sackler family trust balance sheets.
18	11/17/2020	Kim, Ye Darm	0.4	Process updates to balance sheet summary analysis.
18	11/17/2020	Bromberg, Brian	0.7	Review files on Sackler assets for call with Huron.
18	11/17/2020	Bromberg, Brian	1.0	Review files on situs of Sackler assets and trusts.
18	11/17/2020	Diaz, Matthew	1.5	Review the trust transfer analysis as requested by Counsel.
18	11/17/2020	Kim, Ye Darm	1.8	Review UCC Presentation re: avoidance actions.
18	11/18/2020	Kim, Ye Darm	0.6	Identify variances between internal and UCC net asset analyses.
18	11/18/2020	Kim, Ye Darm	0.5	Participate in call re: updates to equity roll analysis.
18	11/18/2020	Kim, Ye Darm	2.9	Prepare revisions to equity roll analysis per internal comments.
18	11/18/2020	Kim, Ye Darm	0.4	Process revisions to B-side equity roll analysis.
18	11/18/2020	Kim, Ye Darm	0.9	Process revisions to Sackler trust balance sheet analysis.
18	11/18/2020	Kim, Ye Darm	1.3	Process revisions to Theresa Sackler related trust asset abridged tracing analysis.
18	11/18/2020	Bromberg, Brian	1.8	Review analyses on situs of Sackler assets.
18	11/18/2020	Diaz, Matthew	0.6	Review diligence correspondence relating to the A and B side transfers.
18	11/18/2020	Diaz, Matthew	0.6	Review the Sackler trust asset analysis.
18	11/18/2020	Blonder, Brian	7.2	Search for information on agreements relied on Ocean Tomo in its loss of exclusivity analysis and creation of summary of information found.
18	11/19/2020	Blonder, Brian	1.5	Created file summarizing key highlights from review of Ocean Tomo agreements and related information.
18	11/19/2020	Kim, Ye Darm	0.4	Participate in discussion re: OxyContin royalty damages sensitivity model.
18	11/19/2020	Kurtz, Emma	1.6	Prepare analysis re: historical OxyContin royalties based on Bates White proposed royalty rates ranges.
18	11/19/2020	Kim, Ye Darm	2.9	Prepare model for OxyContin sensitivity calculations.
18	11/19/2020	Blonder, Brian	0.5	Process revisions to spreadsheets reviewing agreements relied upon by Ocean Tomo.
18	11/19/2020	Kim, Ye Darm	1.1	Process revisions to Theresa Sackler related trust asset abridged tracing analysis.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
18	11/19/2020	Kurtz, Emma	0.4	Review Bates White report re: analysis of OxyContin royalty damages calculation.
18	11/19/2020	Kim, Ye Darm	1.8	Review historical royalty growth rates in UCC analysis against IAC supporting data.
18	11/19/2020	Bromberg, Brian	1.2	Review latest Bates White diligence materials and related analysis.
18	11/19/2020	Bromberg, Brian	2.2	Review royalties calculation on historical sales.
18	11/19/2020	Diaz, Matthew	0.6	Review the updated A side transfers analysis.
18	11/19/2020	Diaz, Matthew	0.9	Review the updated royalty damages analysis.
18	11/20/2020	Blonder, Brian	4.0	Begin review of agreements relied upon by Bates White to assess royalty rates.
18	11/20/2020	Bromberg, Brian	0.5	Discuss the asset transfers analyses with internal team.
18	11/20/2020	Bromberg, Brian	0.8	Participate in call with UCC re: collectability of assets.
18	11/20/2020	Kim, Ye Darm	0.9	Participate in call with UCC re: transfer considerations.
18	11/20/2020	Kim, Ye Darm	1.9	Process updates to equity roll bridge analysis.
18	11/20/2020	Kim, Ye Darm	1.8	Process updates to Purdue trust balance sheet analysis and tie variance to UCC reports.
18	11/20/2020	Bromberg, Brian	1.3	Review asset situs files from UCC.
18	11/20/2020	Kim, Ye Darm	1.3	Review the UCC trust balance sheet asset analysis.
18	11/20/2020	Diaz, Matthew	0.4	Review the updated A-side transfers analysis.
18	11/20/2020	Diaz, Matthew	0.8	Review the updated B-side transfers analysis.
18	11/20/2020	Diaz, Matthew	0.7	Review the updated OxyContin royalty analysis.
18	11/20/2020	Kim, Ye Darm	0.6	Review UCC trust balance sheet asset diligence question list.
18	11/22/2020	Blonder, Brian	3.5	Continue review of agreements relied upon by Bates White.
18	11/22/2020	Bromberg, Brian	0.8	Prepare summary of call with Counsel re: collectability.
18	11/22/2020	Diaz, Matthew	0.7	Review collectability issues and discuss related next steps.
18	11/23/2020	Blonder, Brian	2.3	Add Bates White agreements description worksheet to file describing all agreements reviewed.
18	11/23/2020	Blonder, Brian	3.7	Begin review of additional OT comp agreements provided by Ocean Tomo.
18	11/23/2020	Blonder, Brian	3.3	Finish review of Bates White agreements received.
18	11/23/2020	Diaz, Matthew	0.9	Participate in a call with Counsel to discuss collectability considerations in connection with certain causes of action.
18	11/23/2020	Bromberg, Brian	0.7	Participate in call on collectability of Sackler assets.
18	11/23/2020	Kim, Ye Darm	0.6	Participate in call re: collectability considerations.
18	11/23/2020	Bromberg, Brian	0.8	Review collectability diligence files provided.
18	11/23/2020	Kim, Ye Darm	1.1	Review documents received re: Ocean Tomo's comparable agreements.
18	11/23/2020	Bromberg, Brian	0.7	Review Ocean Tomo comparable agreements.
18	11/23/2020	Kurtz, Emma	0.2	Review recently received diligence documents re: backup files to UCC transfers analysis to share with team.
18	11/23/2020	Diaz, Matthew	0.3	Review related documents in preparation for the call with Counsel re: collectability scenarios.
18	11/23/2020	Diaz, Matthew	1.1	Review the updated collectability analysis and related next steps.
18	11/24/2020	Blonder, Brian	2.1	Begin review of additional OT LOE agreements received from Ocean Tomo.
18	11/24/2020	Blonder, Brian	4.4	Finish review of additional OT comp agreements received from Ocean Tomo.
18	11/24/2020	Diaz, Matthew	0.5	Participate in a call with Huron to discuss the A-side requests.
18	11/24/2020	Bromberg, Brian	1.0	Participate in discussion re: latest work on Sackler assets with Huron.
18	11/24/2020	Kim, Ye Darm	1.8	Prepare asset tracing exercise for the MDAS Investment Trust.
18	11/24/2020	Kim, Ye Darm	3.1	Prepare draft presentation re: collectability considerations.
18	11/24/2020	Bromberg, Brian	3.3	Review the B-side asset transfer tracing analysis.
18	11/24/2020	Diaz, Matthew	0.7	Review the updated A-side transfer analysis.
18	11/24/2020	Kim, Ye Darm	1.1	Update Collectability presentation for executive summary and B-side analysis.
18	11/24/2020	Blonder, Brian	1.5	Update worksheet of OT comps to include descriptions of new OT comp agreements reviewed.
18	11/25/2020	Blonder, Brian	2.2	Add comments to set of agreements reviewed based on considerations for assessing comparables.
18	11/25/2020	Bromberg, Brian	0.8	Continue review and process revisions re: collectability considerations slides.
18	11/25/2020	Blonder, Brian	0.7	Create word file with summary of key considerations for assessing comparability of agreements
18	11/25/2020	Bromberg, Brian	0.5	Discuss latest royalties diligence status.
18	11/25/2020	Bromberg, Brian	1.1	Discuss workplan re: transfers analysis diligence.
18	11/25/2020	Blonder, Brian	2.2	Finish review of additional OT LOE agreements received from Ocean Tomo.
18	11/25/2020	Kim, Ye Darm	0.5	Participate in discussion re: royalties analysis.
18	11/25/2020	Kim, Ye Darm	0.6	Prepare sensitivity tables for damages calculations.
18	11/25/2020	Kim, Ye Darm	1.1	Prepare updated draft transfers analysis diligence presentation.
18	11/25/2020	Kim, Ye Darm	0.8	Process revisions to collectability presentation per internal comments.
18	11/25/2020	Kim, Ye Darm	0.9	Process revisions to presentation re: collectability considerations.
18	11/25/2020	Kim, Ye Darm	1.3	Process updates to OxyContin royalties sensitivity model.
18	11/25/2020	Bromberg, Brian	0.9	Review and process revisions re: collectability considerations slides.
18	11/25/2020	Kim, Ye Darm	1.2	Review Bates White calculation of royalty product contributions against historical figures.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
18	11/25/2020	Kim, Ye Darm	1.3	Review dataroom for information on historical OxyContin patents.
18	11/25/2020	Kurtz, Emma	0.3	Review historical royalty payments from the IACs and comparison to Debtors and UCC analysis.
18	11/25/2020	Kim, Ye Darm	0.6	Review IP team draft review of comparable royalty agreements.
18	11/25/2020	Bromberg, Brian	2.8	Review royalties damages calculation on historical sales.
18	11/25/2020	Diaz, Matthew	1.1	Review the collectability presentation for AHC counsel.
18	11/25/2020	Kim, Ye Darm	1.1	Review updated version of the Bates White Report.
18	11/25/2020	Blonder, Brian	0.9	Update OT LOE worksheet to add descriptions of additional agreements reviewed.
18	11/29/2020	Diaz, Matthew	1.3	Review and finalize the updated collectability presentation.
18	11/29/2020	Bromberg, Brian	0.5	Review royalties calculation on historical sales.
18	11/30/2020	Blonder, Brian	1.0	Participate in call re: royalty analysis workproduct and status.
18	11/30/2020	Kim, Ye Darm	1.0	Participate in discussion re: transfers diligence progress.
18	11/30/2020	Bromberg, Brian	1.0	Participate in meeting re: royalty comps.
18	11/30/2020	Bromberg, Brian	1.3	Participate in meeting with Sackler counsel re: asset information.
18	11/30/2020	Diaz, Matthew	1.4	Perform detailed review of the Bates White analysis of the non cash transfers.
18	11/30/2020	Kurtz, Emma	1.4	Prepare analysis of illustrative value of OxyContin rights transferred in 2017.
18	11/30/2020	Kurtz, Emma	0.6	Prepare revisions to analysis of illustrative value of OxyContin rights transferred in 2017.
18	11/30/2020	Kim, Ye Darm	0.4	Review draft list of Bates White transfers diligence questions.
18	11/30/2020	Bromberg, Brian	2.7	Review royalties calculation on historical sales.
18	11/30/2020	Diaz, Matthew	0.5	Review the non cash transfer diligence question list to Bates White.
18	11/30/2020	Diaz, Matthew	1.5	Review updated royalty rates and findings re: the Debtors' and UCC's analysis.
18	12/1/2020	Kim, Ye Darm	2.6	Continue processing updates to draft transfers analysis presentation.
18	12/1/2020	Bromberg, Brian	0.5	Discuss non-cash transfers diligence with team.
18	12/1/2020	Kurtz, Emma	0.3	Discuss with team re: updates to analysis of historical transfers and comparison to other advisors damages conclusions.
18	12/1/2020	Kim, Ye Darm	0.6	Participate in call re: transfers diligence analysis presentation.
18	12/1/2020	Kim, Ye Darm	2.9	Process updates to draft transfers analysis presentation.
18	12/1/2020	Blonder, Brian	2.3	Review Horst Frisch reports re: transfers analysis diligence.
18	12/1/2020	Bromberg, Brian	0.8	Review materials provided on royalty transfers.
18	12/1/2020	Bromberg, Brian	2.3	Review the non-cash transfers report.
18	12/2/2020	Blonder, Brian	0.8	Gather materials regarding success probabilities for drug development projects.
18	12/2/2020	Blonder, Brian	1.9	Perform searches on ktMine in effort to find 8 Horst Frisch (HF) agreements or related materials re: transfers analysis.
18	12/2/2020	Kim, Ye Darm	1.1	Process revisions to transfers diligence analysis presentation.
18	12/2/2020	Bromberg, Brian	1.8	Process updates to non-cash transfers slides.
18	12/2/2020	Bromberg, Brian	2.6	Review and edit non-cash transfers report.
18	12/3/2020	Blonder, Brian	2.4	Begin review of information found in ktMine regarding 8 HF agreements.
18	12/4/2020	Blonder, Brian	1.4	Create excel worksheet summary of information regarding 8 HF agreements.
18	12/4/2020	Blonder, Brian	2.7	Finish review of materials from ktMine regarding 8 HF agreements.
18	12/4/2020	Bromberg, Brian	1.6	Review latest draft of non-cash transfers diligence report.
18	12/8/2020	Kim, Ye Darm	1.0	Participate in call w/ Huron re: B-Side real estate support.
18	12/8/2020	Kurtz, Emma	1.5	Participate in call w/ Huron re: B-Side real estate support.
18	12/8/2020	Bromberg, Brian	1.6	Participate in call w/ Huron re: B-Side real estate support.
18	12/8/2020	Blonder, Brian	1.5	Participate in call with Bates White to discuss royalty analysis.
18	12/8/2020	Diaz, Matthew	1.5	Participate in call with Bates White to discuss royalty analysis.
18	12/8/2020	Kim, Ye Darm	1.5	Participate in call with Bates White to discuss royalty analysis.
18	12/8/2020	Bromberg, Brian	0.7	Participate in call with Huron re: Side B transfers.
18	12/8/2020	Bromberg, Brian	0.7	Review royalty materials after call with Bates White.
18	12/9/2020	Blonder, Brian	1.1	Create worksheet summarizing info on Bates White agreements covering pain medications.
18	12/9/2020	Blonder, Brian	0.5	Participate in call with restructuring team to discuss royalty analysis status.
18	12/9/2020	Kim, Ye Darm	0.5	Participate in discussion re: royalty analyses for transfers damages.
18	12/9/2020	Bromberg, Brian	0.6	Participate in discussion re: royalty analyses for transfers damages.
18	12/9/2020	Bromberg, Brian	0.6	Prepare for call re: royalties transfers damages.
18	12/9/2020	Blonder, Brian	1.7	Research drug formulations in 27 Bates White agreements for those covering pain medications.
18	12/9/2020	Diaz, Matthew	0.7	Review the updated royalty rate observations in connection with the non-cash transfer analysis.
18	12/11/2020	Diaz, Matthew	0.5	Review the updated side-b asset analysis.
18	12/15/2020	Kim, Ye Darm	0.6	Review latest draft of the collectability presentation on transfers.
18	12/16/2020	Bromberg, Brian	2.5	Process revisions to transfer analysis diligence presentation.
18	12/16/2020	Kim, Ye Darm	1.1	Review latest draft of the transfer analysis presentation.
18	12/17/2020	Bromberg, Brian	0.8	Finalize draft transfer analysis presentation.
18	12/17/2020	Blonder, Brian	3.0	Prepare slides for portion of presentation discussing royalty analysis work.
18	12/17/2020	Kim, Ye Darm	0.9	Review and process revisions to the transfers analysis presentation.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
18	12/17/2020	Kurtz, Emma	0.3	Review presentation analyzing damages related to historical transfers to ensure correctness.
18	12/18/2020	Blonder, Brian	3.0	Prepare worksheets supporting the summary of conclusions regarding royalty analysis and creating slide presenting these results.
18	12/18/2020	Kim, Ye Darm	1.1	Review royalty analysis presentation slides and analysis.
18	12/22/2020	Diaz, Matthew	1.7	Review the updated transfers analysis.
18	1/4/2021	Kim, Ye Darm	0.7	Process additional revisions to the transfers analysis presentation.
18	1/4/2021	Kim, Ye Darm	1.3	Process revisions to analysis re: insider holdings.
18	1/4/2021	Kim, Ye Darm	1.8	Process revisions to the transfers analysis presentation.
18	1/4/2021	Diaz, Matthew	0.7	Review the non cash transfers analysis.
18	1/5/2021	Kim, Ye Darm	0.6	Review summary of A-side trust provided by Huron.
18	1/7/2021	Diaz, Matthew	0.5	Participate in a call with Huron to discuss various A-side and B-side due diligence items.
18	1/7/2021	Kim, Ye Darm	0.5	Participate in call w/ Huron re: Family A/B asset support files.
18	1/7/2021	Bromberg, Brian	0.6	Participate in call with Huron on asset backup.
18	1/7/2021	Bromberg, Brian	0.8	Review asset backup files from Sacklers.
18	1/7/2021	Kim, Ye Darm	0.7	Review Family A/B asset support documents.
18	1/12/2021	Kim, Ye Darm	0.7	Review supporting schedule of trust assets re: Sackler assets.
18	1/13/2021	Bromberg, Brian	1.6	Review Sackler asset supporting schedule information.
18	1/14/2021	Bromberg, Brian	2.4	Assemble prior information on Sackler assets.
18	1/14/2021	Diaz, Matthew	0.6	Review certain documents to be sent to KL re: collateral issues.
18	1/15/2021	Bromberg, Brian	0.6	Participate in call with Counsel re: Sackler assets.
18	1/15/2021	Kim, Ye Darm	0.5	Participate in call with Counsel re: settlement collateral.
18	1/20/2021	Diaz, Matthew	0.9	Participate in a call with the UCC and the AHC's advisors to discuss the plan b analysis.
18	1/26/2021	Diaz, Matthew	0.5	Participate in a call with the AHC sub-mediation group to discuss mediation.
18	1/27/2021	Bromberg, Brian	1.4	Participate in meeting with Sackler counsel and meeting debrief.
18	1/27/2021	Diaz, Matthew	1.0	Participate in the mediation between the Sacklers and the AHC.
18	1/29/2021	Bromberg, Brian	0.4	Review new Sackler proposed terms.
18	1/30/2021	Diaz, Matthew	0.8	Design the sensitivity slides on the Sackler report.
18	1/30/2021	Diaz, Matthew	1.0	Participate in a call with counsel to discuss the Sackler settlement and related next steps.
18	1/30/2021	Diaz, Matthew	0.8	Participate in a call with Houlihan to discuss and design certain analyses related to the proposed Sackler settlement.
18	1/30/2021	Diaz, Matthew	0.9	Review the sensitivity slides on the Sackler settlement.
18	1/31/2021	Diaz, Matthew	1.1	Review the updated Sackler analysis presentation.
18 Total			475.0	
19	10/13/2020	Kim, Ye Darm	0.6	Participate in call re: outstanding diligence workstreams.
19	10/13/2020	Kurtz, Emma	0.4	Review recently uploaded dataroom documents to update dataroom index and share with team.
19	10/14/2020	Kurtz, Emma	0.7	Update dataroom index to include recently received diligence items to share with team.
19	10/16/2020	Bromberg, Brian	0.5	Participate in call re: diligence work plan with internal team.
19	10/16/2020	Kim, Ye Darm	0.6	Participate in call re: outstanding diligence workstreams.
19	10/26/2020	Kurtz, Emma	0.3	Prepare updates to dataroom index to include recently uploaded documents.
19	11/2/2020	Kurtz, Emma	0.8	Participate in call to discuss outstanding workstreams and upcoming deliverables.
19	11/2/2020	Kim, Ye Darm	0.8	Participate in discussion re: ongoing diligence workstreams.
19	11/2/2020	Kim, Ye Darm	0.6	Participate in follow-up discussion re: ongoing diligence workstreams.
19	11/5/2020	Kurtz, Emma	0.3	Review recently uploaded diligence documents to update dataroom index and distribute to team.
19	11/6/2020	Kurtz, Emma	0.4	Prepare revisions to dataroom index to include recently uploaded diligence documents.
19	11/10/2020	Kim, Ye Darm	1.0	Participate in call re: ongoing diligence workstreams.
19	11/10/2020	Kurtz, Emma	1.0	Participate in call to discuss project work plan and upcoming deliverables.
19	11/13/2020	Kurtz, Emma	0.4	Prepare updates to dataroom index to reflect recently received diligence documents to share with team.
19	11/16/2020	Bromberg, Brian	1.3	Discuss latest diligence workstreams with internal team.
19	11/16/2020	Kim, Ye Darm	1.2	Participate in call re: outstanding workstreams.
19	11/16/2020	Kurtz, Emma	1.3	Participate in call to review workplan and identify upcoming deliverables.
19	11/16/2020	Diaz, Matthew	0.9	Review case open items and plan related next steps for workstreams.
19	11/17/2020	Simms, Steven	0.4	Participate in correspondence re: follow-ups from hearing.
19	11/25/2020	Kim, Ye Darm	0.8	Participate in discussion re: ongoing diligence workstreams.
19	11/25/2020	Kurtz, Emma	0.7	Participate on call to discuss outstanding case items and upcoming deliverables, including transfers analysis and asset reports.
19	11/25/2020	Diaz, Matthew	0.8	Review case open items and plan related next steps for workstreams.
19	11/30/2020	Kurtz, Emma	0.7	Prepare updates to dataroom index to incorporate recently received diligence documents to share with team.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
19	12/7/2020	Kurtz, Emma	0.4	Review recently received diligence documents to update dataroom index and share with team.
19	12/9/2020	Simms, Steven	0.4	Correspond with team on latest settlement considerations.
19	12/9/2020	Bromberg, Brian	0.8	Participate in call re: ongoing diligence workplan.
19	12/9/2020	Kurtz, Emma	0.6	Participate in call with team to discuss ongoing workstreams and identify open items.
19	12/9/2020	Kim, Ye Darm	0.6	Participate in discussion re: open workstreams and diligence.
19	12/9/2020	Bromberg, Brian	0.7	Prepare for internal call on ongoing diligence workplans.
19	12/10/2020	Kurtz, Emma	0.9	Review recently received diligence documents to update dataroom index.
19	12/14/2020	Kurtz, Emma	0.4	Prepare updated dataroom index to reflect recently received diligence documents from the Company.
19	12/16/2020	Kurtz, Emma	0.5	Participate in call with team to discuss open items and upcoming deliverables, with a focus on the 2021 domestic and IAC business plans.
19	12/16/2020	Bromberg, Brian	0.9	Prepare for internal call re: ongoing diligence workstreams.
19	12/17/2020	Kim, Ye Darm	0.6	Participate in meeting re: outstanding workstreams.
19	12/21/2020	Kurtz, Emma	0.4	Review recently uploaded diligence documents to the dataroom to share updates with team.
19	12/28/2020	Kim, Ye Darm	0.5	Participate in discussion re: ongoing diligence workstreams.
19	1/4/2021	Kim, Ye Darm	1.0	Participate in call re: Purdue workstream updates.
19	1/4/2021	Kurtz, Emma	0.7	Participate in internal call to discuss outstanding items and upcoming deliverables.
19	1/4/2021	Kim, Ye Darm	0.6	Participate on pre-call to prepare list of workstreams to discuss with team.
19	1/4/2021	Diaz, Matthew	0.6	Review case open items and related next steps.
19	1/4/2021	Kurtz, Emma	1.1	Review recently received diligence documents to share with team.
19	1/12/2021	Simms, Steven	0.4	Participate in correspondence with team on case items.
19	1/13/2021	Kurtz, Emma	0.6	Prepare updates to dataroom index to incorporate recently received diligence documents to share with team.
19	1/20/2021	Simms, Steven	0.6	Participate on call re: updates on ongoing case items.
19	1/25/2021	Kurtz, Emma	0.7	Review recently received dataroom files to share with team.
19	1/26/2021	Simms, Steven	0.6	Review and discuss presentation on cash payments.
19 Total			31.1	
20	10/9/2020	Diaz, Matthew	0.5	Participate on a call with the Debtors' to discuss possible buyers' interest.
20	10/10/2020	Diaz, Matthew	0.6	Participate in a call with PJT to discuss the results of the call with the NCSG.
20 Total			1.1	
21	10/7/2020	Simms, Steven	1.6	Participate in call with AHC on proposed settlement and Sackler investigation progress.
21	10/7/2020	Diaz, Matthew	1.1	Participate in the Purdue AHC call to discuss the Sackler mediation and other topics.
21	10/9/2020	Diaz, Matthew	0.5	Participate in a call with AHC counsel to discuss possible inbound interest.
21	10/13/2020	Diaz, Matthew	1.0	Participate in a call with the AHC to discuss the post emergence structure.
21	10/13/2020	Simms, Steven	1.1	Participate in call re: Presentation on Sackler issues with AHC.
21	10/15/2020	Simms, Steven	0.7	Participate in call with AHC re: ongoing diligence and case issues.
21	10/15/2020	Diaz, Matthew	0.6	Participate in the AHC call to discuss the Sackler mediation, current issues and other topics.
21	10/15/2020	Kim, Ye Darm	0.8	Participate in weekly AHC call to discuss mediation issues and ongoing diligence.
21	10/15/2020	Bromberg, Brian	0.6	Participate in weekly Committee call re: diligence updates.
21	10/21/2020	Kim, Ye Darm	0.9	Participate in AHC call re: ongoing diligence.
21	10/21/2020	Bromberg, Brian	0.7	Participate in weekly Committee call re: diligence updates.
21	10/28/2020	Diaz, Matthew	1.1	Participate in a call with the AHC to discuss the mediation, presentation to be presented to the NCSG re post emergence trust structure and other topics.
21	10/28/2020	Suric, Emil	1.2	Participate in AHC meeting re: diligence updates on product forecasts.
21	10/28/2020	Bromberg, Brian	1.1	Participate in call with AHC re: IAC diligence updates.
21	10/28/2020	Kim, Ye Darm	0.7	Participate in weekly AHC call re: diligence updates.
21	11/13/2020	Diaz, Matthew	0.5	Participate in a call with AHC counsel to discuss open due diligence and related next steps.
21	11/18/2020	Diaz, Matthew	1.5	Participate in a committee call to discuss the go forward plan structure.
21	11/18/2020	Kim, Ye Darm	1.2	Participate in AHC call re: governance considerations.
21	11/30/2020	Diaz, Matthew	0.7	Participate in a call with the AHC and the NCSG to discuss our call with the mediators.
21	12/2/2020	Diaz, Matthew	1.5	Participate in a call with the AHC to discuss the status of the mediation and other topics.
21	12/2/2020	Joffe, Steven	0.5	Participate in call with AHC re: tax considerations.
21	12/6/2020	Diaz, Matthew	1.9	Participate in a call with the AHC professionals to discuss the updated distributable value presentation.
21	12/9/2020	Diaz, Matthew	1.9	Participate in a call with the AHC to discuss the updated distributable value model and certain strategic alternatives.
21	12/9/2020	Kim, Ye Darm	1.6	Participate in AHC call re: strategic alternatives.
21	12/9/2020	Diaz, Matthew	0.9	Prepare for the call with the AHC on distributable values and strategic alternatives.
21	12/16/2020	Diaz, Matthew	2.0	Participate in a call with the AHC to discuss the updated distributable value analysis.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
21	12/16/2020	Kim, Ye Darm	2.0	Participate in call with AHC re: strategic considerations.
21	12/22/2020	Joffe, Steven	1.6	Participate in AHC meeting re: domestic strategic options for potential tax considerations.
21	12/22/2020	Simms, Steven	1.1	Participate in call with AHC on outstanding plan issues.
21	1/6/2021	Diaz, Matthew	1.0	Participate in a call with the AHC meditation group to discuss future of Purdue issues.
21	1/6/2021	Diaz, Matthew	0.7	Participate in a call with the full AHC to discuss mediation, future of Purdue and other topics.
21	1/6/2021	Bromberg, Brian	0.7	Participate in Committee Call re: mediation.
21	1/6/2021	Kim, Ye Darm	1.1	Participate in weekly AHC meeting re: diligence updates.
21	1/13/2021	Kim, Ye Darm	1.0	Participate in committee call re: diligence updates.
21	1/13/2021	Suric, Emil	1.0	Participate in meeting with AHC to discuss diligence updates.
21	1/13/2021	Diaz, Matthew	1.0	Participate in the AHC call to discuss the status of the mediation, the proposed bid and other topics.
21	1/13/2021	Diaz, Matthew	0.4	Prepare for the AHC call re: mediation, bid, and other topics.
21	1/20/2021	Diaz, Matthew	1.1	Participate in a meeting with the AHC re: bid diligence.
21	1/20/2021	Kim, Ye Darm	1.0	Participate in weekly committee call re: bid diligence.
21	1/20/2021	Bromberg, Brian	0.9	Participate in weekly Committee call re: diligence updates.
21	1/27/2021	Diaz, Matthew	1.3	Participate in the AHC call to discuss the mediation and other topics.
21	1/27/2021	Diaz, Matthew	1.2	Participate in the call with the AHC to discuss mediation and other topics.
21	1/27/2021	Kim, Ye Darm	1.0	Participate in weekly committee call re: bid diligence.
21	1/27/2021	Bromberg, Brian	1.0	Participate in weekly Committee call re: updated bid diligence.
21 Total			47.0	
22	10/9/2020	Diaz, Matthew	1.9	Participate in a call with the NCSG to discuss the Sackler mediation.
22	10/9/2020	Diaz, Matthew	0.6	Prepare for the call with the non consenting states regarding mediation issues.
22	10/29/2020	Diaz, Matthew	2.3	Participate in a call with the NCSG to discuss the proposed go forward emergence structure.
22	11/3/2020	Diaz, Matthew	2.0	Participate in a presentation with the AHC and the DOJ to discuss post emergence structure.
22	12/3/2020	Diaz, Matthew	1.6	Participate in a call with the AHC, NCSG and the DOJ to discuss plan emergence structures.
22	12/8/2020	Diaz, Matthew	0.3	Participate in a call with Province to discuss certain strategic alternatives.
22	12/10/2020	Diaz, Matthew	1.4	Participate in a call with the NCSG, AHC and DOJ to discuss possible plan alternatives.
22	12/23/2020	Diaz, Matthew	2.0	Participate in a call with the DOJ, key creditor groups and the AHC to discuss the distributable value analysis.
22 Total			12.1	
24	10/22/2020	Kim, Ye Darm	2.1	Continue to prepare the September Fee Application.
24	10/22/2020	Kim, Ye Darm	2.3	Continue to prepare the September fee application.
24	10/22/2020	Kurtz, Emma	0.4	Prepare revisions to analysis re: fee application write offs to incorporate internal revisions.
24	10/22/2020	Kim, Ye Darm	2.4	Prepare the Purdue September fee application.
24	10/22/2020	Kim, Ye Darm	1.2	Process revisions to the September Purdue fee application.
24	10/22/2020	Diaz, Matthew	0.7	Review the September bill.
24	10/23/2020	Kim, Ye Darm	0.6	Process updates to the August Fee App per comments from Counsel.
24	10/26/2020	Kim, Ye Darm	1.9	Prepare the third interim fee application.
24	10/27/2020	Kim, Ye Darm	1.6	Prepare the third interim fee application.
24	10/28/2020	Kim, Ye Darm	2.6	Prepare the third interim fee application.
24	10/28/2020	Kim, Ye Darm	2.7	Prepare the third interim fee application.
24	10/28/2020	Kim, Ye Darm	1.7	Process revisions to the third interim fee application.
24	10/29/2020	Hellmund-Mora, Marili	0.5	Process the August fee application.
24	10/29/2020	Diaz, Matthew	1.1	Review of the 3rd interim fee application.
24	11/3/2020	Kim, Ye Darm	1.1	Finalize draft of third interim fee application.
24	11/3/2020	Kim, Ye Darm	0.6	Prepare fee and expense detail for fee examiner.
24	11/6/2020	Diaz, Matthew	0.7	Review of the allocation fee statement.
24	11/13/2020	Kim, Ye Darm	0.3	Finalize the September Fee Application.
24	11/16/2020	Kim, Ye Darm	0.3	Finalize third interim bill.
24	11/18/2020	Kim, Ye Darm	0.8	Prepare fee app support for fee examiner.
24	11/30/2020	Kim, Ye Darm	2.8	Prepare the October fee app.
24	12/1/2020	Kim, Ye Darm	1.1	Process updates to October fee app.
24	12/1/2020	Diaz, Matthew	0.9	Review of the October fee app.
24	12/14/2020	Kim, Ye Darm	0.7	Process revisions to FTI October bill.
24	12/15/2020	Bromberg, Brian	1.5	Participate in omnibus hearing as FTI representative.
24	12/15/2020	Diaz, Matthew	0.3	Review of the proposed interim fee order.
24	12/21/2020	Diaz, Matthew	1.3	Review the Purdue Nov fee app.
24	12/28/2020	Kim, Ye Darm	0.8	Process revisions to Nov fee app.
24	1/8/2021	Kim, Ye Darm	1.3	Prepare Purdue Dec fee statement.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
24	1/29/2021	Kim, Ye Darm	2.4	Prepare the December fee app.
24	1/29/2021	Kim, Ye Darm	2.3	Prepare the December fee app.
24	1/29/2021	Hellmund-Mora, Marili	0.7	Update and finalize the November fee application
24 Total			41.7	
28	9/30/2020	Kim, Ye Darm	1.8	Review the latest IAC model product P&Ls.
28	10/7/2020	Kim, Ye Darm	0.7	Participate in call re: updated IAC business plan.
28	10/7/2020	Bromberg, Brian	1.0	Participate in call with Management Revisions re: latest IAC business plan.
28	10/7/2020	Kurtz, Emma	0.7	Participate in call with Steve Jamieson re: outstanding questions on latest IAC business plan model.
28	10/7/2020	Kim, Ye Darm	0.3	Review financial material re: IAC business plan prior to call.
28	10/12/2020	Diaz, Matthew	1.0	Participate in a call with Deutsche Bank re: the IAC sale process.
28	10/12/2020	Diaz, Matthew	0.5	Participate in a call with the AHC professionals to discuss the IAC due diligence.
28	10/12/2020	Kim, Ye Darm	1.0	Participate in call with Deutsche Bank re: IAC sale process.
28	10/12/2020	Bromberg, Brian	1.1	Participate in call with Deutsche Bank re: IAC sale.
28	10/12/2020	Kurtz, Emma	1.0	Participate in call with Deutsche Bank to discuss IAC sale process.
28	10/12/2020	Bromberg, Brian	0.8	Review the updated IAC business plan financials.
28	10/14/2020	Diaz, Matthew	0.5	Participate in a call with Alix to discuss the IAC tax analysis.
28	10/14/2020	Bromberg, Brian	0.5	Participate in call with Debtor advisors re: IAC tax diligence.
28	10/15/2020	Bromberg, Brian	1.5	Create agenda for upcoming LEK Consulting meeting.
28	10/15/2020	Bromberg, Brian	1.1	Participate in call with LEK Consulting re: IACs.
28	10/15/2020	Kim, Ye Darm	1.0	Participate in call with LEK re: IAC business plan.
28	10/15/2020	Kurtz, Emma	1.0	Participate in call with LEK to review commercial due diligence report and analysis of business plan projections.
28	10/15/2020	Kurtz, Emma	0.4	Prepare detailed summary of call with LEK to share with team.
28	10/16/2020	Diaz, Matthew	0.5	Review notes coming out of the LEK call and related analysis.
28	10/21/2020	Diaz, Matthew	0.5	Participate in a call with counsel to discuss tax efficiency strategies re: the IACs.
28	10/23/2020	Bromberg, Brian	0.9	Create question list for call with IAC CEO.
28	10/23/2020	Diaz, Matthew	0.5	Review the agenda and questions for the call with IAC CEO Marc Princen.
28	10/26/2020	Diaz, Matthew	1.0	Participate in a call with Mundipharma's CEO to discuss the current status of the business.
28	10/26/2020	Diaz, Matthew	0.7	Participate in a call with the Debtors' and AHC's professionals to discuss the ramifications of the IAC CEO call.
28	10/26/2020	Bromberg, Brian	1.2	Participate in call with CEO of Mundipharma.
28	10/26/2020	Kim, Ye Darm	1.0	Participate in call with IAC CEO re: YTD results and strategic initiatives.
28	10/26/2020	Kurtz, Emma	1.0	Participate in call with Marc Princen, Mundipharma CEO, to discuss his initiatives and changes to the business plan.
28	10/26/2020	Bromberg, Brian	0.7	Participate in coordination call with UCC and Debtor advisors re: IACs.
28	10/26/2020	Bromberg, Brian	0.5	Prepare summary of call with the IAC CEO.
28	10/26/2020	Bromberg, Brian	1.2	Review the updated IAC business plan financial information.
28	10/27/2020	Kurtz, Emma	0.9	Prepare revisions to analysis of iterations of IAC business plans to conform with files received from the Company and changes.
28	10/27/2020	Kurtz, Emma	1.1	Review iterations of IAC business plan to evaluate changes to net sales from earlier models to September models.
28	10/27/2020	Bromberg, Brian	1.8	Review prior IAC analyses on sum of the parts valuations.
28	10/27/2020	Diaz, Matthew	0.9	Review the updated IAC operating results.
28	10/27/2020	Bromberg, Brian	1.1	Review YTD IAC financial performance against the business plan.
28	10/27/2020	Kim, Ye Darm	0.8	Review YTD performance against latest IAC business plan.
28	10/28/2020	Bromberg, Brian	1.5	Create summary points for discussion re: IAC diligence status for a call with the AHC.
28	10/28/2020	Bromberg, Brian	0.8	Review and update diligence questions for IACs re: updated business plan.
28	11/2/2020	Diaz, Matthew	0.6	Participate in a call with the IACs to discuss open due diligence.
28	11/2/2020	Bromberg, Brian	0.6	Participate in call with IAC management re: YTD performance.
28	11/2/2020	Kurtz, Emma	1.9	Prepare summary analysis of product-level P&L information to evaluate business plan projections by entity.
28	11/2/2020	Kurtz, Emma	1.2	Prepare summary analysis of revised product-level P&L to evaluate EBITDA contribution by product by entity.
28	11/3/2020	Kurtz, Emma	1.3	Continue to prepare detailed analysis of country and product-level diligence responses received from the Company in preparation for review of revised business plan projections.
28	11/3/2020	Kurtz, Emma	2.6	Prepare detailed analysis of country and product-level diligence responses received from the Company in preparation for review of revised business plan projections.
28	11/3/2020	Kurtz, Emma	0.6	Review diligence responses from the Company and the September IAC sales updates re: evaluation of progress against business plan projections.
28	11/3/2020	Kim, Ye Darm	1.1	Review YTD financial presentations re: IACs.
28	11/4/2020	Kurtz, Emma	1.4	Incorporate relevant product sales information exhibits provided by the Company into the consolidated diligence responses to prepare for business plan projections review.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
28	11/4/2020	Kurtz, Emma	1.6	Prepare revisions to summary analysis of product-level P&L information and related diligence responses re: analysis of revised business plan projections.
28	11/4/2020	Bromberg, Brian	1.1	Review IAC OxyContin sales forecast information.
28	11/4/2020	Bradley, Adam	3.0	Review IAC YTD performance per management's presentation.
28	11/4/2020	Kim, Ye Darm	1.2	Review summary of country-level business plan diligence responses.
28	11/5/2020	Diaz, Matthew	0.5	Participate in a call with Alix to discuss the IAC tax analysis.
28	11/5/2020	Diaz, Matthew	1.0	Participate in a call with the UCC, Debtor and AHC advisors to discuss the IAC tax situation.
28	11/5/2020	Kim, Ye Darm	1.0	Participate in call re: IAC tax considerations.
28	11/6/2020	Bromberg, Brian	0.6	Participate in IAC deposition call.
28	11/6/2020	Bromberg, Brian	0.4	Review IAC information to prepare for IAC deposition call.
28	11/9/2020	Bromberg, Brian	1.1	Review IAC summary financial files.
28	11/10/2020	Bromberg, Brian	1.9	Continue review of IAC summary financial files.
28	11/10/2020	Kurtz, Emma	0.9	Prepare revisions to country level diligence responses analysis to incorporate internal comments.
28	11/10/2020	Kim, Ye Darm	1.1	Review IAC product P&L information for historical margin information.
28	11/11/2020	Bromberg, Brian	1.1	Continue review of IAC summary financial files.
28	11/11/2020	Bromberg, Brian	0.9	Participate in discussion re: historical IAC product margins with team.
28	11/11/2020	Bromberg, Brian	1.8	Perform review of historical IAC product margins.
28	11/11/2020	Kurtz, Emma	0.8	Prepare revisions to summary analysis of revised product P&L to reflect internal comments.
28	11/11/2020	Kim, Ye Darm	1.0	Review updated analysis re: IAC product P&L and diligence responses.
28	11/12/2020	Kim, Ye Darm	1.0	Participate in prep call re: IAC tax considerations.
28	11/13/2020	Diaz, Matthew	1.1	Participate in a tax call with the key case advisors to discuss the tax implications of an IAC sale including various sensitivities.
28	11/13/2020	Kim, Ye Darm	1.0	Participate in call re: IAC business tax considerations.
28	11/13/2020	Diaz, Matthew	0.8	Review of the Purdue YTD performance reports.
28	11/16/2020	Kim, Ye Darm	1.1	Review IAC audited historical financial statements.
28	11/16/2020	Diaz, Matthew	1.6	Review the IAC audited financial statements.
28	11/16/2020	Bromberg, Brian	1.7	Review the IAC audited financial statements.
28	11/19/2020	Diaz, Matthew	0.8	Participate in a call with the tax professionals re: IAC tax considerations and scenarios.
28	11/20/2020	Diaz, Matthew	0.9	Continue review of the IAC audited financial statements.
28	11/20/2020	Bromberg, Brian	0.4	Discuss IAC financials with team and prepare list of diligence questions.
28	11/20/2020	Kurtz, Emma	0.4	Review audited historical financials for 2016 through 2018 to compare to the latest Malta model historical financial results.
28	11/20/2020	Kim, Ye Darm	1.1	Review historical financial statements for 2016-2018 and tie with existing financial information.
28	12/4/2020	Diaz, Matthew	0.3	Participate in a call with Alix to discuss the IAC tax issues.
28	12/4/2020	Diaz, Matthew	0.2	Participate in a call with the UCC to discuss the IAC tax implications.
28	12/7/2020	Diaz, Matthew	0.7	Review the updated IAC business plan analysis.
28	12/9/2020	Bromberg, Brian	0.5	Discuss workplan for IAC business plan diligence.
28	12/9/2020	Kurtz, Emma	0.8	Review analysis of September business plan in preparation for receipt of 2021 business plan.
28	12/10/2020	Diaz, Matthew	0.6	Draft and review correspondence to/from the UCC's financial advisor re tax analysis sensitivities.
28	12/10/2020	Diaz, Matthew	0.7	Review the latest IAC tax analysis.
28	12/14/2020	Kurtz, Emma	1.4	Analyze variance of IACs 2021 business plan to September 2020 business plan to prepare for call with management.
28	12/14/2020	Bromberg, Brian	1.0	Review updated IAC business plan and comparison analysis.
28	12/14/2020	Kim, Ye Darm	0.7	Review updated IAC business plan summary P&L.
28	12/14/2020	Kim, Ye Darm	0.9	Review variance analysis re: updated IAC business plan.
28	12/15/2020	Diaz, Matthew	1.1	Participate in a call with the IAC management team to discuss YTD results and the revised budget.
28	12/15/2020	Bromberg, Brian	1.1	Participate in call with CEO and CFO of Mundipharma.
28	12/15/2020	Kim, Ye Darm	1.0	Participate in call with IAC CEO re: YTD performance and 2021 business plan.
28	12/15/2020	Kurtz, Emma	1.0	Participate in call with IACs management and advisors to discuss the October YTD results and the 2021 business plan.
28	12/15/2020	Shah, Jayshree	1.0	Participate in call with IACs management and advisors to discuss the October YTD results and the 2021 business plan.
28	12/15/2020	Bromberg, Brian	1.0	Review IAC materials provided in dataroom.
28	12/15/2020	Broadhead, Gary	1.0	Review latest diligence files uploaded re: IAC diligence.
28	12/15/2020	Diaz, Matthew	0.8	Review the historical IAC budgets to prepare for the call with the CEO and CFO on the revised budget.
28	12/16/2020	Diaz, Matthew	0.4	Draft correspondence to Counsel re: the IAC budget and YTD results call.
28	12/16/2020	Diaz, Matthew	0.6	Review and supplement IAC tax due diligence questions to KPMG.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
28	12/16/2020	Bromberg, Brian	0.8	Review IAC slides to create presentation outline.
28	12/17/2020	Kurtz, Emma	1.7	Prepare analysis of 2021 business plan to bridge 2020 to 2025 projections and evaluate growth drivers.
28	12/17/2020	Kurtz, Emma	1.3	Prepare analysis re: October YTD IAC results to compare to budget.
28	12/17/2020	Kurtz, Emma	1.4	Prepare presentation for Committee re: IAC financial update, including October YTD results and 2021 business plan.
28	12/17/2020	Kurtz, Emma	0.3	Prepare revisions to IAC financial update presentation for the Committee re: internal comments.
28	12/17/2020	Kim, Ye Darm	1.3	Review BoD presentation to financial advisors re: IAC diligence.
28	12/17/2020	Kim, Ye Darm	0.7	Review draft deck of IAC 2021 business plan update.
28	12/17/2020	Bromberg, Brian	1.5	Review draft IAC slides on latest business plan and YTD results.
28	12/17/2020	Kim, Ye Darm	0.6	Review IAC finance update presentation re: YTD performance.
28	12/21/2020	Bromberg, Brian	0.7	Finalize and distribute slides on IAC business plan and YTD results.
28	12/21/2020	Kurtz, Emma	0.3	Prepare revisions to IAC update slides re: October YTD performance and 2021 business plan per internal comments.
28	12/30/2020	Kim, Ye Darm	0.6	Clean up call notes for distribution to internal team re: IAC sale process update call.
28	12/30/2020	Kim, Ye Darm	0.6	Participate in call re: IAC sale process updates w/ DB.
28	12/30/2020	Bromberg, Brian	0.6	Participate in call re: IAC sale process.
28	1/6/2021	Bromberg, Brian	0.8	Review IAC presentation for updates.
28	1/7/2021	Kurtz, Emma	0.3	Prepare updates to IAC update presentation per comments from Houlihan.
28	1/7/2021	Kim, Ye Darm	2.2	Review GL data and prepare P&L analysis.
28	1/7/2021	Kim, Ye Darm	0.4	Review HL updated slide re: IAC diligence.
28	1/7/2021	Bromberg, Brian	1.0	Review IAC general ledger file.
28	1/8/2021	Bromberg, Brian	0.8	Finalize draft IAC update and send to counsel.
28	1/8/2021	Kim, Ye Darm	0.5	Participate in call re: IAC GL Analysis.
28	1/8/2021	Kim, Ye Darm	0.9	Review GL hierarchy data provided by Huron.
28	1/8/2021	Kim, Ye Darm	1.3	Revise GL analysis for account items.
28	1/11/2021	Kim, Ye Darm	3.1	Analyze IAC general ledger information by account level.
28	1/11/2021	Kim, Ye Darm	0.6	Participate in call re: IAC general ledger information.
28	1/11/2021	Kurtz, Emma	0.4	Participate in call to discuss 2021 business plan projections backup file received from the Company.
28	1/11/2021	Kim, Ye Darm	0.9	Prepare draft question list for IAC advisors re: general ledger data.
28	1/11/2021	Kim, Ye Darm	2.7	Process revisions to the IAC general ledger analysis.
28	1/11/2021	Bromberg, Brian	1.9	Review IAC financial information.
28	1/11/2021	Bromberg, Brian	1.3	Review IAC general ledger file.
28	1/11/2021	Diaz, Matthew	1.1	Review the updated IAC business plan.
28	1/12/2021	Bromberg, Brian	0.5	Discuss IAC GL file with Houlihan.
28	1/12/2021	Diaz, Matthew	0.5	Participate in a call with Alix to discuss the updated IAC Plan.
28	1/12/2021	Kim, Ye Darm	0.5	Participate in call to discuss IAC general ledger analysis with HL.
28	1/12/2021	Kim, Ye Darm	0.8	Review HL general ledger analysis re: IAC forecasts.
28	1/12/2021	Diaz, Matthew	0.8	Review the updated IAC business plan supporting financials.
28	1/14/2021	Kurtz, Emma	1.3	Prepare summary for Counsel re: key IAC entities.
28	1/14/2021	Kurtz, Emma	0.4	Prepare updates to summary of key IAC entities for Counsel to include relevant organizational charts.
28	1/15/2021	Kurtz, Emma	0.7	Participate in call with Counsel to discuss potential collateral value of the IACs for deal with Sacklers.
28	1/22/2021	Bromberg, Brian	0.5	Review new IAC financial support files.
28	1/22/2021	Kurtz, Emma	0.3	Review recently received IAC business plan support files to summarize for team.
28	1/25/2021	Kurtz, Emma	1.6	Prepare analysis to reconcile general ledger files to 2021 business plan.
28	1/26/2021	Kurtz, Emma	2.9	Analyze intercompany general ledger entries and total general ledger entries to evaluate how they tie to 2021 P&L.
28	1/26/2021	Kurtz, Emma	2.2	Incorporate intercompany general ledger entries for 2022 through 2025 into comparison analysis to the 2021 business plan.
28	1/26/2021	Bromberg, Brian	1.3	Review provided IAC financial information.
28 Total			142.4	
29	3/11/2020	Diaz, Matthew	0.6	Participate in call with Committee call to discuss mediation-related issues.
29	3/11/2020	Joffe, Steven	0.6	Participate in call with Committee call to discuss mediation-related issues.
29	3/11/2020	Knechtel, Karl	0.6	Participate in call with Committee call to discuss mediation-related issues.
29	3/18/2020	Diaz, Matthew	0.8	Participate in call with Committee re: mediation-related issues, ERF funding.
29	3/18/2020	Knechtel, Karl	0.8	Participate in call with Committee re: mediation-related issues, ERF funding.
29	4/1/2020	Diaz, Matthew	1.1	Participate in call with Committee re: mediation-related issues, ERF funding.
29	4/1/2020	Joffe, Steven	1.1	Participate in call with Committee re: mediation-related issues, ERF funding.
29	4/1/2020	Knechtel, Karl	1.1	Participate in call with Committee re: mediation-related issues, ERF funding.
29	4/15/2020	Diaz, Matthew	0.9	Participate in call with Committee re: mediation-related issues, ERF funding.
29	4/29/2020	Diaz, Matthew	1.1	Participate in call with Committee call to discuss mediation-related issues.
29	4/29/2020	Suric, Emil	0.8	Participate in call with Committee call to discuss mediation-related issues.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD OCTOBER 1, 2020 TO JANUARY 31, 2021

Task Category	Date	Professional	Hours	Activity
29	5/18/2020	Diaz, Matthew	1.0	Participate in call with Committee call to discuss mediation-related issues.
29	5/19/2020	Bromberg, Brian	1.3	Participate in Committee call re: abatement/mediation issues.
29	5/20/2020	Bromberg, Brian	0.8	Review abatement plan document from non-state groups.
29	5/20/2020	Bromberg, Brian	1.6	Participate in Committee call re: abatement issues.
29	5/20/2020	Bromberg, Brian	1.5	Participate in follow-up Committee call re: abatement issues.
29	5/20/2020	Diaz, Matthew	1.5	Participate in Committee call re: abatement issues.
29	5/20/2020	Diaz, Matthew	1.0	Participate in follow-up Committee call re: abatement issues.
29	5/21/2020	Bromberg, Brian	1.0	Participate in Committee call re: abatement considerations.
29	5/21/2020	Diaz, Matthew	0.5	Participate in Committee call re: abatement considerations.
29	5/28/2020	Kim, Ye Darm	2.0	Participate in meeting with Committee re: tribal claims allocation.
29	5/28/2020	Bromberg, Brian	2.0	Participate in meeting with Committee re: tribal claims allocation.
29	6/3/2020	Bromberg, Brian	0.7	Review abatement plan document.
29	6/3/2020	Bromberg, Brian	0.7	Continue review of abatement plan document.
29	6/30/2020	Bromberg, Brian	1.5	Participate in call re: mediaton strategy with public side entities.
29	7/8/2020	Bromberg, Brian	1.3	Participate in Committee call re: mediation updates.
29	7/8/2020	Diaz, Matthew	1.0	Participate on call with the Committee to discuss the mediation and related plan discussions.
29	7/15/2020	Diaz, Matthew	1.5	Participate on call with the Committee re: mediation updates.
29	8/5/2020	Bromberg, Brian	1.0	Participate on call with the Committee to discuss the mediation updates and related issues.
29	8/5/2020	Diaz, Matthew	0.8	Participate on call with the Committee to discuss the mediation updates and related issues.
29	8/12/2020	Bromberg, Brian	1.3	Participate in the AHC call to discuss the recovery analysis, business update and mediation
29	8/12/2020	Diaz, Matthew	1.5	Participate in the AHC call to discuss the recovery analysis, business update and mediation
29	8/12/2020	Kim, Ye Darm	1.0	Participate in the AHC call to discuss the recovery analysis, business update and mediation
29	8/17/2020	Bromberg, Brian	2.8	Prepare model summarizing illustrative allocation of value to claimant groups.
29	8/19/2020	Diaz, Matthew	0.9	Participate on call with the Committee to discuss the mediation and the updated recovery
29	8/24/2020	Bromberg, Brian	0.5	Process revisions to distributable value allocation spreadsheet model.
29	9/1/2020	Bromberg, Brian	0.8	Process updates to distributable value allocation spreadsheet model.
29	9/1/2020	Bromberg, Brian	0.8	Review latest version of distributable value allocation spreadsheet model.
29	9/4/2020	Bromberg, Brian	2.5	Review and revise distributable value and allocation assumptions based on commentary.
29	9/4/2020	Kim, Ye Darm	1.4	Prepare updated distributable value allocation model for revised term sheets.
29	9/8/2020	Bromberg, Brian	0.7	Review latest distributable value allocation model.
29	9/8/2020	Bromberg, Brian	1.0	Participate in call re: personal injury claimant settlements.
29	9/8/2020	Diaz, Matthew	0.9	Participate in Committee call re: settlements with creditor groups.
29	9/8/2020	Kim, Ye Darm	1.0	Participate in Committee call re: settlements with creditor groups.
29	9/21/2020	Diaz, Matthew	0.6	Review the latest mediators' report.
29	9/30/2020	Diaz, Matthew	0.3	Review the updated mediation order.
29	9/30/2020	Diaz, Matthew	0.3	Review of the updated mediation order.
29	10/20/2020	Kim, Ye Darm	0.7	Review accrued bill for intercreditor allocation work.
29	11/3/2020	Kim, Ye Darm	2.6	Prepare draft of intercreditor allocation fee application.
29 Total			53.8	
Grand Total			2,111.5	